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Amyotrophic Lateral Sclerosis is a devastating disease involving progressive 
degeneration of motor neurons in the brain, brainstem, and spinal cord. Life expectancy 
 
 
after diagnosis is between 3-5 years on average, with current treatments only extending 
life by several months. Novel therapeutic targets are sorely needed. 
We combined RNA-Sequencing, systems biology analyses, and molecular biology 
assays to elucidate sALS group-specific differences in postmortem cervical spinal 
sections (7 sALS samples and 8 neurologically healthy controls) that may be relevant to 
disease pathology. >55 million paired end (2X150) RNA-sequencing reads per sample 
were generated, processed, and aligned to an hg19 human reference transcriptome then 
genome.  
In the work presented in Chapter 2, we used bioinformatics tools to identify 
differentially expressed genes (DEGs) between our sALS and control sample groups. 
Further, we used Weighted Gene Co-Expression Network Analysis (WGCNA), an 
unsupervised analysis, to identify gene co-expression networks associated with sALS 
disease status in our sample set. Qiagen’s Ingenuity Pathway Analysis revealed our sALS 
group-specific DEGs and a sALS group-specific gene co-expression network were both 
associated with inflammatory processes and TNF-α signaling. Further, Tumor Necrosis 
Factor Alpha Induced Protein 2 (TNFAIP2) was identified as a sALS group-specific 
upregulated DEG and a network hub gene in that gene co-expression network. We 
hypothesized its upregulation in our patients’ tissues was a result of increased TNF-α 
signaling and that it functionally contributed to motor neuron death via TNF superfamily 
apoptotic pathways. Transient overexpression of TNFAIP2 led to decreased cell viability 
in both neural stem cells and induced pluripotent stem cell (iPSC)-derived motor neurons. 
Further, inhibition of activated caspase 9 (a protein necessary for TNF superfamily 
mitochondrial-mediated apoptosis) reversed this effect in neural stem cells.  
 
 
In the work presented in Chapter 3, we used bioinformatics tools to identify sALS 
group-specifc mitochondrial DEGs. We did not identify any in our sample set. 
In the work presented in Chapter 4, we used DEXSeq to identify sALS group-
specific differentially used exons (DUEs). Qiagen’s Ingenuity Pathway Analysis revealed 
our sALS group-specific DUEs were associated with cholesterol biosynthesis. Cholesterol 
biosynthesis defects cause several rare neurodegenerative disorders, and may 
















I. Perturbations in Amyotrophic Lateral Sclerosis:  
Amyotrophic Lateral Sclerosis (ALS) is a devastating disease involving 
progressive degeneration of motor neurons in the brain, brainstem, and spinal cord. Life 
expectancy after diagnosis is between 3-5 years on average, with current treatments only 
extending life by several months. Novel therapeutic targets are sorely needed. 
We hypothesize perturbed cellular processes in ALS patients’ tissues promote 
motor neuron death, and these perturbations are caused by aberrant gene expression 
events. Further, we presume these aberrant gene expression events can be identified 
using techniques commonly used in gene expression studies.  
We combined RNA-Sequencing, systems biology analyses, and molecular biology 
assays to elucidate sALS group-specific gene and exon expression level differences in 
postmortem cervical spinal sections (7 sALS samples and 8 neurologically healthy 
controls) that may be relevant to disease pathology. For each tested gene or exon, a 
sALS group-specific difference was identified when the sALS sample group’s 





neurologically healthy control sample group’s representative expression value after 
multiple corrections. The remainder of this introductory section provides background 
information relevant to our gene expression study.  
 
II. Known RNA species in eukaryotic cells: 
A gene’s deoxyribonucleic acid (DNA) sequence is used to generate a 
complementary ribonucleic acid (RNA) transcript via transcription. In Eukaryotic cells, 
transcription of each RNA molecule requires an RNA polymerase (RNAP) and general 
transcription factors (TFs). In eukaryotic cells, known types of RNA can be broadly 
separated into three major groups based on their functions. These groups are 1) RNAs 
involved in protein synthesis and localization, 2) RNAs involved in post-transcriptional 
modification or telomere DNA replication, and 3) regulatory RNAs.  
RNAs involved in protein synthesis and localization include pre-messenger RNAs 
(pre mRNAs), messenger RNAs (mRNAS), ribosomal RNAs (rRNAs), transfer RNAs 
(tRNAs), and signal recognition particle RNAs (7SL RNA).  Pre mRNAs undergo splicing 
prior to becoming mature mRNAs. mRNAs are then used to encode polypeptides via 
ribosomal-mediated translation in the cytosol, with contributions from rRNAs and tRNAs. 
7SL RNA comprises part of the signal recognition particle, a protein-RNA complex that 
mediates the transport of secretory and membrane proteins to a cell’s plasma membrane 
or endoplasmic reticulum (Luirink, Sinning 2004).  
RNAs involved in post-transcriptional modification or telomere DNA replication 
include small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNA), Ribonucleases 





snRNAs comprise part of the spliceosome complex, and functionally contribute to 
processing pre mRNAs into mature mRNAs. Additionally, U1 snRNA has been shown to 
regulate RNA Polymerase II’s initiation phase (Kwek et al. 2002). snoRNAs are most 
widely known for their role in chemically modifying rRNAs during their maturation process. 
snoRNAs also modify other non-coding RNAs (ncRNAs), impact protein translation, and 
play a role in maintaining genome stability (Matera, Terns, Terns 2007). Ribonucleases 
P and MRP are essential for the maturation of tRNAs and rRNAs, respectively (Piccinelli, 
Rosenblad, Samuelsson 2005). Finally, TERC is an RNA component of telomerase, a 
ribonucleoprotein that extends telomeric DNA repeat sequences at the end of 
chromosomes. Telomerase reverse transcribes TERC’s RNA sequence into telomeric 
DNA repeat sequences. These are added onto chromosome ends during telomere 
elongation, and protect those chromosomes’ ends from degradation (Artandi 2006). 
Regulatory ncRNAs include piwi-interacting RNAs (piRNAs), microRNAs 
(miRNAs), small interfering RNAs (siRNAs), and long noncoding RNAs (lncRNAs). 
piRNAs bind piwi proteins to form RNA-protein complexes, and prevent translation of 
RNA transcripts from mobile elements in germ line cells across various species (Weick, 
Miska 2014). Mobile elements are DNAs that insert themselves into various parts of the 
genome, and their RNA transcripts encode proteins that mediate their movement from 
one genomic location to another. Silencing mobile elements’ RNA transcripts in germline 
cells is important, as it can prevent the transmission of deleterious mutations (caused by 
the insertion of mobile elements into susceptible genomic regions) to offspring. 
miRNAs and siRNAs are single stranded RNAs (ssRNA) derived from transcribed 





endogenous siRNAs (or siRNAs encoded by the host’s genome) was only recently 
confirmed in vertebrate species (Piatek, Werner 2014). miRNA synthesis involves two 
RNA selective endonucleases (Drosha and Dicer), an Argonaute protein, and other 
species-specific protein factors. siRNA synthesis involves these same components, 
except it does not involve contributions from Drosha (Piatek, Werner 2014). A miRNA or 
siRNA binds to an Argonaute protein (forming an RNA-induced silencing complex known 
as RISC) prior to hybridizing their target mRNA via complementary basepairing. 
Hybridization typically occurs between the RISC’s miRNA (or siRNA) and a portion of the 
mRNA’s 3’ untranslated region. After hybridization, the RISC complex reduces translation 
of the target mRNA by 1) rendering it vulnerable to degradation after shortening its polyA-
tail, 2) reducing how efficiently it is translated into a corresponding polypeptide (or 
polypeptides), or 3) cleaving it into multiple pieces (Fabian, Sonenberg, Filipowicz 2010).  
lncRNAs are defined as non-protein coding RNA transcripts longer than 200 
nucleotides (a size that was arbitrarily chosen). While genomic analyses have identified 
>10,000 lncRNAs encoded by the human genome, their functions remain largely 
unknown. However, a variety of lncRNAs have been shown to 1) regulate transcription 
and splicing of pre-mRNAs, 2) alter translation of mRNAs, 3) inhibit protein activities, and 
4) yield small ncRNAs after they undergo post-transcriptional processing (Chen 2015, 
Wilusz, Sunwoo, Spector 2009). Mutations and dysregulations of lncRNAs have been 
linked to cardiovascular diseases, neurological diseases, diabetes, HIV, and various 
types of cancers (Chen 2015). 
 





Most pre mRNAs undergo post-transcriptional processing in the nucleus prior to 
becoming mature mRNAs. Various protein complexes mediate the addition of a 7-
methylguanosine cap and a poly-A tail (comprised of linked adenosine monophosphates) 
to nearly all pre-mRNAs’ 5’ and 3’ ends, respectively. The cap protects the pre-mRNA 
from degradation, promotes downstream nuclear export of the eventual mRNA, and aids 
in downstream translation of the eventual mRNA into a polypeptide (Cowling 2009). The 
poly-A tail is also known to protect the pre-mRNA from degradation, and aids in translation 
of the eventual mRNA (Subtelny et al. 2014). 
The majority of eukaryotic genes’ sequences transcribed into pre-mRNAs contain 
stretches of deoxyribonucleotides called introns and exons. As a pre-mRNA is processed 
into a mature RNA, introns are generally removed whereas some (or all) exons are 
retained. Most mammalian pre-mRNAs contain introns that are a few hundred to several 
thousand nucleotides long, whereas the size of exons are typically around 120 
nucleotides long (Will, Luhrmann 2011). 
The spliceosome is a biological complex comprised of numerous snRNAs and 
proteins. It removes intronic (and occasionally exonic) sequences from a pre-mRNA, 
followed by ligating retained exonic sequences to each other. I will next describe a typical 
two-step process for spliceosome-mediated removal of an intronic sequence in a pre-
mRNA that is illustrated in Figure 1.  
First, snRNAs in the spliceosome recognize specific nucleotide sequences (called 
splice sites and a branch site) in a pre-mRNA’s intron. Next, the spliceosome complex 
carries out consecutive transesterification reactions to remove the intron and connect the 





in the intron’s branch site) executing a nucleophilic attack on the intron’s 5’ splice site. 
This results in cleavage at that site, followed by ligation of the 5’ end of the intron to the 
adenosine in the branch site. Next, the recently liberated 5’ exon’s 3’ hydroxyl group 
attacks the intron’s 3’ splice site. This leads to ligation of the two exons that were flanking 
the intron and removal of that intron (Will, Luhrmann 2011).  
While researchers initially believed the spliceosome removed each pre-mRNA’s 
introns and retained its exons to generate a single mature mRNA, we now know this isn’t 
the only possibility. Alternative splicing events enable the generation of multiple mature 
mRNAs from a given pre-mRNA, despite the fact that each copy of that pre-mRNA 
possesses the same introns and exons. Figure 2 shows various alternative splicing 
events for a given pre-mRNA molecule, and the variety of resultant mature mRNAs.  
Alternative splicing events occur in ~95% of eukaryotic genes (Kornblihtt et al. 
2013), and lead to a greater diversity of RNA transcripts and polypeptides (transcribed 
from the variety of resultant mRNAs). These events are regulated by many factors 
including (but not limited to) pre-mRNA nucleotide sequences, cell signaling cascades, 
and protein-mediated modifications of spliceosome components.  
Alternative splicing likely played an integral role in increasing biological complexity 
amongst vertebrate species and has been implicated in numerous human diseases. A 
recent study discovered primates have significantly higher frequencies of alternative 
splicing events in various organs compared to other vertebrate species when comparing 







Figure 1. Spliceosome-mediated removal of an intron from a pre-mRNA. This figure shows 
a cartoon schematic of spliceosome-mediated removal of an intron. E1 and E2 are exons 1 and 
2 flanking the intron, respectively. 5’SS and 3’SS are the intron’s 5’ and 3’ splice sites, 
respectively. A is the adenosine located in the intron’s branch point (BP). Adapted from Will, 

















likely contribute to primates’ increased biological complexity relative to other vertebrates, 
as vertebrates have comparable numbers of protein coding genes. Aberrant alternative 
splicing events (and their deleterious impact on biological processes) have been 
implicated in various human diseases including myotonic dystrophy, dilated 
cardiomyopathy, autism spectrum disorder, and cancer (Cieply, Carstens 2015). 
 
IV. Transcription, splicing, and translation of mitochondrial genes in 
eukaryotic cells: 
Mitochondria are energy-transducing organelles in eukaryotic cells responsible for 
synthesizing the majority of cellular adenosine triphosphate (ATP). Proteins use ATP to 
conduct various essential cellular processes including biosynthetic reactions, cell motility, 
and cell divison (Taanman 1999). Cells in eukayotic organisms have different numbers of 
mitochondria depending on energy demands of their respective tissues. Each 
mitochondria contains multiple copies of maternally derived, ~16 kb circular genomes free 
of intronic regions (Ladd, Keeney, Govind, Bennett 2014). The mitochondrial genome’s 
two strands (light and heavy) collectively have 37 total genes encoding 2 rRNAS, 22 
tRNAs, and 13 polypeptides.  
Transcription of mitochondrial genes is less understood than transcription of 
nuclear genes, but the two processes are thought to share many commonalities. 
Mitochondrial transcription involves initiation, elongation, and termination stages. Further, 
mitochondrial transcription requires contributions from a mitochondrial RNAP (POLRMT), 







Figure 2. Alternative splicing events for a pre-mRNA molecule. This figure shows various 
alternative splicing events for a single pre-mRNA molecule that can be executed by the 














TFB1M or TFB2M (Asin-Cayuela, Gustafsson 2007). Other proteins may also contribute 
to during these steps, though there is less definitive evidence to support this.  
During the initiation step, a transcription initiation complex comprised of POLRMT, 
TFB2M, and TFAM binds to one of three promoter regions (HSP1, HSP2, or LSP) found 
on the heavy and light strand of the mitochondrial genome. It is not fully understood how 
the mitochondrial transcription initiation complex recognizes DNA sequences in these 
promoter regions or begins transcription. However, TFAM is suspected to mediate 
structural alterations in mtDNA, unwinding it to expose transcription start sites to the 
initiation complex.  
Fewer details are known about the elongation step. Recent finding suggest 
POLRMT binds a protein called mitochondrial transcription elongation factor to form an 
elongation complex (Posse et al. 2015). POLRMT is thought to function in the same way 
RNA Polymerases I-III do during their respective elongation processes, generating 
complementary ssRNA molecules from deoxyribonucleotide sequences. The initiation 
complex begins transcription from one of the heavy strand promoters (HSP1 or HSP2), 
or the light strand promoter (LSP). Different RNA products are generated depending on 
which promoter is used, as discussed in Figure 3. 
When transcription is initiated at the HSP1 site, POLRMT stops transcribing 
mtDNA upon encountering a termination site (or specific sequence of nucleotides) at the 
end of the 16s rRNA sequence. This may involve contributions from a protein (mTERF1). 
It is unclear how POLRMT terminates transcription after beginning at HSP2 or LS, though 
other termination sites (and interacting proteins) are suspected (Asin-Cayuela, 







Figure 3. Mitochondrial transcription. This figure shows the mtDNA genome, and transcription 
initiation sites for the heavy (HSP1 and HSP2) and light (LSP) mitochondrial DNA strands. HSP1’s 
corresponding RNA transcript terminates at the 3’ end of the 16S rRNA region. HSP2’s 
corresponding RNA transcript nearly incorporates the entire heavy strand sequence (including all 
of genes depicted in blue). Finally, LSP’s corresponding RNA transcript includes the ND6 gene 
(in yellow) and primers for initiation of DNA synthesis at the heavy strand origin of replication 











(including mitochondrial RNase P) that mediate endonucleolytic excision of these pre-
mRNA transcripts into smaller pieces (Smits, Smeitink, van den Heuvel 2010). These 
pieces are mitochondrial mRNAs (encoding rRNAs, tRNAs, mRNAs), or primers involved 
in initiation of DNA synthesis.   
Translation of mitochondrial mRNAs involves initiation, elongation, and termination 
steps. Further, this process involves contributions from 1) mitochondrial-encoded rRNAs 
and tRNAs, 2) initiation, elongation, and termination translation proteins, 3) mitochondrial  
ribosomal proteins, and 4) mitochondrial aminoacyl-tRNA synthetases and methionyl-
tRNA transformylases (Smits, Smeitink, van den Heuvel 2010).   
During the initiation phase, mitochondrial ribosomes are thought to recognize 
unique mitochondrial mRNAs with their unstructured 5’ sequences (as mitochondrial 
mRNAs do not have caps). The current model proposes a translation factor (mtIF3) 
promotes formation of an initiation complex, and the mitochondrial mRNA’s start codon 
(with the nucleotide sequence AUG) is bound to the mitochondrial ribosome’s P site. A 
different translation factor (mtIF2) facilitates entry of a tRNA carrying a methionine residue 
into the mitochondrial ribosome. This tRNA’s anticodon binds the mitochondrial mRNA’s 
start codon in the P site, as the tRNA still carries the methionine residue (Smits, Smeitink, 
van den Heuvel 2010). 
During the elongation step, translation factor proteins assist the mitochondrial 
ribosome, tRNAS, and rRNAs in generating a polypeptide from the mitochondrial mRNA. 
At this point, the mitochondrial mRNA’s 2nd codon is situated in the mitochondrial 





2nd codon is recruited into the mitochondrial ribosome’s A site, and the tRNA’s anticodon 
binds to the mitochondrial mRNA’s 2nd codon. A peptide bond is formed between the 
amino acids carried by the tRNAs in the mitochondrial ribosome’s A and P sites, followed 
by the mitochondrial mRNA being shifting three nucleotides to the left. This results in the 
tRNA bound to the mitochondrial mRNA’s start codon being ejected from the 
mitochondrial ribosome, as it no longer carries an amino acid. During this shift, the 
mitochondrial mRNA’s 2nd and 3rd codons were moved into the mitochondrial ribosome’s 
P and A sites, respectively.  
An iterative process ensues involving 1) recruitment of a tRNA with an anticodon 
complementary to the mitochondrial mRNA’s codon located in the mitochondrial 
ribosome’s A site, 2) formation of a peptide bond between the amino acids carried by the 
tRNAs in the mitochondrial ribosome’s A and P sites, 3) the mitochondrial mRNA being 
shifted 3 nucleotides to the left, and 4) ejection of the tRNA hybridized to the mitochondrial 
mRNA’s most 5’ codon (as it no longer carries an amino acid). This process is repeated 
until a stop codon (with a sequence of UAA, UAG, AGA, or AGG) is shifted into the 
mitochondrial ribosome’s A site (Smits, Smeitink, van den Heuvel 2010).  
During the termination phase, a mitochondrial release factor (mtRF1a) recognizes 
the stop codon in the mitochondrial ribosome’s A site, and triggers the release of the 
polypeptide from the mitochondrial ribosome. This involves hydrolysis of the ester bond 
linking the polypeptide chain to the tRNA in the P site. The ribosome and its associated 
proteins then dissociate, and the mitochondrial mRNA transcript is freed. The 
mitochondrial mRNA transcript is either translated into additional polypeptide copies by 





V. Gene expression levels: 
Gene expression is the process by which a gene’s deoxyribonucleotide sequence 
is used to generate structural or functional gene products. These include RNAs and/or 
proteins. A given gene’s expression level in a biological sample can be estimated by 
measuring the amount of its RNA transcripts in that sample. Gene expression levels can 
change in response to factors inherent to an organism (such as age, gender, and 
hormones), environmental factors (such as drugs, temperature, and light) the organism 
encounters (Arslan-Ergul, Adams 2014, Che, Gingerich, Lall, Howell 2002, Rhodes, 
Crabbe 2005, Podrabsky, Somero 2004, Rossel, Wilson, Pogson 2002), or an interaction 
between the internal and external factors. The temporal, developmental, topographical, 
histological, and physiological patterns in which a gene is expressed can provide clues to 
its biological role (Shena, Salon, Davis, Brown 1995).  
Researchers have long hypothesized multiple genes’ expression patterns 
contribute to phenotypic diversity (Romero, Ruvinsky, Gilad 2012). However, 
simultaneous measurement of multiple genes’ expression levels was not common 
practice (due its technical infeasibility) until DNA microarrays were created for this 
purpose in the 1990s (Schena, Salon, Davis, Brown 1995). Next generation RNA-
Sequencing has since been created in the late 2000’s (Wang, Gerstein, Snyder 2009), 
and both techniques are now commonly used to measure gene expression levels. 
 





DNA microarrays are glass slides with covalently bound single stranded 
oligonucleotide probes (typically 60-mers in length) (Mantione et al. 2014). On a 
microarray designed to measure gene expression, each probe is complementary in 
sequence to part (or all) of an annotated gene’s known or predicted RNA transcripts 
(Mantione et al. 2014). There are typically multiple probes assigned to each gene’s RNA 
transcripts. The synthesis of these probes relies on known genomic sequence, and/or 
known or predicted open reading frames (Malone, Oliver 2011).  
When using a DNA microarray to estimate a given sample’s gene expression 
levels, researchers will typically 1) isolate that sample’s total RNA or polyA+ RNA, 2) 
convert it into double stranded complementary DNA (dscDNA) via reverse transcription, 
3) label the dscDNA with a fluorescent dye, 4) denature the labeled dscDNA, 5) hybridize 
the denatured cDNA strands to the DNA microarray’s probes via complementary 
basepairing, 6) shine a laser on the DNA microarray’s probes to excite the fluorescent 
dyes attached to hybridized cDNA strands, 7) record each probe’s fluorescence intensity, 
8) process and normalize all probes’ fluorescence intensities, and 9) use all resultant 
fluorescence intensity values to estimate each gene’s expression level. The presumption 
is each gene’s expression level is positively correlated with its corresponding probes’ 
fluorescence intensities. When a researcher wants to compare two samples’ gene 
expression levels to each other on the same DNA microarray, they follow the steps above 
with the exception of labeling each sample’s dscDNAs with a different colored fluorescent 
dye in step 3. 
DNA sequencing involves determining the identity (and order) of nucleotides in 





reports this information. Current RNA-Sequencing workflows involve isolating a given 
sample’s RNAs, converting them into dscDNAs, and generating sequenced reads from 
those dscDNAs’ denatured strands. These sequenced reads undergo an alignment step, 
where their nucleotide sequences are compared to known genes’ nucleotide sequences. 
Each sequenced read is aligned (or assigned) to the genomic location with the highest 
level of similarity to it in that comparison. Each gene’s expression level is estimated based 
on the total number of sequenced reads that aligned to its transcribed regions.  
When using RNA-Sequencing to estimate a given sample’s gene expression 
levels, researchers will typically 1) isolate that sample’s total RNA or polyA+ RNA, 1a) 
remove rRNAs from total RNA (in cases where polyA+ RNA is not used), 2) fragment 
isolated RNA transcripts into a distribution of smaller fragments, 3) convert RNA 
fragments into dscDNA molecules, 4) ligate sequencing adaptors to those dscDNA 
molecules, 5) amplify dscDNA molecules that were properly ligated with sequencing 
adaptors (by targeting sequences in the adaptors) using PCR, 6) denature all residual 
dscDNA molecules, 7) hybridize a portion of those dscDNA molecules’ strands to a 
sequencing chip (via complementary basepairing between their sequencing adaptors 
and oligonucleotides on the chip), 8) generate sequenced reads of those dscDNA 
molecule’s bound strands via a sequencer-specific protocol, 9) align sequenced reads 
to an organism’s reference transcriptome and/or genome, and 10) use bioinformatic 
tools to estimate each gene’s expression level using the aligned sequenced reads. 
 





Next generation RNA-Sequencing has several advantages over DNA 
microarrays when measuring gene expression. First, RNA-Sequencing does not rely on 
probes generated using known (or predicted) RNA transcripts from an organism’s 
annotated reference transcriptome and/or genome. RNA-Sequencing thereby enables 
simultaneous detection of both annotated and novel RNA transcripts (including novel 
alternatively spliced RNA transcripts). Second, RNA-Sequencing can detect a much 
larger range of gene expression levels compared to a standard whole genome 
microarray (Mantione et al. 2014). Intriguingly, RNA-Sequencing doesn’t have known 
upper or lower limits for detecting gene expression levels (though detection of lowly 
expressed transcripts is intricately related to the number of sequenced reads generated 
as discussed later in this dissertation). Third, a given sample’s RNA-sequencing reads 
can be used to: estimate each annotated gene’s expression levels, estimate annotated 
exons’ expression levels, identify novel RNA transcripts (and novel alternatively spliced 
RNA transcripts), detect coding and non-coding RNA transcripts, identify single 
nucleotide variants (SNVs), detect insertions and deletions (indels), and identify gene 
fusion events (Mantione et al. 2014). Separate DNA microarrays must be custom-made 
to separately estimate each annotated exon’s expression level, identify SNVs, detect 
non-coding RNA transcripts, or reveal gene fusion events. Finally, a given sample’s 
RNA-Sequencing data can be re-analyzed as an organism’s annotated transcriptome 
and genome files are updated (Mantione et al. 2014). 
There are several disadvantages to using next generation RNA-Sequencing over 
DNA microarrays. First, most current RNA-Sequencing platforms preferentially generate 





(Mantione et al. 2014). This can occur even when a longer and shorter RNA transcript 
have equal expression levels in the studied biological sample. As gene expression 
estimates rely on the number of sequenced reads that align to each gene’s transcribed 
regions, this technical bias reduces the accuracy of those estimates. Mathematical 
corrections are often applied to account for this bias, but are unlikely to completely 
remove its effects. Second, the cost per sample is typically higher for an RNA-
Sequencing experiment compared to a DNA microarray experiment, especially when 
considering laboratory reagents and data storage. For a given sample, a typical RNA-
Sequencing data file is generally larger than 5 gigabytes (GB), whereas a typical DNA 
microarray file is usually <1 megabyte (MB) (Mantione et al. 2014). Third, analysis of 
RNA-Sequencing data generally requires more training and computer skills compared to 
analysis of microarray data (Mantione et al. 2014). All of these disadvantages will likely 
change as RNA-Sequencing technologies improve, much like what has been seen as 
microarray technologies were refined over the last 15 years.  
 
VIII. Gene expression studies and hypothesis testing: 
Gene expression studies compare measured gene expression levels between two 
or more groups, allowing identification of differentially expressed genes (DEG). DEGs are 
genes with statistically significantly different expression levels between groups. Over-
representation analyses can be used to infer a set of DEGs’ likely biological relevance. 
These analyses detect statistically significant associations between an input set of genes 





Gene expression studies comparing disease and control sample groups can 
identify DEGs specific to the disease group (or groups), and reveal cellular processes 
associated with those DEGs using over-representation analyses. This approach can 
uncover perturbed cellular processes that may reflect disease pathology, and enables 
researchers to form novel hypotheses about which genes in a list of DEGs may 
functionally impact those cellular processes.  
Selecting a candidate gene for hypothesis testing in downstream molecular biology 
experiments is rarely trivial, as gene expression studies often yield considerable options. 
Typically, researchers select a candidate gene that 1) was identified as a DEG, 2) was in 
a group of DEGs associated with cellular processes relevant to disease pathology, and 
3) has known structural or functional properties that could plausibly influence one of these 
cellular processes. 
Systems-level gene co-expression network analyses comparing disease and 
control sample groups provide separate criteria for candidate gene selection that can be 
used in conjunction with DEG analysis results. These analyses identify gene co-
expression networks, or sets of genes clustered together based on similarities in their 
measured gene expression levels across samples, associated with disease status. Co-
expressed genes are often functionally related, members of the same pathway or 
protein complex, or modulated by important regulatory transcriptional programs 
(Weirauch 2011). Genes comprising gene-co expression networks associated with 
disease status can be input to over-representation analyses, revealing cellular 
processes associated with those networks that may be relevant to disease pathology.  





(comprising each identified network) associated with disease status. They also predict 
highly connected network hub genes most likely to functionally regulate their network’s 
activities and associated cellular processes (Jeong, Mason, Barabasi, Oltvai 2001, 
Carter, Brechbuhler, Griffin, Bond 2004). Studies using gene co-expression network 
analyses have revealed networks associated with a polygenic trait and plausibly related 
cellular processes. Further, several of these networks’ hub genes were previously linked 
to the polygenic trait using separate molecular biology techniques (Kogelman et al. 2014, 
Maschietto et al. 2015). Arguably more compelling, Horvath et al. showed siRNA-
mediated reduction of Abnormal Spindle Microtubule Assembly (ASPM), a hub gene in a 
gene co-expression network associated with glioblastoma and mitosis, significantly 
reduced proliferation rates in glioblastoma tumor cells in vitro (Horvath et al. 2006). 
Hub genes in a gene co-expression network associated with both disease status 
and cellular processes plausibly related to disease pathology are strong candidates for 
hypothesis testing. Hypotheses about a given hub gene’s functional impact on these 
cellular processes can be tested using appropriate molecular biology assays in an in vitro 
or in vivo model system. Specifically, a researcher can test whether imitating a hub gene’s 
expression level as it was observed in their disease sample group perturbs a cellular 
process in a manner consistent with what is known about disease pathology.  
 
IX. Amyotrophic Lateral Sclerosis and its genetic epidemiology: 
Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease 





cord. The incidence of ALS in European populations is 2-3 people per year per 100,000 
of the general population over the age of 15 years, with men at a slightly higher risk 
than women (Al-Chalabi, Hardiman 2013). Clinical features vary considerably across 
ALS patients, but always involve progressive muscle weakness and paralysis. Muscles 
in the hands and feet (as well as those involved in speaking and swallowing) often 
atrophy early in disease progression. The average life expectancy after diagnosis is 
between 2-5 years, with patients dying of respiratory failure (as the neurons innervating 
their diaphrams and other respiratory muscles die) (Al-Chalabi, Hardiman 2013). 
Unfortunately, current drug treatments cannot stop ALS disease progression and only 
extend life by a few months.  
10% of patients report a first degree relative with ALS and receive a familial ALS 
(fALS) diagnosis, whereas the remaining 90% of patients report no family history 
(receiving a diagnosis of sporadic ALS [sALS]). Early familial aggregation studies, twin 
studies, and epidemiological studies suggested genetic factors contribute to both forms 
of ALS (Al-Chalabi et al. 2010, Chio et al. 2013, Fang et al. 2009, Wingo et al. 2011). 
While discerning fALS from sALS is extremely challenging using the traditional El 
Escorial clinical guidelines (Al-Chalabi 2013), genetic studies have revealed important 
differences between their molecular etiologies.  
fALS is transmitted in a Mendelian fashion. Bonafide causal mutations have been 
identified within 9 genes using classic linkage and/or next generation DNA sequencing 
techniques, and there is preliminary evidence for causal mutations in an additional 15 
genes to date (Renton, Chio, Traynor 2014). As sequencing costs decrease and more 





genes) is expected to grow. As of 2014, causal mutations in the 9 thoroughly 
substantiated ALS genes account for ~67% of fALS in Caucasian patients as of 2014 
(Renton, Chio, Traynor 2014).   
Interestingly, causal mutations in those same 9 genes only account for ~11% of 
sALS in Caucasian patients (Renton, Chio, Traynor 2014). While it is likely causal 
mutations residing in other genes account for some portion of the remaining sALS 
cases, the majority of sALS is suspected to have polygenic and environmental 
contributions (Al-Chalabi, Hardiman 2013, Hardiman, Greenway 2007).  Various 
exploratory approaches have been (and continue to be) adopted to elucidate sALS’ 
polygenic contributions.  
14 Genomewide association studies (GWAS) comparing allele frequencies at 
millions of single nucleotide polymorphisms (SNPs) in sALS cases vs. neurologically 
healthy controls have implicated numerous chromosomal regions, though only one 
association signal on chromosome 9 has been replicated across studies. That signal 
was instrumental in cloning Chromosome 9 Open Reading Frame 72 (C9ORF72), a gene that 
carries variable amounts of intronic repeat sequences across individuals. An excess number of 
repeats has been shown to cause ALS, and accounts for 7% of sALS in Caucasians as of 
2014 (Renton, Chio, Traynor 2014). Larger sample sizes in ALS GWAS will likely increase the 
number of identified and replicated signals moving forward, as has been observed in other 
neurodegenerative diseases (Hollingworth et al. 2011, Nalls et al. 2011). 
A recent study (Cirulli et al. 2015) compared whole exome sequencing data from 
2,874 ALS patients and 6,405 healthy controls in search of rare (likely deleterious) 





patients had fALS, whereas the rest of the patients had sALS. An excess of rare coding 
SNVs were discovered in 1) genes known to harbor fALS causal mutations and 2) 
genes associated with autophagy and neuroinflammation.  
Other studies focused on identifying de novo mutations in affected sALS patients 
that were absent in his/her parents. Early studies using this approach found de novo 
mutations known to cause fALS in sALS-affected offspring via sequencing individual 
genes of interest (Alexander et al. 2002, Chio et al. 2011). A more recent study (Chesi 
et al. 2013) surveyed sALS-affected offsprings’ protein coding regions for de novo 
mutations using whole exome sequencing. These researchers discovered sALS-
affected offspring had a statistically significant excess of de novo mutations in chromatin 
regulator genes. While replication and functional validation is needed, this is an 
interesting finding and represents a promising approach for identifying rare genetic 
variants in sALS patients that may be relevant to disease pathology. 
 
X. Scope of this dissertation project: 
 
In the subsequent chapters of this dissertation project, I will detail our lab’s ALS 
gene expression study comparing tissues from sALS patients and neurologically healthy 
controls. Our overarching goal was to identify sALS group-specific differences and their 
associated cellular processes that may be relevant to disease pathology.   
Broadly, we used RNA-Sequencing and selected bioinformatics analyses to 
compare gene (and exon) expression levels in postmortem cervical spinal sections from 





sALS group-specific differences. We relied on systems biology analyses to identify 
cellular processes associated with these sALS group-specific differences. We presumed 
sALS group-specific differences in select genes’ (or exons’) expression levels 
holistically induced changes in their associated cellular processes, and some of these 
changes may have functionally contributed to disease pathology. Finally, we used 
molecular biology techniques to assess whether overexpression of an identified hub 
gene’s expression level (as observed in our sALS sample group) perturbed an 
associated cellular process in a manner consistent with what is known about ALS 
pathology. Findings from this study have been used as rationale in the development of 
























CHAPTER 2: Tumor Necrosis Factor-mediated Inflammation is identified as a 





 A comprehensive review of ALS gene expression studies dating back to 2001 was 
recently published (Heath, Kirby, Shaw 2006). Tissue types compared between ALS and 
control samples included: human bicep muscle, human lymphocytes, human and rodent 
spinal tissue containing disease-vulnerable motor neurons, rodent gastrocnemius, and 
isolated human and rodent spinal motor neurons.   
There was a broad range in the number (14 to 1,182) and identity of ALS group-
specific DEGs discovered in each study. Interestingly, a recurrent set of associated 
cellular processes emerged across over-representation analyses using these sets of 
DEGs. These included oxidative stress, mitochondrial dysfunction, apoptosis, 
cytoskeletal architecture, inflammation, RNA processing, and protein aggregation. 
Separate molecular biology assays revealed various ALS tissues from human patients 
and rodents carrying fALS causal mutations showed increased oxidative damage 





1999, Chang et al. 2008), abnormal mitochondrial morphology (Sasaki and Iwata 2007, 
Sasaki and Iwata 1996, Hirano, Donnenfeld, Sasaki, Nakano 1984, Higgins, Jung, Xu 
2003, Kong and Xu 1998, Damiano et al. 2006, Mattiazzi et al. 2002), and elevated 
inflammation (Schiffer, Cordera, Cavalla, Migheli 1996, Nagy, Kato, Kushner 1994, Zhao, 
Beers, Appel 2013, Turner et al. 2004, Corcia et al. 2012, Henkel et al. 2004, Lewis et al. 
2014, Alexianu, Kozovska, Appel 2001, Henkel, Beers, Siklos, Appel 2006, Poloni et al. 
2000, Babu et al. 2008, Cereda et al. 2008, Elliott 2001, Hensley et al. 2002, Yoshihara 
et al. 2002). Increased inflammatory tumor necrosis factor (TNF-α) signaling (Poloni et al. 
2000, Babu et al. 2008, Cereda et al. 2008, Elliott 2001, Hensley et al. 2002, Yoshihara 
et al. 2002) in ALS tissues may have therapeutic relevance, as it is known to carry out 
cell fate decisions that may contribute to motor neuron death (Probert 2015). Further, 
elevated TNF-α signaling been previously shown to induce motor neuron death (He, Wen, 
Strong 2002, Robertson et al. 2001, Terrado et al. 2000). Taken together, it is likely 
aberrations in these cellular processes contribute to ALS onset, progression, and 
symptoms.  
Previous studies identified ALS group-specific gene co-expression networks 
associated with immune response, stress response, post-translational modifications, and 
neuroprotective processes (Holtman et al. 2015, Saris et al. 2009). Further, several of 
these networks’ predicted hub genes were shown to functionally impact a cellular process 
associated with their respective network. Glutathione synthetase (GSS) and Aconitase2 
(ACO2) both play important roles in stress response. GSS encodes a protein important 
for generation of glutathione, an antioxidant that prevents DNA damage from reactive 





preserving mitochondrial DNA integrity, and preventing mitochondrial-mediated apoptosis 
(Kim et al. 2014). AXL receptor tyrosine kinase (AXL) plays an important role in 
neuroprotective processes, and was recently implicated in microglial phagocytosis of 
apoptotic cells and myelin (Holtman et al. 2015). 
In this chapter, we used a combination of RNA-sequencing, bioinformatics tools, 
systems biology analyses, and in vitro molecular biology experiments to elucidate sALS 
group-specific nuclear gene expression level differences and assess their biological 
significance. Specifically, we set out to 1) identify cellular processes associated with sALS 
group-specific nuclear gene expression level differences that may be relevant to disease 
pathology, and 2) test hypotheses generated from those results assessing whether a 
network hub gene’s expression level was functionally related to apoptosis in relevant cell 
types in vitro.  
 
II. Methods: 
Biological samples used: Human cervical spinal section tissues from 7 ALS patients 
and 8 neurologically healthy controls were procured from the National Disease Research 
Interchange (Philadelphia, PA). We defined neurologically healthy controls as individuals 
that were not diagnosed with ALS or any other neurodegenerative disorder. In addition to 
ALS disease status, we received information about each individual’s age (at time of 
death), ethnicity, and gender. Unfortunately, we did receive information about any 
individual’s history of medication use or postmortem interval, which may have influenced 





human cervical spinal sections, as they included disease-vulnerable motor neurons (as 
well as astrocytes and microglia). 
Each sample’s frozen tissue embedded in OCT was shipped to us on dry ice. NDRI 
provided age, ethnicity, gender, and disease status data for each sample. On average, 
ALS patients were 67.71 years old at death (standard deviation of 7.99 years), whereas 
neurologically healthy controls were 69.75 years old at death (standard deviation of 11.29 
years). There was no statistically significant difference in age between the two groups as 
assessed by a Student’s T test (p=0.697). All 7 ALS patients were Caucasian, with 4 
Males and 3 Females. 6 of the neurologically healthy controls were Caucasian, and 2 
were African American. There were 4 males and 4 females in the neurologically healthy 
control sample group. Each sample’s age, ethnicity, and gender information can be found 
in Table 1. 
Total RNA isolation: For each sample, twenty 20-micron cross sections of cervical spinal 
tissue embedded in OCT were iteratively cut using a Cryostat. The cross sections were 
placed in a tube of Qiazol within the Cryostat, and then repeatedly passed through a 19G 
hypodermic needle attached to a 1 mL sterile syringe to lyse cell membranes. Total RNA 
was extracted following the miRNeasy Mini (Qiagen) kit workflow, including the optional 
on-column DNase treatment step to prevent downstream DNA-derived sequencing reads. 
Eluted total RNA was further purified using the RNeasy Micro kit (Qiagen) to remove 
organic contaminants. We elected to use total RNA (instead of polyA+ RNAs only) for 
generating RNA-sequencing libraries. This allowed us to measure pre-mRNAs, mRNAs, 
lncRNAs, tRNAs, and mitochondrial RNAs (mtRNAs). We selected the Qiagen miRNeasy 






                                Table 1: Sample demographics 
 Age Ethnicity Gender 
Patients    
ALS1 70 Caucasian Male 
ALS2 67 Caucasian Male 
ALS3 80 Caucasian Female 
ALS4 57 Caucasian Male 
ALS9 75 Caucasian Female 
ALS10 64 Caucasian Female 
ALS14 61 Caucasian Male 
    
Controls    
CTL6 80 African-American Male 
CTL8 67 Caucasian Female 
CTL16 66 Caucasian Female 
CTL22 54 Caucasian Male 
CTL23 65 African-American Female 
CTL24 83 Caucasian Male 
CTL25 59 Caucasian Male 










performed well at preserving RNA quality in a recent comparative analysis with other RNA 
isolation products (Sellin, Kiss, Smith, Oris 2014).  
For each sample, smaller RNA transcripts (<100 nucleotides) were lost in a 
purification step using the RNeasy Micro kit columns. This included miRNAs, piRNAs, 
siRNAs, snRNAs, and snoRNAs. We used this purification step as 1) organic 
contaminants may interfere with downstream rRNA removal, and 2) sequencing smaller 
RNA transcripts requires Illumina sequencing parameters (shorter single end reads) 
incompatible with those that best suited for our scientific questions. 
RNA quantification and quality assessments: Each sample’s isolated total RNA was 
next quantified using a Nanodrop 2000c spectrophotometer (Thermo Scientific), and its 
quality was assessed using the Experion automated electrophoresis system (Bio-Rad). 
Bio-Rad’s Experion calculated an RNA Quality Index (RQI) score for each sample via 
comparing three portions of the sample’s electrophoretic profile to a manufactured 
standard of degraded RNAs. RNA Quality Index (RQI) values ranged between 1-10, with 
increasing values representing higher quality RNA with less degradation. 
Sample inclusion criteria: We used 500 ng of high quality total RNA (RQI score ≥7) to 
construct each sample’s RNA-sequencing library. The Illumina Truseq® Stranded Total 
RNA HT kit required between 100-1,000 ng of total RNA per sample, and was designed 
to accept RNA with any level of degradation (RQI score 1-10).  
Using a larger amount of input total RNA buffers the inevitable loss of isolated RNA 
transcripts across the RNA-sequencing library preparation kit’s reaction and purification 





increases the chance of generating sequencing reads that preserve longer stretches 
(more nucleotides) of their originating RNA molecules. In general, these sequencing 
reads have a higher probability of aligning to the human genome in a downstream step 
compared to sequencing reads containing shorter stretches of their originating RNA 
molecules. 
Taken together, using a larger amount of high quality RNA for each sample likely 
increased 1) the number and variety of isolated RNA transcripts represented in their final 
RNA-Sequencing library, and 2) the proportion of their sequencing reads that aligned to 
the reference genome. Concurrently, this likely increased our downstream gene 
expression level estimates. 
RNA-Sequencing library preparation kit overview: We used the Illumina Truseq® 
Stranded Total RNA HT kit to generate each sample’s final RNA-sequencing library. This 
kit converted fragmented pieces of each sample’s isolated RNA transcripts into dscDNAs 
with Illumina sequencing adaptors ligated to their 5’ and 3’ ends, hereby referred to as 
sequenceable dscDNA molecules.  
Denatured strands from these sequenceable dscDNA molecules were bound to 
the Illumina NextSeq 500 flowcell and underwent amplification prior to sequencing. All 
details related to these processes are provided in a subsequent section. Ultimately, the 
Illumina NextSeq 500 workflow produced two sequencing reads from each bound strand 
that was amplified and sequenced, hereby referred to as Read 1 and Read 2. Each of 
these reads reported the identity of 150 nucleotides beginning at opposite ends of the 





sequenced reads were generated from in each sequenced strand. 
RNA-Sequencing library preparation kit workflow: The Illumina Truseq® Stranded 
Total RNA HT kit converted fragmented pieces of each sample’s isolated RNA 
transcripts into sequenceable dscDNA molecules. This multi-step process involved 1) 
removal of rRNAs from total RNA, 2) RNA fragmentation using divalent cations and 
heat, 3) dscDNA generation, 4) addition of a single A nucleotide to the 3’ end of both 
cDNA strands in each dscDNA molecule, 5) ligation of Illumina i5 and i7 sequencing 
adaptors with single T nucleotide overhangs to both ends of each dscDNA molecule, 
and 6) enrichment PCR amplification to increase the ratio of sequenceable dscDNA 
molecules to dscDNA molecules ligated with one or zero sequencing adaptors. DNA 
purification steps were performed after steps 3, 5, and 6. 
rRNA comprises 80-90% of total RNA in human cell types surveyed (O’Neil, Glowatz, 
Schlumpberger 2013; Wilhelm, Landry 2009). The Illumina Truseq® Stranded Total 
RNA HT kit removed rRNAs from each of our sample’s total RNA via Ribo-Zero 
technology shown in Figure 5. This rRNA removal step ensured 80-90% of our 
downstream RNA-sequencing reads didn’t correspond to rRNA transcripts. This 
involved 1) denaturing each sample’s total RNA, 2) hybridizing rRNA molecules to 
oligonucleotides (attached to magnetic probes) with complementary sequences, 3) 
placing all sample tubes on a magnet, and 4) allowing time for the magnetized beads 
(with attached rRNA-probe complexes) to be pulled to the side of each tube. Each 









Figure 4. Sequenceable dscDNA molecule and sequencing reads. This figure shows what 
part of the sequenceable dscDNA molecule strand is read to generate Read 1 and Read 2 
sequences. Part A shows a sequenceable dscDNA molecule generated by converting a fragment 
of a single stranded RNA transcript into a dscDNA molecule (blue dots) flanked by double 
stranded Illumina i5 (green dots) and i7 (yellow dots) sequencing adaptors. The sequenceable 
dscDNA molecule was denatured, enabling one or both of its denatured strands to bind to the 
Illumina NextSeq 500 flowcell. A PCR bridge amplification was performed, followed by NextSeq 
500 sequencing. Part B shows where Illumina NextSeq 500 sequencing reads 1 and 2 come from 










RNA transcripts were next fragmented to a size range between 120-220 
nucleotides (with a median fragment size of 150 nucleotides) using divalent cations and 
heat. Based on annotated (known) RNA transcripts in the hg19 human genome, the 
average length of a mature mRNA transcript is 2,227 nucleotides long (Kim et al. 2013). 
RNA fragmentation ensured sequenceable dscDNA molecules generated from isolated 
RNA transcripts were amenable to Illumina Nextseq 500 sequencing parameters using 
150 nucleotide reads. Fragmented RNAs were subsequently primed with random 
hexamers for first strand cDNA synthesis.  
First strand synthesis was performed using standard components (reverse 
transcriptase, reaction buffer, nucleotides) and Actinomycin D to prevent DNA-
dependent DNA synthesis. This increased the likelihood resultant sequencing data had 
a minimal number of reads derived from DNA molecules. 
Second strand synthesis using standard reagents (DNA polymerase, RNase H, 
reaction buffer, dATPs, dCTPs, dGTPs) and dUTPs in place of dTTPs was next. The 
DNA polymerase incorporated dUTPs instead of dTTPs into the second strand, thereby 
marking that strand. During a downstream enrichment PCR amplification step, that DNA 
polymerase didn’t incorporate nucleotides past the first dUTP it encountered in the 
second strand. This ensured only the first strand of cDNAs (antisense to the original 
RNA transcript it was reverse transcribed from) were ultimately sequenced. This 
allowed us to align each sequenced read to the DNA strand its corresponding RNA 
molecule was transcribed from. This was especially important for identifying antisense 
transcripts, determining which strand of lncRNAs was transcribed, and identifying 







Figure 5. Ribo-Zero technology. This figure shows a cartoon schematic of how ribosomal RNAs 
(rRNAs) are removed from each sample’s total RNA. DNase-treated total RNA is mixed together 
with rRNA removal solution. This solution contains magnetic rRNA removal probes carrying 
oligonucleotide sequences complementary to rRNA species. After these probes’ oligonucleotides 
hybridize to their complementary rRNAs in the total RNA mixture, magnetic beads are added into 
the entire solution. These magnetic beads bound the magnetic rRNA removal probes regardless 
of whether their oligonucleotides were hybridized to rRNAs or not. Tubes were then placed on a 
magnet, and RNAs unbound to these rRNA removal probes were collected for proceeding 










dscDNAs next underwent consecutive ligation-based reactions to add i5 and i7 
Illumina sequencing adaptors to their 5’ and 3’ ends. In the first reaction, a single dATP 
nucleotide was ligated to the 3’ end of both cDNA strands in each dscDNA molecule. 
Next, both ends of each dscDNA molecule were ligated to a double stranded i5 or i7 
Illumina sequencing adaptor via complementary dATP-dTTP hybridization. This was 
successful as these adaptors had single dTTP overhangs that complemented the 
dscDNA molecule’s single dATP overhangs. Each sample was assigned a different 
Illumina i5 sequencing containing a unique 8-nucleotide index sequence, and one 
identical i7 Illumina sequencing adaptor.  
As each sample’s sequenceable dscDNA molecules possessed a different 8-
nucleotide index sequence in their respective i5 adapters, we were able to mix multiple 
sample’s sequenceable dscDNA molecules together prior to Illumina NextSeq500 
sequencing. We could then denature and sequence denatured dscDNA strands from 
these multi-sample pools. Most importantly, resultant Read 1 and 2 sequencing reads 
generated from each sequenced strand could be assigned to their correct sample using 
that strand’s index sequence. 
The final step in this kit’s workflow involved an enrichment PCR amplification. 
This amplification used standard reagents (DNA polymerase, buffer, dNTPs), and 
served to increase the number of sequenceable dscDNA molecules relative to dscDNA 
molecules improperly ligated with one or zero sequencing adaptors. This ensured a 
negligible amount of unsequenceable denatured strands (from improperly ligated 





DNA purification steps were performed after steps 3, 5, and 6. These relied on 
Agencourt AMPure XP beads. Agencourt Ampure XP beads are paramagnetic 
polystyrene beads coated in carboxyl molecules. They are suspended in a solution 
containing polyethylene glycol and salt, as these components cause DNA to bind to the 
AMPure XP beads’ carboxyl groups provided proper stoichiometry. Specified amounts 
of the Ampure XP bead solution were added to each sample after the steps listed 
above. DNA molecules were given time to bind the paramagnetic beads. Sample tubes 
were next placed on a magnet, allowing the DNA-paramagnetic bead complexes to be 
pulled to the side of the tube. The supernatant was discarded, and the beads 
(complexed to DNA molecules) were washed twice with 70% ethanol. DNA molecules 
were finally eluted from the paramagnetic beads using 1X TE and gathered for the next 
step. 
Quality control: We next ran several quality control steps to ensure we generated high 
quality RNA-Sequencing libraries, as this increased the likelihood our downstream gene 
expression estimates were accurate. We assessed whether each sample had 1) the 
expected size distribution of sequenceable dscDNA molecules (mean fragment size 
around 260 basepairs) generated by the Illumina Truseq® Stranded Total RNA HT kit, 
and 2) comparable molar amounts of sequenceable dscDNA molecules across 
samples.  
We determined the size distribution of each sample's sequenceable dscDNA 
molecules using the BioRad Experion (Bio-Rad). We measured each library’s molar 
amount of sequenceable dscDNA molecules using a CFX96 Touch Real-Time PCR 





This kit provided qPCR amplification reagents for absolute quantitation, including 6 
standards containing different molar amounts of a 452-basepair DNA fragment ligated 
with Illumina sequencing adaptors to generate a standard curve.  
NextSeq 500 pre-sequencing steps: We employed Cofactor Genomics (St. Louis, 
MO) to perform two Illumina NextSeq 500 sequencing runs to generate all samples' 
sequencing data. Prior to the first run, we created a composite RNA-Sequencing pool 
by combining an equimolar amount of sequenceable dscDNA molecules from 6 of our 
samples. This same approach was used for the remaining 9 samples prior to the 
second run several months later. 
An aliquot of each pooled RNA-Sequencing library containing sequenceable 
dscDNA molecules was first denatured before being washed over the surface of a 
NextSeq 500 flowcell. The flowcell had two types of covalently bound oligonucleotides. 
The first type was complementary to each strand's Illumina i5 sequencing adapter, and 
the second type was complementary to each strand's Illumina i7 sequencing adapter. 
Approximately 400 million denatured strands attached to the flowcell via their i5 or i7 
Illumina sequencing adaptor hybridizing to a complementary oligonucleotide covalently 
bound to the flowcell surface. Figure 6A shows a denatured strand's i5 Illumina 
sequencing adaptor hybridizing to a complementary oligonucleotide covalently bound to 
the flowcell surface.  
DNA polymerase and unlabeled dNTPs (dATP, dCTP, dGTP, and dTTP) were next 
added to the flowcell. The polymerase extended each covalently bound oligonucleotide 





those in the denatured strand. This created a complementary copy of each denatured 
strand that hybridized an oligonucleotide bound to the flowcell. Further, each 
complementary copy was attached to the flowcell via the covalently bound oligonucleotide 
at its base. Each resultant double stranded molecule was then denatured, and the original 
denatured strand was washed away. These events can be seen in Figure 6B and 6C. 
Each covalently bound strand next underwent a three-step PCR bridge 
amplification process that can be seen in Figure 7. First, the free end of each strand 
physically bent over, allowing its Illumina i5 or i7 sequencing adaptor to hybridize to its 
complementary oligonucleotide covalently bound to the flowcell. Second, DNA 
polymerase and unlabeled dNTPs (dATP, dCTP, dGTP, dTTP) were added. The 
polymerase extended each recently hybridized covalently bound oligonucleotide, 
iteratively incorporating complementary nucleotides to the strand that just attached to it. 
Finally, resultant double stranded molecules were cleaved, causing the ends of each 
strand that were not covalently bound to the flowcell to be released. Both strands took on 
a vertical position.   
These three steps were iteratively repeated to generate each strand's cluster. A 
cluster is a clonal population of a single bound strand, comprised of up to one thousand 
covalently bound copies of it.  After the final bridge PCR amplification cycle was complete, 
the reverse strand from every double stranded molecule in each cluster was cleaved and 









Figure 6. Creation of a complementary copy of each denatured strand. This figure shows a 
cartoon schematic of how a denatured strand from a sequenceable dscDNA molecule hybridized 
to the flowcell (A), was copied (B), and was washed away (C). Its complementary copy remained 
attached to the flowcell via a covalently bound oligonucleotide at its base. Illumina; [accessed 
















Figure 7. PCR Bridge amplification of each covalently bound strand. This figure shows a 
cartoon schematic of (A) hybridization between a bound strand’s sequencing adaptor and a 
complementary flowcell oligonucleotide after the strand bent over, (B) a double stranded 
molecule after a complementary copy of that strand was generated, and (C) two covalently 
bound strands after their free (non-bound ends) were released from the flowcell. This three-step 
process was repeated to generate up to one thousand copies of the original bound strand. 















NextSeq 500 sequencing overview and Read 1 preparatory steps: The remaining 
steps of Illumina NextSeq 500 sequencing ultimately produced two sequencing reads for 
each bound strand that was clonally amplified to generate each cluster. These two 
sequencing reads, Read 1 and Read 2, each reported 150 nucleotides beginning at 
opposite ends of each bound strand's cDNA fragment. A visual depiction of these reads 
can be seen in Figure 4. 
Prior to beginning Read 1's "sequencing by synthesis" process, two types of 
sequencing primers were added to the flowcell. The first type was complementary to a 
portion of each strand's Illumina i5 sequencing adapter, and the second type was 
complementary to a portion of each strand's Illumina i7 sequencing adapter. A 
sequencing primer hybridized to a portion of the sequencing adapter (i5 or i7) in every 
strand's unbound end via complementary basepairing. An example of the first type of 
sequencing primer hybridizing to its complementary i5 sequencing adaptor in a strand's 
unbound end can be seen in Figure 8A. 
Read 1 "Sequencing by Synthesis": Read 1 acquisition involved 150 iterative 
"sequencing by synthesis" cycles following the same four steps.  First, DNA polymerase 
and 4 unique reversible terminator nucleotides complementary to each covalently bound 
strand’s dNTPs (dATP, dCTP, dGTP, dTTP) were added to the flowcell.  Each reversible 
terminator nucleotide was unique in that it emitted a different wavelength when excited 
by a laser in a downstream step. Second, each of the four fluorescently labeled reversible 
terminator nucleotides competed to extend the chain of nucleotides (beginning adjacent 
to the recently hybridized sequencing adaptor) towards the flowcell. Only the reversible 






Figure 8. Read 1 “Sequencing by Synthesis”. This figure shows a cartoon schematic of (A) 
hybridization between a bound strand’s sequencing adaptor and a complementary sequencing 
primer (purple circles), and (B) a close-up of that strand’s growing Read 1 oligonucleotide chain 
comprised of complementary reversible terminator nucleotides after the first 7 cycles. These 
reversible terminator nucleotides are color coded by their unique emission wavelengths when 










position was incorporated (with the exception of rare errors). Third, a laser was shone at 
every cluster on the flowcell. A detector recorded the emission wavelength (and signal 
intensity) from incorporated reversible terminator nucleotides at that position in every 
strand in every cluster. The signal-to-noise ratio for detection of reversible terminator 
nucleotides’ emitted wavelengths was improved in each cluster as a result of the strand’s 
clonal amplification.  Lastly, the inhibitor on each incorporated reversible terminator 
nucleotide was removed, allowing this iterative process to repeat until the 150th cycle 
was completed. A cartoon depiction of a Read 1 molecule after the first 7 cycles can be 
seen in Figure 8B. 
Index Read acquisition: Index read acquisition involved 8 iterative “sequencing by 
synthesis” cycles, enabling us to retrieve the 8-nucleotide index sequence in the i5 
sequencing adapter of every strand in every cluster. As mentioned in a previous section, 
each of our samples was assigned a different Illumina i5 sequencing adapter containing 
a unique 8-nucleotide index sequence (and an identical Illumina i7 sequencing adapter) 
following generation of dscDNAs.  Retrieving the index sequence in each strand's i5 
sequencing adapter allowed us to determine which sample that sequenced strand came 
from. More importantly, it enabled us to determine which sample Read 1 and Read 2 
sequencing reads (generated from that same strand) belonged to. 
Prior to the 8 “sequencing by synthesis” cycles, the recently generated chain of 
150 nucleotides (corresponding to Read 1) hybridized to each covalently bound strand in 
each cluster was washed away. An index sequencing primer complementary to a portion 
of each strand's i5 sequencing adaptor was added to the flowcell, and allowed time to 





Eight iterative “sequencing by synthesis” cycles were carried out following the 
same four steps.  First, DNA polymerase and 4 unique reversible terminator nucleotides 
complementary to each covalently bound strand’s dNTPs (dATP, dCTP, dGTP, dTTP) 
were added to the flowcell.  Each reversible terminator nucleotide was unique in that it 
emitted a different wavelength when excited by a laser in a downstream step. Second, 
each of the four fluorescently labeled reversible terminator nucleotides competed to 
extend the chain of nucleotides (beginning adjacent to the recently hybridized index 
primer) towards the flowcell. Only the reversible terminator nucleotide complementary to 
the covalently bound strand's dNTP at each position was incorporated (with the exception 
of rare errors). Third, a laser was shone at every cluster in the flowcell. A detector 
recorded the emission wavelength (and signal intensity) from incorporated reversible 
terminator nucleotides at that position in every strand in each cluster. The signal-to-noise 
ratio for detection of reversible terminator nucleotides’ emitted wavelengths was improved 
in each cluster as a result of the strand’s clonal amplification. Lastly, the inhibitor on each 
incorporated reversible terminator nucleotide was removed, allowing this iterative process 
to repeat until the 8th cycle was completed. 
Read 2 preparation and acquisition: Prior to beginning Read 2’s “sequencing by 
synthesis” process, the recently generated chain of 8 nucleotides (corresponding to the 
index read) hybridized to each covalently bound strand in each cluster was washed away. 
The remaining steps prior to Read 2 acquisition can be seen in Figure 9.  
First, the free end of each strand then physically bent over, allowing its Illumina i5 
or i7 sequencing adaptor to hybridize to its complementary oligonucleotide covalently 





dTTP) were added. The polymerase extended each recently hybridized covalently bound 
oligonucleotide, incorporating nucleotides complementary to the strand that just attached 
to it. Finally, resultant double stranded molecules were cleaved, causing the ends of each 
strand that were not covalently bound to the flowcell to be released. Both strands took on 
a vertical position.    
Each resultant forward strand was cleaved and washed away. The remaining 
reverse strand remained unaltered. Two types of sequencing primers were added to the 
flowcell. The first type was complementary to a portion of each strand's Illumina i5 
sequencing adapter, and the second type was complementary to a portion of each 
strand's Illumina i7 sequencing adapter. A sequencing primer hybridized to a portion of 
the sequencing adapter (i5 or i7) in every reverse strand's unbound end via 
complementary basepairing.  
Read 2 acquisition involved 150 iterative “sequencing by synthesis” cycles 
following the same four steps as Read 1 acquisition. Each covalently bound reverse 
strand used for Read 2 acquisition was an inverted complementary copy of the strand 
used for Read 1 acquisition. Read 2 thereby began at the opposite end of each bound 
strand’s cDNA fragment (directly adjacent to the Illumina i5 or i7 adaptor) relative to where 
Read 1 began. 
Data processing, FastQ files, and phred scores: Proprietary Illumina software 
algorithms were used to process the emission wavelength and signal intensity from 
incorporated reversible terminator nucleotides at every position in every strand in every 













Figure 9. Steps prior to Read 2 “Sequencing by Synthesis”. This figure shows a cartoon 
schematic of (A) the covalently bound strand used for Read 1 generation after its index read was 
washed away, (B) hybridization between this strand’s sequencing adaptor and a complementary 
flowcell oligonucleotide after the strand bent over, (C) a double stranded molecule after a 
complementary copy was generated, (D) two covalently bound complementary strands after their 
free (non-bound ends) were cleaved from the flowcell, (E) removal of the forward strand, and (F) 
hybridization of a Read 2 sequencing primer to the bound strand’s sequencing adaptor prior to 















was clonally amplified to generate each cluster, corresponding Read 1 and Read 2 150 
nucleotide sequences (hereby referred to as a paired end read) were reported. Each 
paired end read was assigned to the correct sample using their sequenced strand’s index 
read. 
For each sample, all paired end reads’ Read 1 and Read 2 sequences were sent 
in separate FastQ text files. Each Read 1 and Read 2 sequence reported the identity of 
all 150 sequenced nucleotides and each nucleotide’s associated PHRED quality score. 
This PHRED quality score signified the probability that nucleotide’s reported identity was 
the result of a sequencing error. Table 2 details several possible PHRED scores and their 
corresponding error probabilities.  
FastQC for initial quality check: Each sample’s FastQ files were separately input into 
FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) to identify data 
quality issues pertaining to the sequencer and/or the RNA-Sequencing library itself. 
Quality was assessed across a range of metrics including average PHRED quality score 
per position across reads, overall GC content, sequence length distribution, 
overrepresented sequences, and duplicate read frequency.  
Processing of sequencing reads prior to alignment: For each sample, we processed 
all paired end reads to increase their probability of aligning to the hg19 human reference 
genome in a proceeding step. A small portion of each sample’s paired end reads were 
generated from sequenced strands containing a cDNA fragment <150 nucleotides in 
length. 150 nucleotide Read 1 and Read 2 sequencing reads generated from these 





                                Table 2: PHRED quality scores 





Nucleotide is Accurate 
10 1 in 10 90% 
20 1 in 100 99% 
30 1 in 1000 99.9% 
40 1 in 10,000 99.99% 




















Further, nucleotides towards the 3’ end of Read 2 sequencing reads are known to have 
lower PHRED scores as a result of Illumina sequencing chemistry degradation towards 
the end of a run.  
For each paired end read, we used Trimmomatic (Bolger, Lohse, and Usadel 
2014) to remove nucleotides 1) belonging to Illumina i5 or i7 sequencing adaptors 
and/or 2) with a PHRED score <20 found in the 3’ end of their Read 1 or Read 2 
sequences. This ensured paired end reads didn’t fail downstream alignment to the hg19 
human reference genome because they contained 1) Illumina sequencing adaptor 
nucleotides that didn’t match any sequence in the hg19 human reference genome or 2) 
an excess of incorrectly identified nucleotides (as a result of sequencing errors) that 
didn’t match the hg19 human reference genome. We only retained reads that were ≥ 50 
nucleotides in length after removing these select nucleotides. Each sample’s processed 
Read 1 and Read 2 sequences were output into new Read 1 and Read 2 fastQ text files 
for downstream analyses. 
FastQC for pre-alignment quality check: Each sample’s Read 1 and Read 2 fastQ text 
files output by Trimmomatic were separately input into FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) to ensure Illumina 
sequencing adaptor sequences were successfully removed, and the average PHRED 
score for nucleotides towards the 3’ end of Read 2 sequencing reads increased. 
Alignment of paired end reads: We selected Tophat2 (Kim et al. 2013), an open 
source program specially designed for RNA-Sequencing data, to attempt alignment of 
each sample’s paired end reads to the hg19 human reference transcriptome then hg19 





(known RNA transcripts) and genome (known primary sequence) text files from the 
Illumina iGenomes UCSC hg19 directory on the Tophat2 webpage 
(https://ccb.jhu.edu/software/tophat/igenomes.shtml).  
In the context of this RNA-Sequencing experiment, alignment involved comparing 
the nucleotide sequences of each paired end read (Read 1 and 2) to the nucleotide 
sequences of all known RNA transcripts, 22 autosomes, X chromosome, Y chromosome, 
and mitochondrial genome. Each paired end read’s alignment reflected what part of the 
genome that paired end read’s corresponding RNA molecule was transcribed from.  
A paired end read qualified for alignment if it did not exceed Tophat2’s default 
quality thresholds for the number of nucleotides that 1) didn’t match the reference genome 
(as a result of biological variation and/or sequencing errors), or 2) were not present in the 
reference genome. 
Prior to Tophat2’s first step, we used the Burrows-Wheeler Aligner (Li and Durbin 
2010), an open source software program, to align 5 million of each sample’s paired end 
reads to the hg19 human reference transcriptome. This allowed us to estimate the 
average size (and standard deviation) of cDNA fragments in each sample’s sequenced 
strands. Tophat2 creators reported their software aligns a larger number of each sample’s 
paired end reads to the hg19 human reference transcriptome and genome when these 
calculated metrics are provided relative to when they are not. 
For each sample, Tophat2 attempted to align each paired end read (Read 1 and 
Read 2 from each sequenced strand) to the hg19 human reference transcriptome then 





attempted to align (or map) each paired end read to all known transcripts in the hg19 
human reference transcriptome. If the complete sequences of both reads in a paired end 
read mapped within the boundaries of a known transcript, that paired end read was 
aligned to that transcript. Second, Tophat2 attempted to map each unaligned paired end 
read to all known exons in the reference genome. If the complete sequences of both reads 
in a paired end read mapped within the boundaries of a known exon, that paired end read 
was aligned to that exon.  
Prior to the next step, Tophat2 generated a list of putative spliceosome splice sites 
(GT and AG) across introns in the hg19 human reference genome. Third, Read 1 and 
Read 2 in each unaligned paired end read were broken into smaller segments no greater 
than 25 nucleotides in length. Tophat2 attempted to align these segments to all known 
exons in the hg19 human reference genome. If multiple segments from a given paired 
end read mapped to exons separated by one or more introns flanked with putative splice 
sites, those segments were aligned to those exons. Fourth, Tophat2 concatenated 
sequences flanking putative splice sites in the hg19 human reference genome, and then 
attempted to map all unaligned segments to them. These concatenated sequences did 
not belong to known exons in the genome. Aligned segments in steps 3 and/or 4 were re-
joined to make full-length reads. Fifth, TopHat2 attempted to re-map any portion of an 
aligned paired end read mapped to an intron to exonic sequence. For each sample, 
Tophat2 output an accepted_hits.bam file reporting where each aligned paired end read 
mapped in the genome.  
Calculation of sequencing alignment metrics: We used Picard Tools 






Figure 10. Tophat2 alignment of each sequenced read. This figure shows a cartoon schematic 
of Tophat2’s method for aligning a RNA-Sequencing read to a reference transcriptome then 
genome. This illustration depicts alignment of a single end read (equivalent to a Read 1 in our 






alignment metrics for each sample’s aligned paired end reads. For each sample, Picard 
Tools reported: the total number of sequenced nucleotides (contained in their paired end 
reads) that Tophat2 attempted to align to the hg19 human reference genome, the % of 
sequenced nucleotides that were successfully aligned to the hg19 human reference 
genome, the % of sequenced nucleotides that aligned to mRNA species, the % of 
sequenced nucleotides that aligned to rRNA, tRNA, or mtRNA species, and the % of 
sequenced nucleotides that aligned to intronic or intergenic regions.  
For each sample, Picard Tools calculated these metrics via comparing aligned 
paired end reads to 1) the Illumina iGenomes refFlat text file that contained all known 
RNA transcripts, introns, and intergenic regions in the hg19 human reference genome, 
and 2) an interval file I created containing known rRNA, tRNA, and mtRNA transcripts in 
the hg19 human reference genome. 
fALS causal point mutation analysis: We assessed whether any of our sALS samples 
carried any of 471 known pathogenic coding variants (contained across 21 different 
genes) mutually reported to cause fALS in three separate databanks (Abel, Powell, 
Andersen, Al-Chalabi 2013, Landrum et al. 2014, Stenson et al. 2014). All of these genes 
have been reported to carry mutations that cause ALS in a recent publication (Renton, 
Chio, Traynor 2014). This involved using a variety of open source bioinformatic software 
programs including the Genome Analysis Tool Kit (GATK) (McKenna et al. 2010, DePristo 
et al. 2011, Van der Auwera et al. 2013), STAR (Dobin et al. 2013), and Picard Tools 
(http://picard.sourceforge.net). For each sALS sample, GATK identified qualifying 






This pipeline involved 1) attempting to align each sALS sample’s paired end reads 
to the hg19 human reference genome using STAR, 2) removing each sALS sample’s 
paired end reads that aligned to an identical genomic location, 3) re-assigning PHRED 
scores to all nucleotides in each sALS sample’s remaining aligned paired end reads, and 
4) identifying each sALS sample’s sequence variants that passed GATK’s default quality 
filters.  
We used STAR, an open source program specially designed for RNA-Sequencing 
data, to attempt to align each sALS sample’s paired end reads to the hg19 human 
reference genome. STAR used each sALS sample’s Read 1 and Read 2 FastQ files from 
Trimmomatic as input, and output a file containing their aligned paired end reads for 
downstream analysis. The GATK developers recommended STAR over Tophat, as it 
yielded a higher proportion of validated sequence variants within their pipeline in an 
unpublished comparative analysis.  
We used Picard Tools to remove each sALS sample’s paired end reads that 
aligned to an identical genomic location (aka duplicate reads). For each qualifying 
genomic location, one aligned paired end read was retained for downstream analysis. 
This step was taken as duplicate reads can result from PCR amplification reactions during 
RNA-Sequencing library preparation as opposed to transcriptional events that occurred 
in that sample’s tissues. Further, sequencing variants identified in such duplicate reads 
may reflect a PCR artifact (i.e. a DNA polymerase erred and that nucleotide was 






GATK next re-assigned a PHRED score to every nucleotide in each sALS sample’s 
remaining aligned paired end sequencing reads. GATK reported Illumina sequencing 
workflows assign biased PHRED scores to select nucleotides depending on what cycle 
that nucleotide was sequenced and what nucleotides preceded it. GATK re-assigned new 
PHRED scores to nucleotides that were likely affected by these biases, and did not alter 
other nucleotides’ PHRED scores. 
Finally, GATK identified each sALS sample’s qualifying sequence variants using 
all remaining aligned paired end reads. A sequence variant qualified for identification if it 
1) had a GATK GQ score of ≥20 (indicating a 99% or better chance the identity of that 
reported sequence variant was correct at that genomic position), and 2) passed all 
GATK’s default quality filters designed to prevent false positives from technical artifacts. 
These default quality filters disqualified sequence variants if there was evidence for 
technical bias related to 1) sequencing depth, 2) where the sequence variant was located 
in aligned paired end reads containing it, and 3) the quality of alignment for all aligned 
paired end reads containing that sequence variant. GATK output a text file for each 
sample listing all their identified sequence variants. We used these lists to determine 
whether any sALS sample contained a sequence variant that represented any of the 471 
pathogenic fALS mutations. 
Gene expression estimate overview: For each sample in this study, a given gene’s 
expression level reflected the quantitative amount of its RNA transcripts in that sample’s 
postmortem cervical spinal sections. For a given sample, we presumed each gene’s 
expression level was preserved by a proportionate number of paired end reads that 





illustrated in Figure 11. Our downstream gene expression estimates relied on this 
presumption. For each sample, we estimated gene expression levels for all annotated 
genes in the hg19 human reference genome using several bioinformatics workflows 
described in later sections of this document.  
Illumina NextSeq 500 sequencing parameters and accuracy of gene expression 
estimates: Relative to single end sequencing, paired end sequencing has been shown 
to increase both the accuracy of downstream gene expression estimates (Salzman, 
Jiang, Wong 2011) and the number of detected splice sites (Chhangawala, Rudy, Mason, 
Rosenfeld 2015). Relative to shorter read options, longer reads (≥100 nucleotides) have 
been shown to increase both the number of aligned sequenced reads (Cho et al. 2014) 
and detected splice sites (Chhangawala, Rudy, Mason, Rosenfeld 2015). These findings 
support our decision to use Illumina NextSeq500 paired end 150 nucleotide reads as 
opposed to single end (or shorter paired end) reads, and likely increased the accuracy of 
our downstream gene expression estimates. 
In an RNA-Sequencing study, the total number of sequenced reads obtained for a 
given sample is positively correlated with 1) the likelihood genes with lower expression 
levels are represented in their sequencing data, and 2) how accurate their gene 
expression estimates are likely to be. These relationships reflect Illumina’s (and many 
other sequencing platform’s) sampling procedure, where denatured strands from only a 
portion of each sample’s sequenceable dscDNA molecules are sequenced. These 
concepts are illustrated in Figure 12.  









Figure 11. Presumption underlying our gene expression estimates. This figure shows a 
cartoon schematic of the presumption underlying our gene expression estimates. On the left are 
a biological sample’s RNA transcripts from three different genes (color-coded red, blue, and 
yellow). Each gene’s RNA transcripts were converted into a proportional amount of sequenceable 
dscDNA molecules. In the middle, these molecules’ denatured strands hybridized to all the 
available spots (or covalently bound complementary oligonucleotides) on the NextSeq500 
flowcell. Those spots are color-coded by what gene’s denatured strands bound to them. On the 
right is the sample’s paired end reads color-coded by which gene they aligned to, with read 1 and 
read 2 sequences on the left and right of the black dash marks, respectively. For this sample, 
each gene’s expression level was preserved in their sequencing data. 50%, 40%, and 10% of the 











Figure 12. Read count and detection of lowly expressed genes. This figure illustrates how 
increasing the number of paired end reads obtained for a given sample is positively correlated 
with 1) the likelihood a gene with a low expression level is represented in their sequencing data, 
and 2) how accurate gene expression estimates are likely to be.  The top and bottom half of the 
figure shows what happens when a smaller or larger amount of sequencing reads are generated 
for a given sample, respectively. On the left are a biological sample’s RNA transcripts from three 
different genes (color-coded red, blue, and yellow). Each gene’s RNA transcripts were converted 
into a proportional amount of sequenceable dscDNA molecules. In the middle top half of the 
figure, denatured strands from the sample’s more highly expressed genes (red and blue) 
hybridized to the smaller number of flowcell spots allotted to this sample. This occurred as a result 
of their being more prevalent relative to denatured strands from the yellow gene, and thereby 
being more likely to bind the flowcell. In the middle bottom half of the figure, denatured strands 
from all three genes hybridized to the larger number of flowcell spots allotted to this sample. On 
the right are paired end reads from each scenario. Each paired end read is color-coded by the 
gene it aligned to, and Read 1 and Read 2 sequences are on the left and right of the dash mark, 
respectively. In the top half of the figure, the lowly expressed yellow gene didn’t have any 
corresponding aligned paired end reads in the dataset. Further, the blue and red genes’ aligned 
paired end reads made up 65% and 35% of their sequencing data, while their RNA transcripts 
made up 55% and 45% of this sample’s total RNA. In the bottom scenario, each gene’s expression 
level was accurately preserved in their sequencing data. 55%, 45%, and 5% of the total RNA 







input total RNA (after rRNA-depletion) offers a comparable detection level for protein 
coding genes relative to a standard Agilent DNA microarray (Zhao et al. 2014). There is 
not a consensus number of RNA-sequencing reads one should appropriate to each 
sample to achieve highly accurate gene expression estimates for very lowly expressed 
genes. An early study proposed 200 million reads per sample was necessary to detect 
the full range of expressed human RNA transcripts, including those from very lowly 
expressed genes (Tarazona et al. 2011). The ENCODE (Encyclopedia of DNA elements) 
consortium more recently generated 214 million 100 nucleotide paired end reads per 
sample from H1 human embryonic stem cells and performed a saturation analysis 
(Djebali et al 2012). They reported 36 and ~80 million paired end reads per sample were 
necessary to accurately estimate genes with expression levels corresponding to FPKM 
values of >10 and <10, respectively. A recent study (Marinov et al. 2014) related the 
number of RNA transcript copies in single GM12878 cells to reported FPKM values, and 
found one transcript copy per cell corresponds to an FPKM value of approximately 10. 
Annotated genes with FPKM values <10 thereby average less than one transcript copy 
per cell, but are expressed in enough of our spinal cells for detection.  
Sequencing depth, biological replicates, and DEG identification: Provided a study 
goal of identifying DEGs between groups and a limited budget, researchers will often 
decrease the number of sequenced reads per sample while increasing the number of 
biological replicates per group. DEG identification analyses model intra-group variability 
in each gene’s aligned sequenced read counts across samples prior to inter-group 
comparisons to identify DEGs. Including more biological replicates per group enables 





number of DEGs identified between groups. A recent analysis revealed ~72% more DEGs 
(6,000 vs. 3,500) were identified when comparing MCF7 breast cancer cell groups 
(treated or untreated with 17β-estradiol) comprised of 7 samples vs. 3 samples (Liu, Zhou, 
White 2014). Every MCF7 breast cancer cell line sample had 30 million total sequenced 
reads in that study. Another study (Zhang et al. 2014) reported a similar increase (~59%) 
in the number of DEGs identified when comparing lymphoblastoid cell line groups 
comprised of 8 samples vs. 3 samples. This study showed further expanding each 
lymphoblastoid cell line groups’ size from 8 to 14 biological replicates increased the 
number of identified DEGs by only ~12.5% (2000 vs. 2250). This suggests diminishing 
returns in how many additional DEGs are identified when including more than 8 biological 
replicates per group. Taken together, these findings supported our decision to acquire 
>55 million paired end reads per sample, and compare 7 sALS samples to 8 
neurologically healthy control samples for DEG identification. 
HTSeq-Count: We used HTSeq-Count (Anders, Pyl, Huber 2015), an open source 
program specially designed for RNA-Sequencing data, to report the total number of paired 
end reads that aligned to each annotated gene’s transcribed regions. A paired end read 
was counted for an annotated gene if the majority (or all) of its Read 1 and Read 2 
sequences aligned to that gene’s transcribed regions. Figure 13 shows various 
hypothetical alignments of a sequenced read to a fictitious gene_A, and whether HTSeq-
Count would count that sequenced read. For each sample, HTSeq-Count produced a 
matrix with all annotated genes and their corresponding paired end read count values.  
EdgeR and DEG identification:  We used EdgeR (Robinson, McCarthy, Smyth 2010), 





group specific DEGs. EdgeR first normalized each sample’s paired end read counts (from 
HTSeq-Count) for each annotated gene, producing pseudo counts. Annotated genes’ 
pseudo counts in our sALS and neurologically healthy control sample groups were then 
directly compared to identify sALS group-specific DEGs. 
EdgeR followed a multi-step process to normalize each annotated genes’ paired 
end read counts across samples. This process involved mathematical normalizations 
accounting for 1) differences in the total number of paired end read counts between 
samples, 2) differences in RNA species represented in each samples’ sequencing data, 
and 3) overdispersion in annotated genes’ paired end read counts across samples. 
Differences in the total number of paired end read counts between samples could 
reflect each sample’s total number of RNA-Sequencing reads as opposed to differences 
in annotated genes’ expression levels. Assume two of our samples’ RNA-Sequencing 
libraries had an equal number of sequenceable dscDNA molecules corresponding to a 
given annotated gene (suggesting that gene had an equal expression level in both 
samples’ postmortem cervical spinal sections). 
If more total sequencing reads were generated for one of those samples, that 
sample’s sequencing data would likely have more total paired end read counts align to 
that annotated gene’s transcribed regions relative to the other sample. This is because 
denatured strands from that annotated gene’s sequenceable dscDNA molecules were 
appropriated more Illumina NextSeq500 binding spots (covalently bound 
oligonucleotides) to potentially hybridize to for sequencing. For each sample, we used 







Figure 13. HT-Seq count scenarios. This figure shows a visual schematic of various 
hypothetical alignments of a sequenced read (in teal) to a fictitious gene_A’s transcribed regions. 
HT-Seq Count would count that sequenced read for gene_A in scenarios A-E. It would not count 
the sequenced read for gene_A in scenarios F-G, as it is unclear whether that read’s 
corresponding cDNA fragment was generated from gene_A or gene_B. While these scenarios 
depict a single end sequenced read (equivalent to a Read 1 in our study), the counting process 
is the same for each paired end read. The program considers the same criteria (the proportion of 
a sequenced read aligning to a given gene’s transcribed regions) for counting.   Counting reads 






transcripts comprising each sample’s input total RNA varied. Differences in a given 
annotated gene’s aligned paired end read counts across samples could reflect varying 
RNA compositions in each sample’s total input RNA (and Illumina’s sampling procedure) 
as opposed to gene expression differences. This concept is illustrated in Figure 14. 
RNA-Sequencing data is often overdispersed. This means the variance of 
sequenced read counts aligned to each gene across each group’s samples often exceeds 
what is expected using a Poisson distribution. Use of the Poisson distribution to model 
sequenced read counts across each group’s samples could lead to a large number of 
false positives in downstream DEG analyses. EdgeR used a negative binomial 
distribution to model each annotated gene’s paired end read counts across each group’s 
samples to better account for this variance.  
EdgeR then estimated the level of dispersion (using conditional maximum 
likelihood modeling) for each annotated gene and all annotated genes together. An 
empirical Bayes’ theorem was used to moderate overdispersion via shrinking each gene’s 
level of dispersion towards the consensus dispersion calculated from all annotated genes 
together. 
EdgeR replaced each annotated genes’ original paired end read counts across 
samples with pseudo counts that incorporated all of the above normalizations. An exact 
test (analogous to a Fisher’s Exact test with modifications to suit data modeled using a 
negative binomial distribution) was used to directly compare each annotated gene’s 






Figure 14. RNA composition differences and gene expression estimates. This figure shows 
the effects of RNA composition differences between samples on a given gene’s expression 
estimates. On the left are two biological samples’ RNA transcripts from three different genes (red, 
blue, and yellow). Each gene’s RNA transcripts were converted into a proportional amount of 
sequenceable dscDNA molecules. In the middle, these molecules’ denatured strands hybridized 
to all the available spots (or covalently bound complementary oligonucleotides) on the 
NextSeq500 flowcell. Those spots are color-coded by what gene’s denatured strands bound to 
them. On the right are each sample’s paired end reads color-coded by which gene they aligned 
to. Read 1 and read 2 sequences are on the left and right of the black dash marks, respectively. 
While both samples had an equal number of RNA transcripts from the yellow gene, sample A 
would have a higher yellow gene expression estimate as a result of having more paired end reads 
aligned to it. The blue and red genes were expressed at a higher level in sample B relative to 
sample A, and the blue gene’s corresponding denatured strands bound more spots on the 
flowcell. This led to the yellow gene’s denatured strands being under sampled in sample B, and 








EdgeR reported an associated p-value for each annotated gene tested. We calculated 
each annotated gene’s Benjamini-Hochberg corrected p-value from their EdgeR reported 
p-value via the R function p.adjust. Each annotated gene with a Benjamini-Hochberg 
corrected p-value < 0.10 was identified as a sALS group-specific DEG. 
We used EdgeR’s default workflow for our DEG analysis. We decided to filter out 
genes with a cpm (counts per million aligned paired end reads) value <1 in 7 samples. 
We chose a cpm value of 1 as smaller values likely reflected noise. We chose 7 samples 
as our threshold, as genes that were only expressed in our disease or control group could 
play an important role in disease pathology.  
DESeq2 and DEG identification: We used DESeq2 (Love, Huber, Anders 2014), an 
open source program specially designed for RNA-Sequencing data, to detect sALS 
group-specific DEGs. DESeq2 first normalized each sample’s paired end read counts 
(from HTSeq-Count) for each annotated gene. Normalized paired end read counts in our 
sALS and neurologically healthy control samples were then directly compared to identify 
sALS group-specific DEGs. 
DESeq2 followed a multi-step process to normalize each sample’s paired end read 
counts for each annotated gene. This process involved mathematical normalizations 
accounting for 1) differences in the total number of paired end read counts between 
samples, 2) overdispersion in annotated genes’ paired end read counts across samples, 
and 3) high variance in gene expression fold change values for annotated genes with low 
paired end read counts across samples.  





variance in each annotated genes’ paired end read counts across each group’s samples. 
Unlike EdgeR, DESeq2 calculated the level of dispersion for each annotated gene and 
annotated genes with similar expression levels across samples. DESeq2 applied an 
empirical Bayes’ theorem to moderate overdispersion via shrinking each gene’s level of 
dispersion towards the level of dispersion estimated for genes with a similar expression 
level.  
Each annotated gene’s normalized paired end read counts across each group’s 
samples were used to calculate a log transformed fold change value between groups via 
a maximum likelihood model. Log fold change values for annotated genes with a small 
number of paired end read counts across both groups’ samples are often artificially high, 
owing to a low signal-to-noise ratio. To mediate this, DESeq2 applied an empirical Bayes 
procedure to shrink all annotated genes’ log fold change estimates towards zero, applying 
more shrinkage to genes with low paired end read counts across samples. This reduced 
the chance of false positives in downstream DEG analyses.  
To identify sALS group-specific DEGs, DESeq2 applied a Wald test where each 
annotated gene’s shrunken log fold change value was divided by its standard error. 
Resultant Z-scores were compared to a normal distribution, and a corresponding p-value 
was generated. We took all annotated genes’ corresponding p-values, and calculated 
corresponding Benjamini-Hochberg corrected p-values using the R function p.adjust. 
Each annotated gene with a Benjamini-Hochberg corrected p-value < 0.10 was identified 
as a sALS group-specific DEG. 





2010), an open source program specially designed for RNA-Sequencing data, to estimate 
each sample’s gene expression levels for all annotated genes in the hg19 human 
reference genome. Prior to estimating each annotated gene’s expression level for each 
sample, Cufflinks calculated each sample’s size distribution of cDNA fragments (in their 
sequenced strands) using their aligned paired end reads. This data was used in a 
downstream step. Cufflinks then followed a 5-step process to estimate each annotated 
gene’s expression level for each sample. 
For a given annotated gene, Cufflinks first identified a given sample’s aligned 
paired end reads whose corresponding cDNA fragments (in their sequenced strands) 
were necessarily generated from different RNA transcripts. This step used maximum 
likelihood statistical modeling. Second, Cufflinks used probabilistic modeling (relying on 
a proof of Dilworth’s theorem) to identify the minimum number of RNA transcripts that 
accounted for that annotated gene’s aligned paired end reads. RNA transcripts identified 
in this step included annotated transcripts in hg19 human reference transcriptome and/or 
novel transcripts. Third, Cufflinks used an algorithm to probabilistically assign each 
aligned paired end read to the RNA transcript its corresponding cDNA fragment was 
generated from. The algorithm used the sample’s calculated distribution of cDNA 
fragment sizes (in their sequenced strands) as well as the annotated genes’ RNA 
transcript splicing structures to accomplish this. Any aligned paired end read whose 
corresponding cDNA fragment could have been generated from more than one RNA 
transcript was assigned to each of those RNA transcripts. This process is illustrated in 





Four, Cufflinks estimated that annotated gene’s RNA transcript expression levels. 
This involved using a statistical model where the probability of observing each transcript’s 
assigned paired end reads from the previous step was linearly related to each transcript’s 
expression level. Maximum likelihood equations calculated the most probable quantitative 
expression levels for that annotated gene’s RNA transcripts. Each transcript’s expression 
level was reported in normalized gene expression units called FPKMs (Fragments Per 
Kilobase of exon per Million fragments mapped) whose calculation is explained in a 
proceeding section. Finally, Cufflinks estimated that annotated gene’s expression level 
by summing all of its RNA transcripts’ FPKM values together.  
We did not include each sample’s paired end reads that aligned to rRNA, tRNA, 
mtRNA, or unannotated transcripts in our transcript expression estimates. This prevented 
RNA composition differences between samples leading to false positives or negatives in 
our downstream Cuffdiff2 DEG analysis. The effects of RNA composition differences 
between samples on gene expression can be seen in Figure 14.  
Cufflinks’ FPKM gene expression units: The Illumina Truseq® Stranded Total RNA HT 
kit broke each sample’s isolated RNA transcripts into 120-220 nucleotide fragments (with 
a median size of 155 nucleotides) prior to generating sequenceable dscDNA molecules. 
For each sample, the length of a given isolated RNA transcript was positively correlated 
with both 1) the number of fragments generated from it, and 2) the number of 
corresponding sequenceable dscDNA molecules generated from its fragments. Relative 
to shorter RNA transcripts, longer RNA transcripts were generally more likely to have a 
greater number of corresponding paired end reads (and paired end read counts). This 






Figure 15. Cufflinks assignment of individual paired end reads to a given annotated gene’s 
RNA transcripts. On the left, this figure shows a visual schematic of Cufflinks assignment of 
individual paired end reads (dumbbell shaped objects of various sizes) to a given annotated 
gene’s three RNA transcripts (colored yellow, purple, and pink and located just above the words 
“Transcript coverage and compatibility”). Paired end reads are color-coded by the transcript they 
aligned to. Black paired end reads could not be exclusively assigned to one RNA transcript. The 
violet paired end read was originally assigned to either the purple or pink transcript. As that sample 
did not have many sequenced strands with large cDNA fragments (as indicated by the cDNA 
fragment length histogram on the right side of this figure), the violet paired end read was ultimately 












of Illumina NextSeq 500 binding spots (covalently bound oligonucleotides) for 
sequencing. Estimating each sample’s gene expression levels using aligned paired end 
reads counts alone could thereby lead one to falsely conclude genes with longer RNA 
transcripts were expressed at a higher level relative to genes with shorter RNA 
transcripts. 
To address this issue, Cufflinks reported all transcript (and gene) expression levels 
in normalized expression units called FPKM’s as opposed to paired end read counts. Any 
given FPKM value was calculated using the equation FPKM = C/LN. C is the number of 
paired end reads that aligned to that gene’s transcribed regions (or to that transcript). L 
is the length of that gene’s transcribed regions (or the transcript itself) in kilobases. N is 
the number (in millions) of sequenced reads acquired for that sample. The FPKM 
measurement accounted for differences in the length of each gene’s transcribed regions 
(or the length of a given transcript), as well as the total number of sequenced reads for 
each sample. The importance of normalizing for differences in the total number of 
sequenced paired end reads and its influences on gene expression estimates are 
described in the EdgeR section. Figure 16 illustrates the advantage of FPKM 
measurements over paired end read counts for accurate expression estimates. 
Cuffdiff2 for DEG identification: We used Cuffdiff2 (Trapnell et al. 2013), an open 
source program specially designed for RNA-Sequencing data, to detect sALS group-
specific DEGs. For each annotated gene, Cuffdiff2 first performed normalizations of its 
transcripts’ FPKM values (from Cufflinks) across samples in our sALS and neurologically 
healthy control groups. Representative FPKM values were calculated for our sALS and 










Figure 16. Transcript length, raw read count, and FPKM values. This figure shows paired end 
read counts vs. FPKM values for four different genes (numbered 1-4) from a hypothetical sample. 
Above each gene are the sample’s aligned sequenced reads. Gene 1 and 2 have equally sized 
transcribed regions, yet gene 2 was more highly expressed in that sample as evidenced by more 
aligned sequenced reads. Both paired end read counts and FPKM values accurately reflected the 
expression difference between genes 1 and 2. Genes 3 and 4 have different sized transcribed 
regions, but were equally expressed in that sample. However, gene 4 has many more aligned 
paired end reads as a result of generating many more denatured strands (from sequenceable 
dscDNA molecules) that bound to the flowcell for sequencing. FPKM values accurately reflected 
genes 3 and 4 as equally expressed by normalizing for their different sized transcribed regions. If 
one were to use the raw read count measurements for genes 3 and 4, they would falsely report a 














Cuffdiff2 applied mathematical normalizations to RNA transcripts’ FPKM values 
that accounted for 1) differences in the total number of assigned paired end reads to RNA 
transcripts across samples in each group, 2) uncertainty associated with Cufflinks’ 
assignment of each paired end read to an RNA transcript, and 3) overdispersion in RNA 
transcripts’ FPKM values across each group’s samples.  
Cuffdiff2 used a mathematical normalization that accounted for differences in the 
total number of paired end reads assigned to RNA transcripts between samples in each 
group. This was the same normalization EdgeR used to account for differences in the 
total number of paired end reads aligned to annotated genes across samples. Rationale 
for this normalization step and its influences on expression level estimates are the same 
for transcripts as they are for genes, and can be seen in the EdgeR section.  
It has been observed that up to 50% of a given sample’s aligned sequenced reads 
can be assigned to more than one RNA transcript in an annotated gene (Trapnell et al. 
2013). This makes sense as human genes’ RNA transcripts often share large amounts of 
sequence, and many genes have paralogs with highly similar sequences. For every 
sample, Cuffdiff2 used a beta distribution to statistically model the level of uncertainty 
associated with each paired end read’s assignment to an RNA transcript. 
Like paired end read counts, FPKM values for each RNA transcript across each 
group’s samples are often overdispersed. This means the variance of each transcript’s 





Poisson distribution. Cuffdiff2 used a negative binomial distribution to model each RNA 
transcript’s FPKM values across each group’s samples to better account for this variance.  
Cuffdiff2 applied an algorithm mixing results from the beta and negative binomial 
distributions for each RNA transcript’s FPKM values across each group’s samples. 
Resultant beta negative binomial distributions accounted for variability in each RNA 
transcript’s FPKM values owing to 1) uncertainty associated with Cufflinks’ assignment of 
each paired end read to an RNA transcript, and 2) overdispersion in RNA transcripts’ 
FPKM values across each group’s samples.   
For each annotated gene, Cuffdiff2 calculated representative FPKM values for our 
sALS and neurologically healthy control sample groups. For each sample group, this 
involved statistically accounting for the mean, variance, and covariance of all of its 
transcripts’ normalized FPKM values across samples. Cuffdiff2 then calculated an 
expression ratio (fold change) by dividing the sALS sample group’s representative FPKM 
value by the neurologically healthy control sample group’s representative FPKM value. 
Log-transforming this expression ratio generated a test statistic that followed a standard 
normal distribution when divided by its variance. Cuffdiff2 then conducted a two-sided t 
test to assess the significance of the test statistic, and reported an associated p-value for 
that annotated gene. When an annotated gene had a representative FPKM value of zero 
in one of our groups, a one-sided t test was conducted. We took all annotated genes’ 
corresponding p-values, and calculated their Benjamini-Hochberg corrected p-values 
using the R function p.adjust. Each annotated gene with a Benjamini-Hochberg corrected 





Weighted Gene Co-Expression Network Analysis (WGCNA): We used WGCNA 
(Langfelder, Horvath 2008) to identify gene co-expression networks statistically 
associated with our sALS sample group. WGCNA followed a 6-step process to predict 
which genes were co-expressed, cluster them into gene networks, test which gene 
networks were associated with disease status, and aid our selection of hub genes. The 
mathematical formulas used in each step are not included in this description, but can be 
found in an earlier publication (Zhang, Horvath 2005). 
First, WGCNA calculated an adjacency matrix (a gene network) that reported a 
correlation value between every pair of genes’ expression values across all 15 samples. 
This analysis presumes the higher the correlation value between a pair of genes, the 
more likely they are functionally connected. Once the adjacency matrix was constructed, 
summation of any individual gene’s correlation values to all other genes reflected its level 
of overall connectedness. 
Second, the adjacency matrix was raised to a software-determined exponential 
power determined by the input dataset. This served to reduce noise by pushing lower 
pairwise gene correlation values closer to zero relative to higher values. The exponential 
power used was the lowest value needed to ensure the network approximated scale-free 
topology. In this context, scale-free topology was satisfied when a small number of genes 
(hub genes) were highly connected to other genes, whereas the majority of genes were 
weakly connected to other genes. Many biological (including gene co-expression) 
networks have demonstrated scale-free topology (Zhang, Horvath 2005), and specifically 
manipulating these networks’ highly connected members modulated cellular processes 





Brechbuhler, Griffin, Bond 2004). This step laid the foundation for identification of hub 
genes within smaller modules (networks) of interest later in this analysis.  
Third, the adjacency matrix was transformed into a topological overlap matrix by 
calculating topological overlap (TOM) scores for each gene. This score accounted for 
each pair of genes’ connection strength (adjacency value) to each other as well as their 
connection strengths (adjacency values) to every other gene in the adjacency matrix. 
Higher TOM scores indicated a pair of genes was more likely connected to each other 
and a shared set of other genes. 
Fourth, WGCNA identified gene co-expression networks (or modules) via average 
linkage hierarchical clustering using a dissimilarity score (1-TOM score for every gene) 
as a measure of distance. The resultant dendrogram of clustered genes was segregated 
into individual modules with at least 30 genes using WGCNA’s dynamic tree-cutting 
algorithm (Langfelder, Horvath 2008).  
Fifth, WGCNA calculated each module’s eigengene, or first principle component, 
using all samples’ gene expression values for all genes in each module. A module 
eigengene was considered a summarized expression profile representative of that 
module.  Each module’s eigengene was then correlated against every other module’s 
eigengene. If two or more modules’ eigengenes had a correlation value >.75, those 
modules were merged together to form a larger module. Module eigengenes were re-
calculated at this stage and the process was repeated until no two modules’ eigengenes 





Finally, each module eigengene was tested for statistical association to our 
provided phenotypic traits. We assessed whether each module’s eigenegene was 
associated with disease status, gender, or age. P-values based on the Student’s t-test 
were reported, and are equivalent to a Wald test in a univariable linear regression model.  
For all samples, we input a filtered list of 13,301 genes and their Cufflinks FPKM 
values. All of these genes had an FPKM value >2 in at least 7 samples. We chose an 
FPKM of 2 as smaller values more likely reflected noise.  We chose 7 for our sample 
threshold as genes that were only expressed in our sALS or neurologically healthy control 
sample group could play an important role in disease pathology. We log-transformed 
these FPKM values using log2 (FPKM value +1) as recommended on the WGCNA FAQ’s 
page 
(http://labs.genetics.ucla.edu/horvath/CoexpressionNetwork/Rpackages/WGCNA/faq.ht
ml) prior to analysis.  
Our analysis was guided by steps 1, 2b, and 3 in the R Tutorial listed under I. 
Network analysis of liver expression data from female mice: finding modules related to 
body weight from the WGCNA website 
(http://labs.genetics.ucla.edu/horvath/CoexpressionNetwork/Rpackages/WGCNA/Tutori
als/).  
We deviated from the tutorial several times. We generated a signed weighted 
adjacency matrix as opposed to the default unsigned weighted network. We chose this 
option to preserve the directions of every pair of genes’ correlation, as a positive 





biological repression. Unsigned networks did not preserve the direction of correlation. We 
used the bicor (biweight midcorrelation) correlation in place of the Pearson correlation to 
construct our adjacency matrix and determine the exponential value necessary to 
approximate scale-free topology. We chose this option as we had a small sample size, 
and biweight midcorrelations are more robust to outliers compared to Pearson 
correlations (Langfelder, Horvath 2012). We added the flag 
corOptions=list(maxPOutliers=0.1)) to further reduce outlier effects. 
WGCNA hub gene identification: We identified module hub genes using WGCNA’s 
intramodular connectivity and modular membership scores calculated for every gene in 
each prioritized module. The intramodular connectivity score reflected the cumulative 
connection strength a given module gene had with all other module genes. The modular 
membership score reflected how representative that gene’s expression values were of 
the module as a whole. 
Hub genes typically have large values for both of these metrics. We considered 
each gene’s gene significance score to further prioritize one hub gene over another. This 
score reflected how strongly a given gene’s expression values correlated with disease 
status in our set of samples.  
Ingenuity Pathway Analysis: We used QIAGEN’s Ingenuity Pathway Analysis to assess 
what canonical signaling pathways, diseases/disorders, and upstream regulators 
(molecules known to influence various genes’ expression levels) were statistically 
significantly associated with each of our prioritized gene sets. For each prioritized gene 





set that were separately associated with each canonical signaling pathway, 
disease/disorder, and upstream regulator in the IPA Knowledge base. Association p-
values relating each prioritized gene set to each tested canonical signaling pathway, 
disease/disorder, and upstream regulator were reported.  
In Vitro models for hypothesis testing: For hypothesis testing, we relied on in vitro 
models using neural stem cells and iPSC-derived motor neurons. Neural stem cells are 
precursors of the cervical spinal cell populations (astrocytes, microglia, and motor 
neurons) that we isolated RNA from for each sample. We opted for in vitro cell models 
over transgenic animals carrying a fALS causal point mutation. We suspect findings in 
these cells models would more accurately reflect what occurs in sALS patients’ disease-
vulnerable cervical spinal cells in vivo, as recent studies show the majority of sALS is not 
caused by a monogenic mutations (Renton, Chio, Traynor 2014). 
Neural stem cell derivation and maintenance: Donor blood mononuclear cells were 
reprogrammed to a pluripotent state and neuralized as previously described (O’Brien, 
2015).  The resulting neural stem cells (NSC) were maintained in a dividing state on 
Geltrex (Life Technologies, Grand Island, NY) coated tissue culture ware in NSC Growth 
Medium [KnockOut DMEM/F-12 containing 2 mM GlutaMAX-I supplement, 20 ng/mL 
human recombinant basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), 
2% StemPro neural supplement, 100 ug/mL pyruvate and 50 ug/ml uridine]. NSC were 
grown at 37C in a 5% CO2 incubator with the oxygen concentration held at 5%, and 






NSC treatment groups and transfection: 24 hours before the MTT assay, media was 
exchanged for five groups of NSC cultures with Optimem Media (Thermo-Scientific) 
containing 1) Fugene HD reagent alone, 2) Fugene HD reagent + GFP plasmid, 3) 
Fugene HD reagent + 100 ngs TNFAIP2-IRES-GFP plasmid, 4) Fugene HD reagent + 
100 ngs TNFAIP2-IRES-GFP plasmid + 75 uM caspase 8 inhibitor, or 5) Fugene HD 
reagent + 100 ngs TNFAIP2-IRES-GFP plasmid + 75 uM caspase 9 inhibitor. They were 
then incubated as described in the above section.  
The TNFAIP2-IRES-GFP plasmid can be seen in Figure 17. The GFP plasmid only 
differed in not possessing the TNFAIP2 and internally ribosome entry site (IRES) 
cassettes. Both plasmids were complexed with FuGENE HD Transfection Reagent 
(Promega) according to manufacturer instructions prior to transfection. The cell 
permeable caspase inhibitors used (Sigma Aldrich) were peptides that irreversibly bound 
to the catalytic sites of their respective activated caspases. Each of the 5 NSC treatment 
groups consisted of eight independent cell cultures. Experiment done in collaboration with 
Jim Bennett and Paula Keeney. 
Exposing NSCs to TNF-, Isolating RNA, and qPCR 
48 hours before harvest, medium was exchanged on 80% confluent NSC cultures 
with 1% DMSO (Sigma, St. Louis) in NSC growth medium and incubated as above.  24 
hours before harvest, medium was exchanged with 1% DMSO or 100 ng/mL HumanKine 
Tumor Necrosis Factor- (Sigma) in growth medium and incubated.  After 24 hours, cells 
were lifted using TrypLE (Life Technologies), washed, and each pellet sonicated in 350 
ul Buffer RLT Plus (Qiagen, Valencia, CA). RNA was isolated using an AllPrep DNA/RNA 






Figure 17. TNFAIP2-IRES-GFP plasmid. This figure shows the TNFAIP2-IRES-GFP plasmid. 
The internal ribosome entry site (IRES) cannot be seen, but is located between the TNFAIP2 and 














assessed using a BioRad Experion Electrophoresis Station and a Standard Sensitivity 
Chip.  All samples had a RQI value of 9.5 or higher.  1300 ng of RNA from each sample 
were reverse transcribed to dscDNA using an iScript kit (Bio-Rad, Hercules, CA) 
according to directions. Forward (FP) and reverse primers (RP) for SybrGreen detection 
were designed by Beacon Designer v 8.12 (Premier Biosoft, www.PremierBiosoft.com) 
using human gene cDNA sequences downloaded from PubMed, and were synthesized 
by Operon. qPCR reactions (including forward and reverse primers at 250 nM and 
standard qPCR reagents) were run on the BioRad CFX96. The BioRad CFX96 
automatically detected cycle threshold (Ct) values for each of our 9 DEGs in each tested 
sample. 
Gene normalization was carried out using Qiagen RT2 Profiler Human 
Housekeeping gene plates, with each cDNA tested in duplicate for expression of the 12 
housekeeping genes. qbasePLUS software (BioGazelle, www.Biogazelle.com) was 
used to determine the most stable genes (GAPDH, RPL13A, RPL3O) across all 
experiments. The geometric means of these three genes’ expression levels in each cDNA 
sample were used to normalize expression of the nine DEGs examined by qPCR. 8 
independent NSC cultures were run. Experiment done in collaboration with Jim Bennett 
and Paula Keeney. 
iPSC generation and neural Induction: Integration-free iPSCs were generated from 
peripheral blood mononuclear cells (MNC) from a neurologically healthy, Caucasian male 
donor (aged 62) using a previously described protocol (Dowey et al. 2012) with 
modifications (O’Brien, Keeney, Bennett 2015). Briefly, the pEB-C5 and pEB-Tg plasmids 





(Lonza, Allendale, NJ).  After three weeks, viable colonies were expanded in mTeSR 
medium on Geltrex (Life Technologies) coated plates. Neuralization of iPSCs was 
accomplished using PSC Neural Induction Medium (Life Technologies) according to the 
protocol with modifications (Amoroso et al. 2013). All cultures were maintained at 37°C in 
a humidified CO2 incubator with the oxygen level held at 5%.  
Motor neuron differentiation and transfection: Neuralized iPSCs were grown in neural 
induction media containing DMEM/F12 with 0.2 μM LDN-193189 (LDN; Stemgent), 10 
μM SB431542 (SB; Stemgent), 10 ng/mL BDNF (R&D systems), 0.4 ug/mL L-ascorbic 
acid (Sigma), 2 mM GlutaMAX-I supplement, 1% N-2 supplement, and 1% nonessential 
amino acids (NEAA). Two days later, 1 μM retinoic acid was added. On day four, LDN/SB 
was stopped and 1 μM smoothened agonist (SAG; Calbiochem) and 0.5 μM PM were 
added. On day 14, cells were switched to neurobasal media containing 2 mM GlutaMAX-
I, 2% B-27, 1% NEAA, 0.4 ug/mL AA, 10 ng/mL GDNF (R&D), 10 ng/mL CNTF (R&D). 
Media was replaced every 2-3 days. All cell culture materials were purchased from Life 
Technologies. All cultures were grown at 37°C in 5% oxygen and 5% CO2 conditions. We 
found motor neurons had a ~15-22 fold increase in expression of motor neuron specific 
markers HB9 and ISL1 at day 21, suggesting successful differentiation (O’Brien, Keeney, 
Bennett 2015). 
On day 21 of differentiation, iPSC-derived motor neuron cultures were transfected 
with 100 ngs of TNFAIP2-GFP plasmid or GFP plasmid. The TNFAIP2-GFP plasmid was 
different from the TNFAIP2-IRES-GFP plasmid mentioned above, in that it did not contain 





Both of these plasmids were complexed with FuGENE HD Transfection Reagent 
(Promega) according to manufacturer instructions prior to transfection.  
Real-time quantitative PCR (qPCR): We used qPCR to measure TNFAIP2 expression 
in our iPSC-derived motor neuron groups transfected with either TNFAIP2-GFP plasmid 
or the GFP plasmid. RNA was extracted from iPSC-derived motor neuron cultures with 
the RNeasy Plus Micro Kit (Qiagen) according to manufacturer instructions. Quantification 
of isolated RNA was performed using a Nanodrop 2000c spectrophotometer (Thermo 
Scientific). RNA was reverse transcribed into dscDNA using the iScript cDNA synthesis 
kit (BioRad). For qPCR, 50 ngs of dscDNA per well was loaded into a 96-well plate and 
analyzed with the CFX96 Real Time PCR Detection System (BioRad). All samples were 
analyzed in triplicate. Data was normalized to the geometric mean of two reference genes 
determined to have the greatest stability using the software qbasePLUS-GeNorm 
(BioGazelle; 14.3.3.Z and CYC1). Statistics were calculated using an unpaired two-
sample Welch’s t-test in Prism software (GraphPad, Prism).  
MTT assay: After 24 hours, cell viability was measured in our transfected NSC and iPSC-
derived motor neuron cultures using the In Vitro Toxicology Assay Kit, MTT based 
(Sigma, TOX1) according to manufacturer instructions. For each tested culture, this 
colorimetric assay measured the amount of yellow water-soluble substrate 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) that was converted to 
formazen. This served as a proxy for cell viability, as this conversion process is carried 
out by living cells’ mitochondrial dehydrogenases. Experiments done in collaboration with 





FLICA® 660 Activated Caspase 3/7 Assay: After 24 hours, activated Caspase 3/7 
levels, markers of apoptosis, were measured in iPSC-derived motor neuron cultures using 
the FLICA® 660 Caspase 3/7 Assay Kit (ImmunoChemistry Technologies) according to 
manufacturer instructions. This involved measuring each culture’s amount of fluorescent 
antibodies specific to activated Caspases 3 and 7 that bound to their respective proteins. 
For quantification, cells were fixed and 10 representative fields were taken with an 
Olympus FV1000 confocal microscope. Images were analyzed using MetaMorph image 
analysis software (Molecular Devices) and pixel intensity was normalized to the number 
of cells per image. Cells were identified by DAPI nuclear staining. 
III. Results 
Sequencing metrics: We collected >55 million paired end reads per sample using the 
Illumina NextSeq500. Picard’s CollectRNASeqMetrics (http://picard.sourceforge.net) 
reported the following averaged metrics across samples: 68,613,940 paired end reads, 
65.62% of sequenced nucleotides that passed Tophat2’s filters and aligned to the hg19 
reference genome, 33.23% of nucleotides that aligned to mRNA species, 29.01% of 
sequenced nucleotides that aligned to rRNA, tRNA, or mtRNA species, and 37.76% of 
nucleotides that aligned to intronic/intergenic regions. Individual samples metrics can be 
found in Table 3.  
          Our samples’ averaged % of sequenced nucleotides aligning to mRNA and 
intronic/intergenic regions was highly similar to what has been observed in other RNA-
Sequencing studies using total RNA to construct RNA-Sequencing libraries (Ameur et al. 





Sequencing data quality: For each sample, we used FastQC to assess the quality of 
all paired end reads’ Read 1 and Read 2 sequences prior to and after Trimmomatic 
processing. All samples’ paired end reads passed FastQC’s quality assessments before 
and after Trimmomatic processing. Trimmomatic processing successfully increased 
each sample’s average PHRED quality scores for nucleotides towards the 3’ end of 
their Read 2 sequences, and removed all Illumina sequencing adaptor sequences from 
Read 1 and Read 2 sequences. Figure 18 shows ALS1’s analyzed Read 2 sequences 
before and after Trimmomatic processing. These results are representative of what we 
observed for all samples. 
Presence of known fALS mutations in our sALS samples’ sequenced reads: As of 
2014, 11% of sALS in Caucasian patients was accounted for by causal mutations in 9 
different loci (Renton, Chio, Traynor 2014). Causal fALS mutations have been identified 
in at least 13 other genes, and may account for a larger proportion of sALS in Caucasian 
patients (Renton, Chio, Traynor 2014, Abel, Powell, Andersen, Al-Chalabi 2013). We 
assessed whether any of our sALS samples carried any of 471 known pathogenic coding 
variants contained in 21 different genes shown in Table 4. ELP3 was not included, as it 
did not have any qualifying pathogenic variants in any of the three databanks surveyed. 
We discovered an sALS sample (ALS4) carried a pathogenic variant from this list. 
This variant is a missense mutation (A4V) in the Superoxide Dismutase 1 (SOD1) gene, 
and was found in nearly half of ALS4’s paired end reads (754/1576) that aligned to that 
portion of SOD1. This suggests there was no transcriptional preference for the wildtype 
or mutant DNA sequence. No other fALS pathogenic variants were found in ALS4 or the 
















patient and control samples. We did not remove ALS4 from our sALS sample group in 
downstream analyses despite this finding. A recent review (Heath, Kirby, Shaw 2013) of 
ALS gene expression studies dating back to 2001 revealed various sALS and fALS tissue-
specific DEGs were associated with a recurrent set of cellular processes including 
oxidative stress, mitochondrial dysfunction, apoptosis, cytoskeletal architecture, 
inflammation, RNA processing, and protein aggregation. Despite varying genetic 
etiologies, it appears fALS and sALS share a convergent set of perturbed cellular 
processes, which could explain why distinguishing fALS from sALS using traditional 
clinical guidelines is extremely challenging (Al-Chalabi, Hardiman 2013). Inclusion of 
ALS4 is thereby unlikely to hinder our ability to identify cellular processes that may be 
perturbed in sALS and relevant to disease pathology.  
DEG Testing and associated cellular processes: We elected to identify sALS group-
specific DEGs using Cufflinks/Cuffdiff2, DESeq2, and EdgeR. In a direct comparison, all 
three analyses showed different limitations in DEG identification after analyzing the same 
benchmark datasets (Zhang et al. 2014). EdgeR identified the most DEGs, but also 
reported the most false positive DEGs. DESeq2 identified the fewest DEGs when input 
samples had different numbers of total sequencing reads. Cuffdiff2 identified the fewest 
DEGs when each sample had less than 20 million total sequencing reads. The authors 
recommended a conservative approach of using at least two (if not all three) analyses to 
identify DEGs, and proceeding with DEGs mutually reported by multiple analyses to avoid 
pursuing false positives DEGs. We will likely learn more about which of these DEG tests 
is most accurate via future comparative analyses using larger benchmark datasets with 





















Figure 18. FastQC analyses of ALS1’s Read 2 sequences before and after Trimmomatic 
processing. This figure shows FastQC plots of the average PHRED quality score per position 
across all of ALS1’s Read 2s before (A) and after (B) Trimmomatic processing, and the presence 
of Illumina sequencing adaptor nucleotides per position across all of ALS1’s Read 2s before (C) 
and after (D) Trimmomatic processing. The x axes in all plots report the nucleotide position in 
analyzed Read 2s. The Y axes in A and B are PHRED quality scores. The blue lines that extend 
from left to right in A and B represent the average PHRED quality score across nucleotide 
positions in analyzed Read 2s. The Y axes in C and D are percentages of nucleotides that 















# of Known 
Pathogenic 
Coding Mutations 
   
ALS2 2q33 15 
ANG 14q11 36 
ATXN2 12q24 3 
C9orf72 9p21 1 
CHMP2B 3p11 5 
DCTN1 2p13 6 
FIG4 6q21 5 
FUS 16p11 66 
HNRNPA1 12q13 2 
HNRNPA2B1 7p15 1 
NEFH 22q12 9 
OPTN 10p13 19 
PFN1 17p13 8 
SETX 9q34 10 
SOD1 21q22 199 
SPG11 15q14 1 
SQSTM1 5q35 16 
TARDBP 1p36 44 
UBQLN2 Xp11 12 
VAPB 20q13 3 







as RNA-Sequencing technologies and analytics mature. 
At an FDR of .10, 74 sALS group-specific DEGs (56 upregulated and 18 
downregulated) were mutually identified using Cuffdiff2, DESeq2, and EdgeR. Figure 19 
shows a Venn diagram comparing the numbers of DEGs identified across and between 
analyses at an FDR of .10.  Cuffdiff2 identified significantly more DEGs at an FDR of <.10 
compared to the other two analyses. We suspect this is largely a result of 
Cufflinks/Cuffdiff2 employing a considerably different approach to estimating and 
comparing gene expression levels compared to the other two analyses.  
These 74 DEGs, their Cuffdiff2 fold change values (sALS group relative to our 
neurologically healthy control group), representative FPKM values for the ALS and 
neurologically healthy control sample groups, and FDR corrected p-values are listed in 
Table 5. QIAGEN’s Ingenuity Pathway Analysis revealed our 74 DEGs were associated 
with multiple canonical signaling pathways, disease/disorders, and upstream regulators 
related to inflammatory cellular processes. TNF-α was identified as an upstream 
regulator. These IPA results are shown in Table 7. 
To avoid false negatives, we identified all DEGs reported at an FDR of <.01 by any 
of the three analyses. QIAGEN’s Ingenuity Pathway Analysis revealed those 200 DEGs 
were also associated with multiple canonical signaling pathways and upstream regulators 
related to inflammatory cellular processes. TNF-α was identified as an upstream 
regulator. Those IPA results are shown in Table 8. 
 
WGCNA and the black module: We used WGCNA to identify gene modules, or 
networks, from our dataset. This unsupervised technique identified 37 interconnected 





without using 1) information about what genes have been shown to interact in previous 
literature, or 2) information about which samples were from our sALS or neurologically 
healthy control groups. These modules can be seen in Figure 20. Two of these modules 
(MEblack and MEsienna4) were associated with sALS disease status at an uncorrected 
p-value <.01. These modules were not significantly associated with age or gender. They 
can be seen in Table 6.  
Interestingly, QIAGEN’s Ingenuity Pathway Analysis revealed the 495 genes 
comprising the module most strongly correlated to sALS disease status (MEblack, 
R=0.68, p=0.006) were associated with multiple canonical signaling pathways, 
disease/disorders, and upstream regulators related to inflammatory cellular processes. 
TNF-α was identified as an upstream regulator. These results can be seen in Table 7.  
As these IPA results were highly similar to those for our sALS group-specific 
DEGs, we next assessed whether any of those 74 DEGs were found in this module. 
Intriguingly, we found approximately 57% (42/74) of our DEGs were contained in this 
module. We decided to prioritize hub genes in this module for candidate gene selection. 
We found it compelling our sALS group-specific DEGs and a gene co-expression network 
associated with sALS disease status were both associated with various inflammatory 
cellular processes and TNF-α signaling. We obtained these results despite discovering 
both gene sets using independent exploratory approaches. Further, these findings are 
consistent with previous studies implicating inflammatory processes and TNF-α signaling 

















Figure 19. DEG Identification using different algorithms. This figure shows a Venn diagram 










































           
HTRA4 5.63 1.66 0.30 0.007  CPM 2.32 15.14 6.52 0.007 
PLA2G7 5.59 22.32 3.99 0.007  HLA-DOA 2.32 15.64 6.74 0.007 
GPNMB 5.39 237.50 44.03 0.007  TNFAIP2 2.29 12.54 5.47 0.007 
OTOA 4.78 0.79 0.16 0.074  ABCG1 2.18 12.55 5.75 0.007 
APOC1 4.61 348.98 75.64 0.007  TBXAS1 2.12 17.90 8.43 0.007 
LILRA4 4.61 6.40 1.39 0.007  HAVCR2 2.07 30.06 14.47 0.007 
SIGLEC8 4.40 17.79 4.04 0.007  CD86 2.01 12.74 6.33 0.007 
CHAC1 4.30 4.05 0.94 0.007  OSBPL11 1.98 30.02 15.10 0.007 
HLA-DRB1 4.10 80.55 19.64 0.007  CD84 1.98 9.86 4.96 0.007 
KLHL6 3.99 9.14 2.29 0.007  IL18 1.97 21.02 10.63 0.041 
DPEP2 3.96 3.39 0.86 0.007  PIK3IP1 1.94 38.02 19.57 0.007 
LILRA2 3.59 6.87 1.91 0.007  DNASE2 1.89 15.81 8.33 0.007 
CPVL 3.40 44.56 13.10 0.007  ASAH1 1.85 305.78 164.90 0.052 
CEBPA 3.29 26.50 8.06 0.007  GPRIN3 1.84 10.27 5.57 0.007 
SLC37A2 3.28 7.81 2.38 0.007  OTUD1 1.79 9.10 5.08 0.070 
APOE 3.25 1785.64 549.01 0.007  CECR1 1.72 15.26 8.83 0.038 
SLC7A7 3.01 14.67 4.88 0.007  WDR91 1.72 7.03 4.08 0.070 
CAPG 2.99 69.99 23.35 0.007  LTA4H 1.65 42.38 25.67 0.062 
LILRB4 2.97 9.59 3.22 0.007  GNB4 1.61 31.09 19.26 0.068 
FCGR2B 2.97 13.68 4.60 0.007  CXCL8 -5.90 4.78 28.23 0.007 
HPSE 2.96 6.28 2.12 0.007  WNT16 -4.83 0.44 2.15 0.007 
SELPLG 2.81 15.91 5.64 0.007  FGF10 -3.40 1.84 6.26 0.023 
HLA-DMB 2.76 49.50 17.91 0.007  DCN -3.17 144.38 458.54 0.007 
BMF 2.73 3.64 1.33 0.007  PTGS2 -3.05 3.08 9.42 0.007 
KCNA5 2.71 8.08 2.97 0.007  LIPG -2.72 1.02 2.78 0.018 
THEMIS2 2.71 29.82 10.99 0.007  CFH -2.58 25.78 66.62 0.007 
ITGAX 2.68 13.65 5.09 0.007  FHL2 -2.44 3.93 9.61 0.007 
CD37 2.66 30.05 11.28 0.007  COL12A1 -2.42 4.01 9.73 0.007 
GK 2.64 15.01 5.68 0.007  KDR -2.26 5.16 11.68 0.007 
FPR3 2.59 10.56 4.07 0.007  MSMO1 -2.23 42.05 93.95 0.007 
ZMYND15 2.56 1.79 0.70 0.083  EPHA3 -2.05 2.93 6.02 0.007 
CD226 2.51 4.16 1.66 0.007  NRP1 -2.04 6.36 12.99 0.007 
ADAMTS1
4 
2.49 0.71 0.28 0.090  HMGCS1 -2.02 17.63 35.74 0.007 
KCNJ5 2.42 4.68 1.93 0.030  PPP1R3C -1.99 20.54 40.97 0.007 
CXCL16 2.39 35.65 14.87 0.007  SQLE -1.92 22.61 43.53 0.007 
CTSS 2.36 38.81 16.42 0.007  ITGA8 -1.90 2.14 4.08 0.007 






WGCNA hub gene identification: 12 genes in the black module had scores in the top 
quartile for intramodular connectivity, modular membership, and gene significance 
metrics. 9 of these genes were separately identified as upregulated sALS group-specific 
DEGs. TNFAIP2, a gene encoding a TNF-α superfamily protein, was one of these nine. 
Figure 21 lists all 12 black module hub genes, and contains a graph plotting each black 
module gene’s module membership vs. gene significance score.  
Selection of TNFAIP2 as our candidate gene for hypothesis testing: We selected 
TNFAIP2 as our candidate gene for hypothesis testing for many data-driven reasons. 
First, TNFAIP2 belonged to the black module associated with sALS disease status, 
inflammatory cellular processes, and TNF signaling. Second, TNFAIP2 was identified as 
one of twelve black module hub genes with a score in the top quartile for intramodular 
connectivity, modular membership, and gene significance metrics.  Third, TNFAIP2 was 
mutually identified as an upregulated sALS group-specific DEG using all three DEG 
analyses.  
Elevated TNF-α signaling plays a known role in cell fate decisions, and induces 
apoptosis under certain biological circumstances (Probert 2015). Elevated TNF-α 
signaling has been shown to kill motor neurons in previous literature (He, Wen, Strong 
2002, Robertson et al. 2001, Terrado et al. 2000). Elevated TNF-α signaling is also 
known to increase TNFAIP2 expression in a variety of cell types (Saito et al. 2013, 
Zhou, Scoggin, Gaynor, Williams 2003, Tian et al 2005), and elevated TNFAIP2 
expression has previously been associated with increased apoptosis (Park et al. 2003, 
Rusiniak et al. 2000, Ma et al. 2003).  Studies linking elevated TNFAIP2 expression to 







Figure 20. WGCNA module identification. This figure shows all 13,301 genes (individual 
black lines at top) clustered into different modules based on their topological overlap 
dissimilarity scores. The multi-colored panel next to “Dynamic Tree Cut” shows 122 identified 
modules using the Dynamic Tree Cut algorithm. The second multi-colored panel shows 37 


































































































MEblack 0.676 0.006 -0.370 0.175 -0.014 0.960 
MEsienna4 0.662 0.007 -0.023 0.934 0.260 0.349 
MEfirebrick3 0.609 0.016 -0.177 0.527 0.027 0.923 
MEhoneydew1 0.561 0.030 0.236 0.398 -0.028 0.920 
MEhoneydew 0.544 0.036 0.096 0.732 -0.045 0.872 
MElightcoral 0.478 0.072 -0.638 0.010 -0.237 0.396 
MEmidnightblue 0.402 0.137 -0.305 0.269 -0.135 0.631 
MEdarkviolet 0.391 0.149 0.039 0.891 -0.043 0.879 
MEdarkred 0.330 0.230 0.115 0.684 0.184 0.513 
MEfirebrick4 0.325 0.238 0.307 0.265 0.147 0.602 
MEpaleturquoise 0.305 0.269 -0.001 0.997 0.145 0.606 
MElavenderblush1 0.269 0.333 -0.003 0.993 0.308 0.264 
MEbrown 0.223 0.425 -0.152 0.588 0.064 0.821 
MEantiquewhite2 0.214 0.444 -0.061 0.828 -0.158 0.574 
MEantiquewhite1 0.110 0.696 0.009 0.973 0.394 0.146 
MEturquoise 0.026 0.927 -0.113 0.688 0.175 0.534 
MEbisque4 0.023 0.935 0.201 0.472 0.048 0.866 
MEdarkolivegreen2 0.009 0.975 0.073 0.797 0.425 0.115 
MEcoral2 0.007 0.982 -0.208 0.458 -0.281 0.311 
MEindianred3 0.001 0.999 -0.209 0.454 -0.076 0.788 
MEdarkmagenta -0.011 0.970 0.042 0.883 -0.156 0.579 
MEnavajowhite1 -0.033 0.907 -0.217 0.437 0.108 0.701 
MEdarkseagreen3 -0.033 0.906 0.031 0.914 0.102 0.718 
MElightcyan -0.046 0.872 0.154 0.584 0.108 0.702 
MElightyellow -0.046 0.869 -0.394 0.146 0.114 0.685 
MEmagenta3 -0.110 0.697 0.392 0.149 0.462 0.083 
MEtan4 -0.169 0.547 -0.128 0.649 0.410 0.129 
MElavenderblush3 -0.220 0.432 -0.062 0.825 0.077 0.786 
MElightpink3 -0.273 0.325 -0.304 0.270 -0.043 0.878 
MEblue -0.348 0.204 -0.211 0.451 -0.118 0.677 
MEdarkseagreen2 -0.436 0.104 -0.127 0.651 0.163 0.562 
MEgreen4 -0.510 0.052 -0.138 0.625 0.013 0.963 
MElightslateblue -0.510 0.052 -0.017 0.953 -0.128 0.650 
MEantiquewhite4 -0.513 0.050 0.044 0.877 0.354 0.196 
MEpink4 -0.569 0.027 0.388 0.153 0.293 0.289 
MEbrown4 -0.625 0.013 0.100 0.724 0.040 0.888 





functionally promoted apoptotic processes directly. We hypothesize elevated TNF-α 
signaling 1) increased TNFAIP2 expression in our sALS patients’ cervical spinal cells, 
and 2) TNFAIP2 functionally contributed to spinal motor neuron death in our sALS 
patients via the TNF non-mitochondrial or mitochondrial apoptotic pathway. 
TNF-α signaling, TNFAIP2, and other black module hub genes’ expression levels:  
IPA identified TNF-α as an upstream regulator of genes comprising the black module 
(Table 7). Elevated TNF-α signaling may have induced changes in black module genes’ 
expression levels, plausibly promoting the black module’s associated inflammatory 
processes (and potentially motor neuron death) in our sALS patients’ cervical spinal cells. 
If this occurred, we suspect TNF-α signaling accomplished this via altering black module 
hub genes’ expression levels. That would be consistent with the theory hub genes 
functionally regulate their gene co-expression network’s activities and associated cellular 
processes. 
Previous literature has already shown elevated TNF-α signaling increases the 
expression level of TNFAIP2 (a black module hub gene) in a variety of cell types (Saito 
et al. 2013, Zhou, Scoggin, Gaynor, Williams 2003, Tian et al 2005). For these reasons, 
we tested whether exposing neural stem cells to TNF-α increased the expression levels 
of TNFAIP2 and/or the other 8 black module hub genes identified as sALS group-specific 
upregulated DEGs. qPCR data revealed exposing neural stem cells to TNF-α increased 
the expression levels of three black module hub genes. These included TNFAIP2, 
Apoliprotein E (APOE), and Chemokine Ligand 16 (CXCL16). These results can be seen 





                               Table 7: Comparing IPA results 












Disease Signaling 5/48 8.10E-07 




Signaling 5/64 3.45E-06 
 
TREM1 Signaling 14/75 1.11E-09 
Atherosclerosis 
Signaling 6/124 5.73E-06 




T Helper Cell 
Differentiation 5/71 5.77E-06 
 Role of NFAT in 




Development 4/33 5.91E-06 
 CD28 Signaling in T 
Helper Cells 
15/118 6.54E-08 
         
Top Diseases and 
Disorders 
 p-Value  


























































IFNG 24/610 4.78E-13 
 lipopolysaccharide 95/763 1.98E-20 
IL13 14/192 1.43E-11 
 IFNG 79/610 2.98E-19 
cholesterol 10/109 5.41E-10 
 genistein 42/212 2.82E-18 
lipopolysaccharide 23/763 7.68E-10 
 TNF-α 75/773 4.85E-12 
CAMP 7/43 3.59E-09 
 fluticasone 22/133 1.41E-11 
TNF-α 19/773 3.16E-07 





Table 8: DEGs identified at an FDR <.01 across analyses 
             200 sALS group-specific DEGs 
Top Canonical Pathways Overlapping Genes p-Value 
Dendritic Cell Maturation 17/177 3.31E-10 
Atherosclerosis Signaling 14/124 1.11E-09 
T Helper Cell Differentiation 11/71 9.72E-09 




     
Top Diseases and Disorders  p-Value 
Metabolic Disease  1.13E-04-9.32E-25 
Endocrine System Disorders  1.35E-04-2.33E-19 
Gastrointestinal Disease  7.33E-05-2.79E-19 
Cardiovascular Disease  7.80E-05-2.79E-19 
Connective Tissue Disorders  7.33E-05-2.79E-19 
     
Upstream Regulators  p-Value 
IFNG 61/610 1.98E-20 
TGFB1 63/813 2.98E-19 
lipopolysaccharide 61/763 2.82E-18 
beta-estradiol 61/844 4.85E-12 
IL13 30/192 1.41E-11 







Figure 21. Black module hub genes and TNFAIP2. This figure lists the 12 black module hub 
genes and reports whether each was separately identified as an sALS group-specific DEG (A), 
and shows a graph plotting each black module gene’s module membership vs. gene significance 
score (B). DPP7, MICAL1, and PSAP were not identified as sALS group-specific DEGs. TNFAIP2 












These findings support IPA’s prediction of TNF-α as an upstream regulator of genes 
comprising the black module, and may account for the inflammatory processes 
associated with those genes. Elevated TNF-α signaling may account for these hub genes’ 
increased expression levels as observed in our sALS patients’ RNA-Sequencing data. 
These findings are also consistent with our hypothesis that elevated TNF-α signaling 
increased TNFAIP2 expression in our sALS patients’ cervical spinal cells. 
TNFAIP2 overexpression and apoptosis: If TNFAIP2 functionally contributed to spinal 
motor neuron death in our sALS patients, we suspect this occurred via a TNF superfamily 
apoptotic pathway. TNF-α signaling can promote cell survival or cell death depending on 
cellular and microenvironmental conditions that remain poorly understood (Probert 2015), 
and elevated TNF-α signaling has been shown to kill motor neurons in previous literature 
(He, Wen, Strong 2002, Robertson et al. 2001, Terrado et al. 2000).  Figure 23 shows a 
visual of these protein-signaling cascades.  
To provide context for the proceeding experiments, I will only describe the TNF 
superfamily non-mitochondrial and mitochondrial apoptotic pathways. After TNF-α binds 
Tumor Necrosis Factor Receptor 1 (TNFR1), TNFRSF1A-Associated via Death Domain 
(TRADD) is recruited. TRADD recruits Fas-Associated Protein With Death Domain 
(FADD) and pro-forms of Caspases 8 and 10 (Al-Lamki, Mayadas 2015). The pro-form of 
Caspase 8 undergoes auto-proteolytic activation, and activated Caspase 8 is released 
into the cytoplasm. The TNF superfamily non-mitochondrial or mitochondrial pathway is 
then used to induce apoptosis depending on the cell type (Al-Lamki, Mayadas 2015). The 






Figure 22. Hub gene expression levels in NSCs after TNF-α exposure. This figure shows 
each of the 9 hub gene’s expression levels in NSCs (n = 8 per group) after treatment with DMSO 
or TNF-α for 24 hours. Multiple t-tests were run using Prism, which included corrections for 
multiple comparisons using the Holm-Sidak method. * P < 0.01; ** P < 0.001. Experiment done in 






Figure 23. TNF signaling cascades. This figure shows proteins involved in TNF-α signaling 
pathways that promote apoptosis (left) and cell survival (right). TNF signaling. eBioscience; 











3 and 7, which then enter the nucleus and initiate heterochromatic formations and DNA 
fragmentation leading to cell death (Al-Lamki, Mayadas 2015, Falschlehner, Emmerich, 
Gerlach, Walczak 2007, Matthews, Newbold, Johnstone 2012).The mitochondrial route 
involves activated Caspase 8 truncating a pro-apoptotic BCL-2 family member, BH3 
interacting-domain death agonist (BID). Truncated BID activates BCL-2-Associated X 
Protein (BAX) and/or BCL-2 Homologous Antagonist Killer (BAK), which move to the 
mitochondrial membrane and form homo-oligomers. These protein oligomers 
permeabilize the outer mitochondrial membrane by inserting themselves into it, leading 
to the release of Cytochrome C. Cytochrome C binds the pro-form of Caspase-9 and 
Apoptotic Peptidase Activating Factor 1 (APAF1) to form the apoptosome, and the 
apoptosome proteolytically activates Caspase-9. Activated Caspase-9 then 
proteolytically activates Caspases 3 and 7, which enter the nucleus and initiate 
heterochromatic formations and DNA fragmentation leading to cell death (Al-Lamki, 
Mayadas 2015, Falschlehner, Emmerich, Gerlach, Walczak 2007, Matthews, Newbold, 
Johnstone 2012). 
We conducted two experiments that assessed 1) whether overexpression of 
TNFAIP2 (observed as a significantly upregulated sALS group-specific DEG) promoted 
cell death within in vitro models of disease-vulnerable cells, and 2) whether TNFAIP2-
mediated cell death relied on activated caspases 8 and/or 9. Specifically, our first 
experiment investigated whether NSCs that transiently overexpressed TNFAIP2 and GFP 
were significantly less viable than neural stem cells that transiently overexpressed GFP 





activated caspase 9 reversed any potential TNFAIP2-mediated reduction in NSC viability. 
Our second experiment investigated whether iPSC-derived motor neuron cultures that 
transiently overexpressed TNFAIP2-GFP (TNFAIP2 protein with a GFP tag fused to its 
N-terminus) were significantly less viable and had increased activated caspase 3 and 7 
levels relative to iPSC-derived motor neuron cultures that transiently overexpressed GFP 
alone. 
For our first experiment, we compared cell viability in NSCs that 1) were treated 
with DMSO alone (DMSO), 2) were transfected with Fugene reagent alone (FG), 3) were 
transfected with Fugene reagent and GFP plasmid to overexpress GFP protein 
(GFP/FG), 4) were transfected with Fugene reagent and TNFAIP2-IRES-GFP plasmid to 
overexpress TNFAIP2 and GFP proteins (TIG/FG), 5) were given Caspase 8 inhibitor and  
were transfected with Fugene reagent and TNFAIP2-IRES-GFP plasmid to overexpress 
TNFAIP2 and GFP proteins (C8i/TIG/FG), and 6) were given Caspase 9 inhibitor and 
were transfected with Fugene reagent and TNFAIP2-IRES-GFP plasmid to overexpress 
TNFAIP2 and GFP proteins (C9i/TIG/FG).  
A one way-between subjects ANOVA revealed there was a significant effect of 
treatment conditions on cell viability at the p<.05 level for the six treatments (F5, 42) = 
106.6, p<0.0001). Post hoc comparisons using the Dunnett’s test for multiple corrections 
indicated the mean score for the TIG/FG group (M = 0.207, SD = 0.011) was significantly 
different than the DMSO group (M = 0.442, SD = 0.030, p=<0.0001), the FG group (M = 
0.324, SD = 0.024, p=<0.0001), the GFP/FG group (M = 0.255, SD = 0.023, p=0.0019), 
and the C9i/TIG/FG group (M = 0.264, SD = 0.031, p=0.0002). Taken together, these 





significantly less viable than NSCs that overexpressed GFP alone. Further, inhibition of 
activated caspase 9 reversed this TNFAIP2-mediated reduction in NSC viability, whereas 
inhibition of activated caspase 8 did not. These results can be seen in Figure 24. 
Compared to iPSC-derived motor neurons transfected with GFP alone, iPSC-
derived motor neuron cultures that transiently overexpressed TNFAIP2-GFP were 1) 
significantly less viable and 2) had significantly elevated levels of activated caspases 3 
and 7. These results can be seen in Figure 25. qPCR data revealed TNFAIP2 expression 
increased >300-fold in iPSC-derived motor neuron cultures transfected with TNFAIP2-
GFP relative to GFP alone.  
These proof of concept experiments demonstrated transient overexpression of 
TNFAIP2 (an upregulated sALS group-specific DEG) promoted cell death within in vitro 
models of sALS disease-vulnerable cell types.  Further, the TNFAIP2-mediated reduction 
in NSC viability relied on activated Caspase 9, a protein necessary for TNF-α superfamily 
mitochondrial-mediated apoptosis. Taken together, these results are consistent with our 
hypothesis that TNFAIP2 functionally contributed to spinal motor neuron death in our 
sALS patients via the TNF superfamily mitochondrial apoptotic pathway. 
IV. Discussion: 
In this chapter, we combined deep RNA-Sequencing, systems biology analyses, 
and molecular biology assays to elucidate sALS group-specific differences in postmortem 
spinal tissues that may be relevant to disease pathology. To our knowledge, our 







Figure 24. Cell viability measurements for NSC transfection groups. This figure shows 
absorbance readings reflecting MTT metabolism (a function viable cells perform) for our NSC 
transfection groups (n = 8 per group). DMSO = DMSO only, FG = Fugene Only, GFP/FG = GFP 
plasmid with Fugene, TIG/FG = TNFAIP2-IRES-GFP and Fugene, C8i/TIG/FG = Caspase 8 
inhibitor, TFNAIP2-IRES-GFP, and Fugene, and C9i/TIG/FG = Caspase 9 inhibitor, TFNAIP2-IRES-
GFP, and Fugene. A one-way ANOVA was run using Prism, which included corrections for 
multiple comparisons using Dunnett’s Test. ** P< 0.01, *** P < 0.001; **** P < 0.0001. Experiment 









Figure 25. Apoptosis assays in iPSC-derived motor neuron transfection groups. This figure 
shows absorbance readings reflecting MTT metabolism (a function viable cells perform) on the 
left, and activated Caspase 3/7 levels measured using fluorescently labeled antibodies on the 
right for our iPSC-derived motor neuron groups (n = 10 per group). EV = GFP plasmid and 
Fugene, TNFAIP2 = TNFAIP2-GFP plasmid and Fugene. Unpaired t-tests were run using Prism. 














(Kratz, Carninci 2014, Wang, Gerstein, Snyder 2009) to measure gene expression 
differences in sALS patients’ postmortem cervical spinal tissues containing disease- 
vulnerable motor neurons. We chose to study gene expression differences in human 
sALS patients’ postmortem tissues over fALS rodent tissues, as recent findings suggest 
the majority of sALS is not accounted for by known monogenic ALS causal mutations 
(Renton, Chio, Traynor 2014). Further, these cervical spinal tissues are inaccessible prior 
to these patients’ deaths. The only other RNA-Sequencing study in human postmortem 
sALS tissues we are aware of used cerebellar and prefrontal cortex tissues (Pavlou, 
Dimitromanolakis, Diamandis 2013), and they also found sALS-group specific DEGs 
associated with inflammatory processes.  
Previous studies have used gene network analyses to reveal cellular processes 
associated with ALS group-specific networks that may be relevant to disease pathology. 
Studies using gene co-expression network analyses identified ALS group-specific 
networks associated with immune response, stress response, post-translational 
modifications, and neuroprotective processes (Holtman et al. 2015, Saris et al. 2009). 
Several ALS studies modeled gene networks by only connecting genes with known 
interactions in previous literature. They identified ALS group-specific networks associated 
with organismal injury, immune response, post-translational modification, regulation of 
the cytoskeleton, and extracellular matrix repair (Satoh et al. 2014, Figueroa-Romero et 
al. 2012).  
Another group (Izik et al. 2015) used a 2-step approach to identify ALS group-
specific gene networks. First, they connected genes based on their co-expression values. 





between genes inferred to be connected based on the strength of their co-expression 
value alone. They then utilized a MARINa algorithm to identify major regulators (such as 
transcription factors) within an ALS group-specific gene network. The MARINa algorithm 
predicted 8 network genes were responsible for the elevated rate of apoptosis observed 
in their in vitro motor neuron model of ALS. One of those genes, Nuclear Factor of Kappa 
Light Polypeptide Gene Enhancer in B-Cells 1 (NFKB1), is a TF with important functions 
in innate immune responses.  Taken together, these findings support the use of systems-
level gene network analyses to identify cellular processes that may be perturbed in ALS 
tissues. Further, they hold potential to unveil therapeutic target genes.  
In this study, QIAGEN’s IPA revealed inflammatory processes and TNF-α signaling 
were statistically significantly associated with sALS group-specific gene expression 
differences identified using independent exploratory DEG analyses (Cuffdiff2, DESeq2, 
and EdgeR) and an unsupervised gene co-expression network analysis (WGCNA). This 
is consistent with previous ALS studies’ findings, as referenced in the introduction. 
qPCR data revealed exposing NSCs to TNF-α increased the expression levels of 
TNFAIP2, Apoliprotein E (APOE), and Chemokine Ligand 16 (CXCL16). All three of these 
genes were identified as 1) upregulated sALS group-specific DEGs, and 2) hub genes in 
a gene co-expression network associated with sALS disease status, inflammatory 
processes, and TNF-α signaling. These findings support IPA’s prediction of TNF-α as an 
upstream regulator of black module genes, and may account for the inflammatory 
processes associated with these genes. The observed increase in TNFAIP2 expression 
after NSCs were exposed to TNF-α corroborates previous findings (Saito et al. 2013, 





hypothesis that elevated TNF-α signaling increased TNFAIP2 expression in our sALS 
patients’ cervical spinal cells. 
MTT assay results revealed NSCs that transiently overexpressed TNFAIP2 and 
GFP were significantly less viable than NSCs that overexpressed GFP alone. Further, 
inhibition of activated Caspase 9 reversed this TNFAIP2-mediated reduction in NSC 
viability. Relative to iPSC-derived motor neuron cultures that transiently overexpressed 
GFP, iPSC-derived motor neuron cultures that overexpressed TNFAIP2-GFP were 1) 
significantly less viable as measured using an MTT assay, and 2) had significantly higher 
levels of activated caspases 3 and 7.  
These proof of concept experiments demonstrated transient overexpression of 
TNFAIP2 (an upregulated sALS group-specific DEG) promoted cell death within in vitro 
models of sALS disease-vulnerable cell types. This is consistent with previous literature 
linking elevated TNFAIP2 expression with increased apoptosis (Park et al. 2003, Rusiniak 
et al. 2000, Ma et al. 2003). The observed TNFAIP2-mediated reduction in neural cell 
viability relied on activated Caspase 9, a protein necessary for TNF-α superfamily 
mitochondrial-mediated apoptosis. Taken together, these results are consistent with our 
hypothesis that TNFAIP2 functionally contributed to spinal motor neuron death in our 
sALS patients via the TNF superfamily mitochondrial apoptotic pathway. 
Modulating TNF signaling activity may be effective in slowing sALS disease 
progression. TNF-α is a potent inflammatory cytokine that plays an instrumental role in 
cell fate decisions, and elevated TNF-α signaling has been shown to kill motor neurons 





TNF signaling-mediated pro-survival processes are largely effected via upregulation of 
the TFs NFKB1 and Jun Proto-Oncogene (JUN) (Micheau, Tschopp 2003, Walczak 
2011), whereas its cell death processes are ultimately carried out by initiator and effector 
caspases. Bioactive forms of TNF-α commence these processes via two cell surface 
receptors, TNFR1 and TNFR2. TNFR1 directs cell survival or death, whereas TNFR2 is 
only known to promote pro-survival effects (Probert 2015).  
The extracellular domains of TNFR1 and TNFR2 are shed into general circulation 
after interacting with bioactive forms of TNF-α, and function in a negative feedback loop 
as they retain their ability to bind TNF-α (Mohler et al. 1993). Intriguingly, elevated levels 
of TNF-α and extracellular domains of TNFR1 and TNFR2 have been found in the blood 
(Poloni et al. 2000) and serum (Babu et al. 2008, Cereda et al. 2008) of human ALS 
patients compared to controls. 
Novel therapies to reduce TNF-α synthesis in human sALS patients could be of 
great therapeutic value. Non-selective TNF-α inhibitors have proven invaluable in the 
treatment of chronic diseases with an inflammatory component including rheumatoid 
arthritis, psoriasis, and inflammatory bowel disease (Probert 2015). Measurement of 
sALS patients’ circulating levels of TNF-α and the extracellular domains of the TNF 
receptors (TNFR1, and TNFR2) at various treatment timepoints could help establish 
therapeutic efficacy. They would also serve as non-invasive biomarkers of disease 
progression. 
Two potential therapeutic agents to reduce TNF-α synthesis are Bupropion and 





α serum levels in mice likely via increasing intracellular cAMP signaling after binding beta-
adrenergic and/or D1 receptors (Brustolim et al. 2006). Curcumin, an anti-inflammatory 
compound in turmeric, reduced TNF-α transcription in human cancer cells (Han, Keum, 
Seo, Surh 2002, Surh et al. 2001) and lipopolysaccharide (LPS)-stimulated murine 
microglia (Jin et al. 2007). Curcumin likely reduced TNF-α transcription via inhibition of 
NFKB1. NFKB1, a TF that is upregulated by TNF signaling, is known to induce TNF-α 
and other inflammatory cytokines under certain biological circumstances (Hoesel, Schmid 
2013). Curcumin is also predicted to bind and inhibit caspase-3 (Khan et al. 2015), an 
effector caspase used by the TNF superfamily mitochondrial and non-mitochondrial 
apoptotic pathways. Curcumin oral bioavailability and brain penetration was substantially 
increased by micellular formulation (Hagl et al. 2015), setting the stage for clinical testing 
of it and Bupropion.  
Our study has several important limitations. First, we measured and compared 
gene expression in a small number of postmortem cervical spinal cord section samples. 
There are ~35,000 persons with ALS in the US. The cost of RNA-sequencing limited the 
numbers of cases we could examine at the sequencing depth employed. As a result, it is 
impossible to state to what degree our findings can be generalized to thousands of 
patients. Second, we used postmortem tissue. As a result, we examined gene expression 
of cells (mainly astrocytes) that were survivors of the neurodegenerative process. To what 
extent ALS modifies gene expression over time is not known, and it is not currently 
possible to examine human CNS tissues across disease progression. It is unclear 
whether the young motor or other neurons we produced using iPSC approaches 





many years as ALS progresses. Third, we did not explore novel transcripts or smaller 
ncRNAs (including miRNAs) in this study.  
Although we focused on TNF-α signaling and modulated TNFAIP2 expression in 
NSCs and iPSC-derived motor neurons in this study, we do not claim aberrant 
inflammatory TNF-α signaling is the sole pathogenic factor in sALS. We identified a 
second sALS group-specific gene co-expression network that was associated with cell 
proliferation, cell cycle functions, interleukin-4 (IL4) signaling, and various metabolic 
compounds’ (methyglyoxal and phenylethylamine) degradation processes. We prioritized 
pursuit of candidate genes in the black module, as that gene co-expression network’s 
associated cellular processes were more plausibly linked to cell death. As sALS patients 
die after the motor neurons that innervate their lungs degenerate, identifying novel 
therapeutic targets to prevent motor neuron death is paramount. The black module 
appeared to be a better option than the sienna4 module for pursuing that goal.  
Aside from TNFAIP2, we identified 8 other hub genes that were also upregulated 
DEGs within the black module. These genes could serve as foci for additional mechanistic 
studies and therapeutic interventions. Specifically, investigating whether transient 
overexpression of each of them (as they were all upregulated in our sALS sample group) 
leads to perturbed cellular processes (such as increased apoptosis) in models of sALS 
disease-vulnerable cell types would be valuable. Previous literature findings highlight their 
potential relationship to perturbed cellular processes important to ALS pathology. 
Genetic variants in APOE, a gene encoding a protein important for transporting 





and features of disease progression (Verghese, Castellano, Holtzman 2011). This may 
be related to aberrant cholesterol transport processes in sALS disease-vulnerable cells, 
as accumulation of cholesterol esters has been linked to oxidative stress-induced motor 
neuron death in ALS tissues previously (Cutler et al. 2002). Cholesterol was identified as 
a significant upstream regulator of genes comprising the black module. It is possible 
upregulation of APOE (as observed in our sALS sample group) contributed to aberrant 
cholesterol transport processes in our sALS patients spinal cells, leading to oxidative 
stress-induced spinal motor neuron death. Transient overexpression of APOE in our in 
vitro models of sALS disease-vulnerable cell types followed by measurement of 
cholesterol ester and cell viability levels would be valuable. 
Bcl2-Modifying Factor (BMF) binds to Bcl2 and related anti-apoptotic proteins and 
promotes mitochondrial-mediated apoptosis. Transient overexpression of BMF in our in 
vitro models of sALS disease-vulnerable cell types followed by characterization of cell 
viability levels could shed light on the potential contributions of mitochondrial-mediated 
apoptosis in sALS. 
CD37, a gene whose expression is restricted to human leukocytes, is integral to T 
cell proliferation (van Spriel et al. 2004). While the majority of immune surveillance in the 
CNS (including the spinal cord) is carried out by microglia, T cells do play a role in this 
process as well (Ousman, Kubes 2012). CD37’s observed upregulation in our sALS 
patients’ spinal cells may reflect recruitment of activated T cells to combat deleterious 
cellular processes induced by the disease. Recruited T cells may have excreted large 
amounts of TNF-α in this process, as they have been shown to do that in a previous study 





neuron death. Modeling CD37 overexpression in a rodent model followed by 
measurement of TNF- α levels in their spinal tissues could help assess the likelihood of 
this connection.   
CXCL16, a transmembrane chemokine produced by reactive astroglial cells, plays 
an important role in immunosurveillance processes and serves as a chemoattractant for 
macrophages. Its expression is increased by TNF-α (Abel et al. 2004), and has been 
shown to sensitize cells to TNF-α mediated apoptosis (Kee et al. 2014). It also promotes 
CXCR6-positive glial cell invasion that favors astrogliosis (Hattermann et al. 2008), a 
feature seen in ALS CNS tissues. Taken together, its observed upregulation in our sALS 
patients’ spinal cells may have played a role in sensitizing spinal motor neurons to TNF-
α mediated apoptosis. This could be tested in our in vitro models of sALS disease-
vulnerable cell types. 
Glycoprotein NMB (GPNMB) was previously identified as an upregulated DEG in 
the spinal cords of fALS rodents. Interestingly, extracellular fragments of GPNMB 
released by activated astrocytes lessened the neurotoxicity of mutant SOD1, suggesting 
it may play a protective role against neurodegeneration (Tanaka et al. 2012). Its observed 
upregulation in our sALS patients’ spinal cells may reflect an attempt to protect motor 
neurons against ongoing neurodegenerative processes related to sALS pathology. 
Integrin Alpha X (ITGAX), a leukocyte-specific integrin, was found as an 
upregulated DEG in leukocytes that invaded the spinal cords of fALS rodents at different 
stages of disease progression (Chiu et al. 2008). ITGAX plays a known role in cell-cell 





patients’ spinal cells may reflect spinal cells’ recruitment of activated T cells to combat 
deleterious effects of sALS pathology. 
Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 4 (LILRB4), a cell 
surface receptor in immune cells, binds MHC class 1 molecules to inhibit immune 
responses. While not directly studied in ALS tissues, LILRB4 expression negatively 
correlated with pathologic inflammation in a mouse model of allergic pulmonary 
inflammation (Fanning et al. 2013). Its observed upregulation in our sALS patients’ spinal 
cells may reflect an attempt to reduce inflammatory processes that may have ultimately 
led to motor neuron death. 
To our knowledge, no study has investigated the function of WDR91 (WD Repeat 
Domain 91), so it is impossible to speculate on its possible connection to ALS pathology. 
While more than half (42/74) of our sALS group-specific DEGs were contained in the 
black module, 32 DEGs were not. These genes could also play an important role in sALS 
disease pathology and may warrant further study. Chemokine C-X-C Motif Ligand 8 
(CXCL8), Decorin (DCN), and Neuropilin 1 (NRP1) are particularly good candidates.  
CXCL8 was found to be statistically significantly increased in the cerebrospinal 
fluid of sALS patients compared to cerebrospinal fluid of patients with other non-
inflammatory neurological diseases. Further, its level was negatively correlated with these 
patients’ scores on the revised ALS functional rating scale (Tateishi 2010). CXCL8 plays 
an important role in sending neutrophils to a site of infection, as well as inducing 
phagocytosis. DCN’s mRNA and protein expression levels were greatly increased in both 





proteoglycan with a known role in attenuating glial scar formation and inflammation. 
(Vargas et al. 2008). Both CXCL8 and DCN downregulation in our sALS patients’ spinal 
cells may have contributed to unresolved inflammatory processes that ultimately led to 
motor neuron death.  
Axon degeneration is often observed in fALS rodent models prior to motor neuron 
death. Semaphorin 3A (SEMA3A), an important axon guidance cue involved in neural 
patterning during development, binds to NRP1. This leads to axonal retraction by 
destabilizing microtubules and microfilament networks. Blocking the interaction between 
SEMA3A and NRP1 in fALS rodents led to decreased axon degeneration and motor 
neuron death, suggesting NRP1 may play a role in ALS pathology prior to clinical 
symptom onset related to motor neuron death (Venkova et al. 2014). 
We anticipate future exploratory studies will continue to uncover polygenic 
contributions, perturbed cellular processes, and potential therapeutic targets in sALS. 
Genome-wide Association Studies (GWAS) comparing sALS cases vs. neurologically 
healthy controls were instrumental in the discovery of excess pathogenic non-coding 
repeats in C9orf72 found in 7% of Caucasian sALS patients (Renton, Chio, Traynor 
2014). Another study identified excess de novo mutations in chromatin regulator genes 
after comparing exome sequencing data from sALS offspring and their neurologically 
healthy parents (Chesi et al. 2013). This ALS gene expression study joins those 
preceding it in identifying perturbed cellular processes and corroborating them using 





In this study, we identified sALS group-specific gene expression differences and 
associated cellular processes that may be relevant to disease pathology.  However, it 
lumped all of our sALS patients together to find commonalities across them without 
elucidating differences between them. 
Emerging findings suggest considerable clinical heterogeneity between patients 
with either form of ALS. A recent study (Ganesalingam et al. 2009) applied a latent class 
cluster analysis to 1,467 ALS patients’ clinical metrics to assess whether there were 
multiple disease sub-groups. These metrics included family history of ALS (fALS vs. 
sALS), sex, ethnicity, site of symptom onset, age of onset, and diagnostic delay after 
symptom onset. Five different groups emerged, with one group showing no deaths and 
another exceeding the average median survival time by 12 years. Heterogeneity in 
disease features has also been observed in fALS patients carrying causal mutations in 
different genes. Patients carrying causal mutations in the FUS gene show a younger age 
of onset and rapid disease progression compared to those with the SOD1 Asp90Ala 
variant (Ganesalingam et al. 2009). Even within the same fALS pedigree, some family 
members who inherit a fALS-causal mutation do not develop disease features. 
Perhaps more striking were study findings where the same fALS causal mutation 
was modeled into two genetically distinct transgenic mouse lines (Nardo et al. 2013) 
These researchers demonstrated introducing the SOD1 G93A point mutation into 129Sv 
and C57 mice led to a rapid and slow disease progression, respectively. They compared 
measured gene expression values from each transgenic line’s spinal motor neurons at 
multiple disease stages, and identified hundreds of DEGs associated with different 





rapid disease progression) were associated with reduced mitochondrial function and 
deficient protein degradation. DEGs specific to the C57 group (showing slow disease 
progression) were associated with upregulated immune system processes. These 
findings suggest even with a pure monogenic form of ALS and a controlled environment, 
genetic differences between animals greatly contributed to clinical disease features.  
The above findings imply elucidating genetic differences between ALS patients will 
likely be necessary to fully explain for their disease features. As we only had 7 sALS 
samples and 8 neurologically healthy controls, we had limited statistical power to identify 
these differences. However, as sequencing costs decrease, larger sample sizes 
conferring greater statistical detection power will become feasible. These data sets will 
likely enable stratification of sALS by its varied molecular phenotypes as has been seen 
in other diseases like breast cancer (Cancer Genome Atlas Network 2012). These 
approaches may ultimately lead to therapies against pathways that are universally 
beneficial to sALS patients, such as TNF signaling, as well as those specifically tailored 


















CHAPTER 3: Mitochondrial gene expression levels were not aberrant in sALS 





Mitochondrial abnormalities have been identified in ALS tissues in numerous 
studies dating back to 1994. Early studies found mitochondria isolated from fALS rodents’ 
spinal motor neurons had aberrant morphologies (Higgins, Jung 2003, Kong, Xu 1998). 
Mitochondria isolated from human sALS and fALS patients’ muscle tissues, spinal cells, 
and postmortem motor neurons have also shown morphological abnormalities (Crugnola 
et al. 2010, Echaniz-Laguna et al. 2006, Sasaki, Iwata 1996, Hirano, Donnenfeld, Sasaki, 
Nakano 1984, Sasaki, Iwata 2007). In addition to aberrant mitochondrial morphology, 
defective electron transport chain (ETC) activity and oxidative phosphorylation 
(OXPHOS) rates have been observed in various tissues from fALS rodents and human 
ALS patients. Mitochondria isolated from fALS rodents’ brain and spinal cord tissues had 
significantly decreased rates of OXPHOS compared to mitochondrial isolated from 
matched control tissues (Mattiazzi et al. 2002). Postmortem spinal cord tissue from both 
sALS and fALS patients have shown decreased activity of ETC complexes I, II, III, IV, 





selective loss of mitochondria in those spinal cells. Further, skeletal muscle from sALS 
patients also displayed aberrant ETC activity, specifically in complexes 1 and 4 (Crugnola 
et al. 2010, Vielhaber et al. 2000, Wiedermann et al. 1998).  
A relatively recent study (Cassina et al. 2008) linked defective OXPHOS activity in 
fALS rodents’ spinal cell mitochondria to increased spinal motor neuron apoptosis. 
Mitochondria isolated from fALS rodent astrocytes had defective OXPHOS characterized 
by decreased oxygen consumption, lack of ADP-dependent respiratory control, and 
decreased membrane potential. Interestingly, these fALS rodents’ astrocytes (but not 
wildtype rodents’ astrocytes) induced death of spinal motor neurons when both cell types 
were co-cultured in vitro. After treating these fALS rodent astrocytes with mitochondrial-
targeted antioxidants (ubiquinone and carboxy-proxyl nitroxide), they showed improved 
mitochondrial OXPHOS and did not induce motor neuron death when co-cultured with 
motor neurons in vitro. Taken together, these findings suggest defective OXPHOS related 
to mitochondrial dysfunction in spinal cells may contribute to spinal motor neuron death.   
             Members of our lab recently published a study (Ladd, Keeney, Govind, Bennett 
2014) comparing 76 (72 nuclear-encoded and 4 mitochondrial-encoded) genes’ 
expression levels in various tissues from ALS patients and neurologically healthy controls. 
These 76 genes encode components of the ETC and OXPHOS complexes I-V. Their 
expression levels were compared in 16 postmortem cervical spinal section samples (10 
ALS and 6 neurologically healthy controls) and 20 peripheral blood mononuclear cell 
samples (9 ALS and 11 neurologically healthy controls). Postmortem spinal sections from 
select samples in my dissertation project (all 7 sALS patients and 3 neurologically healthy 





 Interestingly, the 4 mitochondrial-encoded OXPHOS genes (12s rRNA, COX3, 
ND2, and ND4) had statistically significantly decreased expression levels in both ALS 
sample groups (postmortem spinal sections and peripheral mononuclear blood cells) 
relative to their respective control sample groups. The majority of the 72 nuclear-encoded 
OXPHOS genes had decreased expression levels in the sALS patients’ postmortem 
spinal section samples relative to the neurologically healthy controls’ postmortem spinal 
section samples. Taken together, reduced expression of these OXPHOS genes may have 
led to aberrant OXPHOS activity in these ALS patients’ spinal cells. Further, that may 
have promoted spinal motor neuron death. 
In this chapter, we used a combination of RNA-sequencing and bioinformatics 
tools to elucidate sALS group-specific mitochondrial gene expression level differences. 
We assessed whether any of the 37 annotated mitochondrial genes in the hg19 human 
reference mitochondrial genome were differentially expressed in our sALS patients’ 
postmortem cervical spinal section samples relative to our neurologically healthy controls’ 




Input sample datasets: We used the same 7 sALS and 8 neurologically healthy control 
samples’ Read 1 and Read 2 FastQ files output by Trimmomatic (as described in Chapter 





Pre-alignment steps: Prior to attempting alignment of each sample’s paired end reads 
to the hg19 human reference mitochondrial transcriptome then hg19 human reference 
mitochondrial genome, I needed to generate these files. The hg19 human reference 
transcriptome file obtained from the Illumina iGenomes UCSC hg19 directory as 
described in Chapter 2 did not include mitochondrial RNA transcripts.  
To accomplish this, I downloaded ENCODE’s hg19 human reference 
mitochondrial transcriptome file (known mtRNA transcripts) from the UCSC Table 
Browser using their website (http://genome.ucsc.edu/cgi-bin/hgTables). I specified Feb. 
2009 (GRCh37/hg19) for assembly, GENCODE Genes V19 for track, and chrM in the 
position search field under region. All other fields were unchanged from their default 
entries.  
To generate the hg19 human reference mitochondrial genome file, I simply 
extracted the mitochondrial sequence (ChrM) found in the hg19 human reference genome 
text file obtained from the Illumina iGenomes UCSC hg19 directory as described in 
Chapter 2. 
Alignment of paired end reads: We used Tophat2 (Kim et al. 2013) to attempt alignment 
of each sample’s paired end reads to the hg19 human reference mitochondrial 
transcriptome then hg19 human reference mitochondrial genome. Tophat2 followed the 
same alignment procedure detailed in Chapter 2 and shown in Figure 10.  
HTSeq-Count: We used HTSeq-Count (Anders, Pyl, Huber 2015) to report the total 
number of paired end reads that aligned to each annotated mitochondrial gene’s 





2 and shown in Figure 13. For each sample, HTSeq-Count produced a matrix with all 
annotated mitochondrial genes and their corresponding paired end read count values.  
EdgeR and DEG identification:  We used EdgeR (Robinson, McCarthy, Smyth 2010), 
to detect sALS group-specific mitochondrial DEGs. EdgeR followed the same 
normalization and testing procedures detailed in Chapter 2 to identify sALS group-specific 
mitochondrial DEGs. EdgeR reported an associated p-value for each annotated 
mitochondrial gene tested. We calculated each annotated mitochondrial gene’s 
Benjamini-Hochberg corrected p-value using their corresponding EdgeR reported p-value 
via the R function p.adjust. Each annotated mitochondrial gene with a Benjamini-
Hochberg corrected p-value < 0.10 was identified as a sALS group-specific mitochondrial 
DEG. 
We used EdgeR’s default workflow for our mitochondrial DEG analysis. We 
decided to filter out genes with a cpm (counts per million aligned paired end reads) value 
<1 in 7 samples. We chose a cpm value of 1 as smaller values likely reflected noise. We 
chose 7 samples as our threshold, as genes that were only expressed in our disease or 
control group could play an important role in disease pathology.  
DESeq2 and DEG identification: We used DESeq2 (Love, Huber, Anders 2014) to 
detect sALS group-specific mitochondrial DEGs. DESeq2 followed the same 
normalization and testing procedures detailed in Chapter 2 to identify sALS group-specific 
mitochondrial DEGs. DESeq2 reported an associated p-value for each annotated 
mitochondrial gene tested. We calculated each annotated mitochondrial gene’s 





value via the R function p.adjust. Each annotated mitochondrial gene with a Benjamini-
Hochberg corrected p-value < 0.10 was identified as a sALS group-specific mitochondrial 
DEG. 
Cufflinks for gene expression estimates: We separately used Cufflinks (Trapnell et al. 
2010) to estimate each sample’s mitochondrial gene expression levels for all annotated 
mitochondrial genes in the hg19 human reference mitochondrial genome. Cufflinks 
followed the same procedure detailed in Chapter 2 to estimate these mitochondrial gene’s 
expression levels. 
Cuffdiff2 for DEG identification: We used Cuffdiff2 (Trapnell et al. 2013) to detect sALS 
group-specific mitochondrial DEGs. Cuffdiff2 followed the same normalization and testing 
procedures detailed in Chapter 2 to detect sALS group-specific mitochondrial DEGs. 
Cuffdiff2 reported an associated p-value for each annotated mitochondrial gene. We 
calculated all annotated mitochondrial genes’ Benjamini-Hochberg corrected p-values 
using their corresponding Cuffdiff2 p-values via the R function p.adjust. Each annotated 
gene with a Benjamini-Hochberg corrected p-value < 0.10 was identified as a sALS group-
specific mitochondrial DEG. 
 
III. Results: 
Mitochondrial DEG testing: We elected to identify sALS group-specific DEGs using 
Cufflinks/Cuffdiff2, DESeq2, and EdgeR. We made this decision based on the findings of 
a recent study showing these three analyses have different limitations when they were 





None of the 37 annotated mitochondrial genes were identified as sALS group-
specific DEGs in any of the three analyses. However, 3 of the 4 genes identified as 
statistically significantly decreased in ALS samples in our lab’s previous publication 
(Ladd, Keeney, Govind, Bennett 2014) had decreased expression levels in our sALS 
samples. Further, we found all but three of the 13 mitochondrial protein-coding genes 
(whose translated proteins are part of ETC complexes) were expressed at lower levels in 
our sALS patients relative to our neurologically healthy controls. These results can be 
seen in Figures 26 and 27.  
IV.      Discussion: 
Evidence for mitochondrial dysfunction has been identified in ALS tissues using a 
variety of molecular biology techniques across independent studies. This includes 
findings of aberrant mitochondrial morphology and defective OXPHOS in ALS tissues 
from human patients (both fALS and sALS) and fALS rodents (Higgins, Jung 2003, Kong, 
Xu 1998, Crugnola et al. 2010, Echaniz-Laguna et al. 2006, Sasaki, Iwata 1996, Hirano, 
Donnenfeld, Sasaki, Nakano 1984, Sasaki, Iwata 2007, Mattiazzi et al. 2002, Borthwick 
et al. 1999, Fujita et al. 1996, Wiedemann et al. 2002, Vielhaber et al. 2000, Wiedermann 
et al. 1998, Cassina et al. 2008, Ladd, Keeney, Govind, Bennett 2014).  
Defective OXPHOS activity has been shown to increase the production of reactive 
oxygen species (ROS), a marker for oxidative stress, in affected cells (Duffy, Chapman, 







Figure 26. Mitochondrial gene expression levels. This figure shows 4 mitochondrial genes’ 
expression levels (assessed in our lab’s previous study) in our sALS sample group vs. our 
neurologically healthy control sample group. None of these genes were identified as statistically 







Figure 27. Mitochondrial protein-coding genes’ expression levels. This figure shows all 13 
mitochondrial protein-coding genes’ expression levels in our sALS sample group vs. our 







ultimately promote motor neuron death as a result of elevated oxidative stress. A recent 
study (Cassina et al. 2008) found mitochondria isolated from fALS rodents’ astrocytes 1) 
showed defective OXPHOS activity, and 2) induced motor neuron death when the two 
cell types were co-cultured in vitro. After treating these astrocytes with mitochondrial-
targeted antioxidants, they showed normal mitochondrial respiratory function and did not 
induce motor neuron death when co-cultured with motor neurons in vitro. 
Elevated oxidative stress has been observed in ALS tissues from human patients 
and fALS rodents. One study revealed cerebrospinal fluid from ALS patients had elevated 
levels of 3-nitrotyrosine, a marker of free radical damage related to oxidative stress, 
relative to neurologically healthy control samples’ cerebrospinal fluid (Duffy, Chapman, 
Shaw, Grierson 2011). Further, fALS rodents’ spinal cord motor neurons have shown 
evidence of elevated oxidative stress characterized by increased oxyradical production, 
carbonylation of proteins, and peroxidation of lipids in the mitochondrial membrane. 
Interestingly, peroxidation of cardiolipin disrupts its interaction with cytochrome C, leading 
to cytochrome C release from the mitochondrial membrane. It is widely known that 
cytochrome C release can promote mitochondrial-mediated apoptosis (Al-Lamki, 
Mayadas 2015, Falschlehner, Emmerich, Gerlach, Walczak 2007, Matthews, Newbold, 
Johnstone 2012). Aberrant mitochondrial gene expression could plausibly lead to 
OXPHOS defects (and potentially motor neuron death) in sALS patients’ disease-
vulnerable tissues. 
In this chapter, we combined deep RNA-Sequencing and systems biology 
analyses to identify sALS group-specific mitochondrial DEGs in postmortem spinal 





estimate all 37 annotated mitochondrial genes’ expression levels in sALS patients’ 
postmortem cervical spinal tissues containing disease-vulnerable motor neurons. We did 
not identify any sALS group-specific DEGs in this analysis.  
Further, we did not replicate our lab’s previous findings showing 4 mitochondrial-
encoded OXPHOS genes (12s rRNA, COX3, ND2, and ND4) had statistically significantly 
decreased expression levels in postmortem cervical spinal sections from ALS samples 
relative to neurologically healthy controls. While there was an overlap in the postmortem 
cervical spinal section samples examined in this mitochondrial DEG analysis and our lab’s 
previous study, multiple samples were not shared between the two analyses. This likely 
explains why we did not replicate the previous study’s findings.  
We did not assess whether any of our sALS patients carried known (or novel) 
pathogenic variants that lead to defective OXPHOS. Mitochondrial DNA (mtDNA) has an 
elevated mutation rate, which results in a high frequency of rare variants across 
individuals (Taylor, Turnbull 2009). Further, the pathogenic mtDNA mutations identified 
in various mitochondrial diseases invariably lead in defective mitochondrial OXPHOS, 
resulting in a reduced ability to produce cellular ATP (Tuppen, Blakely, Turnbull, Taylor 
2010).  
To determine whether any of our sALS patients harbored known or novel 
pathogenic mitochondrial variants that lead to defects in OXPHOS, I would first identify 
each patient’s mitochondrial SNVs and indels using the GATK pipeline described in 
Chapter 2. I would next assess whether any of these variants match published pathogenic 





remaining variants, I would 1) assess whether they were found in healthy individuals’ 
mtDNA sequences catalogued in an online database such as The Human Mitochondrial 
Genome Database (Ruiz-Pesini et al. 2007), and 2) input them into a tool such as 
PolyPhen-2 (Adzhubei et al. 2010) to assess whether they are likely deleterious.  
There is considerable heterogeneity in sALS patients’ clinical features (Al-Chalabi, 
Hardiman 2013, Ganesalingam et al. 2009), which likely reflects different genetic 
etiologies underlying different instances of sALS. It is also entirely possible the 
pathogenesis of sALS in our patients did not involve aberrant mitochondrial gene 

























CHAPTER 4: Cholesterol biosynthesis defects may contribute to disease 





A role for RNA processing defects in ALS pathology was largely confirmed via the 
identification of >100 ALS causal mutations in the Fused in Sarcoma/Translocation in 
Liposarcoma (FUS/TLS) and TAR DNA-binding protein (TARDBP) genes (Renton, Chio, 
Traynor 2014). These genes encode the RNA-binding proteins FUS/TLS and TDP-43, 
respectively. FUS/TLS and TDP-43 regulate nuclear RNA processing activities including 
pre-mRNA splicing, RNA stability, RNA transport, protein translation, and microRNA 
maturation (Xu 2012, Colombrita et al 2012). Each protein binds >5,000 RNA transcripts 
(with minimal overlap in which RNA transcripts each binds to), suggesting they are both 
major regulators of nuclear RNA processing activities (Donnelly, Grima, Sattler 2014). 
However, it remains unclear how mutations in these two genes promote 
neurodegenerative processes in ALS patients. 
A recent study found iPSC-derived motor neurons carrying a FUS/TLS causal ALS 
mutation had cytoplasmic aggregates of FUS/TLS (known as FUS/TLS proteinopathy) 





a FUS/TLS causal ALS mutation (Ichiyanagi et al. 2016). Similarly, overexpression of 
mutant TDP-43 proteins (encoded by the TARDBP gene carrying different causal ALS 
mutations) led to increased 1) TDP-43 proteinopathy and apoptosis in HEK-293 cells 
(Mutihac et al. 2015), and 2) TDP-43 proteinopathy and neurodegeneration in a 
Drosophila model (Vanden Broeck et al. 2015). 
 While <4% of Caucasian sALS patients carry a causal ALS mutation in TARDBP 
or FUS/TLS as of 2014 (Renton, Chio, Traynor 2014), ~98% of all ALS patients (both 
fALS and sALS) have TDP-43 proteinopathy in their spinal motor neurons, spinal glial 
cells, and/or select brain cells (Lagier-Tourenne, Cleveland 2009, Donnelly, Grima, 
Sattler 2014, Yang et al. 2014). Interestingly, cells exhibiting FUS/TLS or TDP-43 
proteinopathy (with or without accompanying FUS/TLS or TARDBP causal ALS 
mutations) have reduced levels of FUS/TLS or TDP-43 protein in their nuclei, respectively 
(Kwiatkowski et al. 2009, Yang et al. 2014).  
Reduced nuclear levels of FUS/TLS or TDP-43 promote apoptosis in cellular and 
animals models. iPSC-derived motor neurons with reduced nuclear FUS/TLS had 
elevated rates of apoptosis compared to iPSC-derived motor neurons with basal nuclear 
levels of FUS/TLS (Ichiyanagi et al. 2016). Systemic knockdown of TDP-43 in zebrafish 
led to muscle degeneration, as well as morphological and functional defects in the CNS 
(Schmid et al. 2013). Similarly, systemic knockdown of TDP-43 in a transgenic mouse 
line led to an age-dependent neurodegenerative phenotype characterized by motor 
weakness, paralysis, death of spinal motor neurons and layer V cortical neurons, and 
premature death (Yang et al. 2014). Taken together, 1) the majority of ALS patients’ 





43 proteinopathy, and 2) reduced nuclear levels of TDP-43 (or FUS/TLS) can promote 
neurodegeneration. 
Reduced nuclear levels of FUS/TLS or TDP-43 may lead to apoptosis (or 
neurodegeneration) via disruption of some or all of their normal RNA processing activities 
in the nucleus. Systemic knockdown of TDP-43 in a mouse model induced pre-mRNA 
splicing defects alongside neurodegeneration in affected cells (Yang et al. 2014). 
Whether those pre-mRNA splicing defects contributed to neurodegenerative processes 
or simply coincided with them is unknown. However, disruption of either FUS/TLS or TDP-
43’s pre-mRNA splicing activities could plausibly lead to neurodegeneration.  
Within human primary cortical neurons and mouse brains, FUS/TLS is known to 
splice RNA transcripts from genes associated with neurodegenerative disorders 
(including Microtubule-Associated Protein Tau [MAPT], Calmodulin-Dependent Protein 
Kinase II Alpha [CAMK2A], Fragile X Mental Retardation 1 [FMR1], and NDRG Family 
Member 2 [Ndrg2]) (Masuda, Takeda, Ohno 2016). Further, shRNA-mediated knockdown 
of TDP-43 in human neuroblastoma cells 1) led to splicing changes for genes with known 
roles in neuronal development and survival, and 2) increased expression of BCL-2 
Interacting Mediator of Cell Death (BIM)’s most cytotoxic RNA isoform (Tollervey et al. 
2011).  
None of our sALS patients carried a known causal ALS coding mutation in the 
TARDBP or FUS/TLS genes, as reported in Chapter 2. However, it is likely our sALS 
patients’ cervical spinal cells had TDP-43 proteinopathy, as this feature is seen in 98% of 
ALS patients (Lagier-Tourenne, Cleveland 2009, Donnelly, Grima, Sattler 2014, Yang et 





levels (Yang et al. 2014), corresponding TDP-43 splicing defects may have occurred in 
our sALS patients’ cervical spinal cells as a result.  
In this chapter, we used a combination of RNA-sequencing, bioinformatics tools, 
and systems biology analyses to elucidate sALS group-specific exon usage differences 
in nuclear genes and assess their biological significance. Specifically, we set out to 1) 
identify cellular processes associated with nuclear genes containing exons that were 
statistically significantly differentially used in the sALS sample group, as they may be 
relevant to disease pathology.  
 
II. Methods: 
Input sample datasets: We used the same 7 sALS and 8 neurologically healthy control 
samples’ Read 1 and Read 2 FastQ files output by Trimmomatic (as described in 
Chapter 2) for our downstream DEXSeq (Anders, Reyes, Huber 2012) differential exon 
usage analysis.  
Pre-alignment steps: The DEXSeq analysis’ script was originally written using several 
of Ensembl’s annotated human reference transcriptome and genome files. 
Consequently, DEXSeq is known to have compatibility issues with the hg19 human 
reference transcriptome and genome files I obtained from the Illumina iGenomes UCSC 
hg19 directory as described in Chapter 2. 
Prior to attempting alignment of each sample’s paired end reads to the hg19 
human reference transcriptome then genome, I downloaded Ensembl’s hg19 human 






ftp://ftp.ensembl.org/pub/release-63/fasta/homo_sapiens/dna/, respectively. I combined 
each chromosome’s DNA sequence (contained in individual Fasta files) to create the 
hg19 human reference genome file. 
Alignment: We used STAR, an open source program specially designed for RNA-
Sequencing data, to attempt alignment of each sample’s paired end reads to Ensembl’s 
hg19 human reference genome. STAR used each sample’s Read 1 and Read 2 FastQ 
files from Trimmomatic as input, and output a file containing their aligned paired end reads 
for downstream analysis. 
DEXSeq counting process: For each annotated gene, DEXSeq first identified 
every unique counting bin within each of its exons via comparing known RNA transcripts’ 
sequences (in the Ensembl hg19 human reference transcriptome file) to each annotated 
gene’s exon sequences (in the Ensembl hg19 human reference genome file). Figure 28 
illustrates this process for a fictional gene.   
Ensembl’s hg19 human reference transcriptome file listed some exons as 
belonging to RNA transcripts from multiple genes (rather than one gene) based on 
observations from previous studies. We decided to exclude these exons’ counting bins 
from the DEXSeq analysis, as determining which of those gene’s RNA transcripts 
contained that exon would be impossible in most instances given the length of our RNA-
Sequencing reads. Inputting all of possible genes into the downstream over-







Figure 28. DEXSeq counting bin identification. This figure shows counting bins identified for 
a fictional gene A by DEXSeq. This fictional gene has three annotated RNA transcripts 
(transcribed exons are represented by light gray boxes). The majority of the first exon’s 
sequence is contained in all three RNA transcripts, but transcript 1 has additional transcribed 
sequence on its 5’ end relative to the other two RNA transcripts. DEXSeq thereby splits this 
fictional gene A’s first exon into 2 counting bins. The other counting bins’ boundaries correspond 
exactly to known boundaries for those exons in fictional gene A. Four total counting bins (dark 











For each sample, DEXSeq counted the number of aligned paired end reads that 
fell within each eligible counting bin. Reads that overlapped several counting bins were 
counted for each of those bins. 
DEXSeq analysis: We used DEXSeq to identify sALS group-specific DUEs. The creators 
of DESeq2 made DEXSeq, and DEXSeq applied many of the same mathematical 
procedures used in DESeq2 (and EdgeR) to appropriately model counting bins’ counts 
across samples. These procedures ultimately reduced the number of identified DUEs that 
were false positives. DEXSeq relied on generalized linear models to identify sALS group-
specific DUEs.  
Prior to testing for sALS group-specific DUEs, DEXSeq omitted 1) any gene that 
only contained one counting bin (or had less than two counting bins with counts), and 2) 
any counting bin with an extremely low count sum across samples. It would be impossible 
to identify whether an annotated gene with only one counting bin (or with less than two 
counting bins with counts) was differentially expressed or if its individual counting bin was 
differentially expressed. Removing counting bins with a low count sum across samples 
served to reduce downstream false positive DUEs, as these counting bins had a low 
signal-to-noise ratio. 
To further prevent false positive DUEs, DEXSeq mathematically accounted for 1) 
differences in the total number of counting bin counts between samples, 2) overdispersion 
in each counting bin’s counts across samples, and 3) whether each counting bin’s 
corresponding annotated gene was differentially expressed between groups.  





could reflect each sample’s total number of RNA-Sequencing reads as opposed to 
differences in that counting bin’s expression levels between samples. Assume two of our 
samples’ RNA-Sequencing libraries had an equal number of sequenceable dscDNA 
molecules corresponding to a given counting bin (suggesting that counting bin had an 
equal expression level in both samples’ postmortem cervical spinal sections). If more total 
sequencing reads were generated for one of those samples, that sample’s sequencing 
data would likely have more total paired end reads corresponding to that counting bin 
relative to the other sample. This is because denatured strands from that counting bin’s 
corresponding sequenceable dscDNA molecules were appropriated more Illumina 
NextSeq500 binding spots (covalently bound oligonucleotides) to potentially hybridize to 
for sequencing. 
Like paired end read counts, counting bin counts across samples are often 
overdispersed. This means the variance of counting bin counts across each group’s 
samples often exceeds what is expected using a Poisson distribution. DEXSeq’s DUE 
analysis relied on negative binomial distributions to best account for variance in each 
counting bin’s counts across each group’s samples. DEXSeq also estimated the level of 
dispersion for each individual counting bin (using maximum likelihood modeling) and 
counting bins with similar expression levels across samples. DEXSeq then applied an 
empirical Bayes’ theorem to moderate overdispersion via shrinking each counting bin’s 
level of dispersion towards the level of dispersion estimated for counting bins with a 
similar expression level.  
DEXSeq assessed whether each counting bin’s corresponding annotated gene 





If a given annotated gene was differentially expressed between groups, the authors 
reasoned each of that annotated gene’s counting bins was likely to be differentially used 
between groups by a similar quantitative factor. In cases where a given annotated gene 
was differentially expressed, that quantitative factor was accounted for when testing 
whether each of that annotated gene’s counting bins was differentially used between 
groups.  
For each counting bin, two generalized linear models (full and reduced) were 
generated. Each of these generalized linear models incorporated the above factors and 
a log fold change value calculated via comparing the counting bin’s representative count 
values in our sALS and neurologically healthy control groups. The full generalized linear 
model included a variable that estimated how much of the difference in each counting 
bin’s estimated usage levels between groups was explained by group membership (case 
vs. control status), whereas the reduced generalized linear model omitted that variable. 
To assess whether a given counting bin was differentially used between groups, 
DEXSeq compared the fits of these two generalized linear models using a likelihood ratio 
test. For each counting bin, this comparison produced a corresponding p-value. We 
calculated all counting bins’ Benjamini-Hochberg corrected p-values using DEXSeq’s 
reported p-values via the R function p.adjust. Each counting bin with a Benjamini-
Hochberg corrected p-value < 0.10 was identified as a sALS group-specific DUE. Prior to 
uploading our list of annotated genes containing a DUE to IPA, we converted their 





Ingenuity Pathway Analysis: We used QIAGEN’s Ingenuity Pathway Analysis to assess 
what canonical signaling pathways, diseases/disorders, and cellular functions were 
statistically significantly associated with our 46 annotated genes containing one or more 
DUEs. IPA used a right-tailed Fisher Exact test to assess the number of these annotated 
genes that were separately associated with each canonical signaling pathway, 
disease/disorder, and cellular functions in the IPA Knowledge base. Corresponding 
association p-values relating these annotated genes carrying one or more DUEs to each 
tested canonical signaling pathway, disease/disorder, and cellular function were reported.  
 
III. Results: 
DEXSeq DUE testing and associated cellular processes: At an FDR of .10, DEXSeq 
identified 52 sALS group-specific DUEs (from 46 annotated genes). These results are 
shown in Table 9. A visual schematic of a sALS group-specific DUE can be seen in Figure 
29.  Among various findings, QIAGEN’s Ingenuity Pathway Analysis revealed these 
DUEs’ annotated genes were associated with cholesterol biosynthesis, the mevalonate 































       
LINC00476 CB007 -2.32  ENTPD4 CB003 1.04 
SEMA4G CB044 -1.73  FAM219B CB005 1.09 
SLCO2B1 CB019 -1.69  POLI CB012 1.17 
CTNND2 CB048 -1.53  RNF170 CB004 1.17 
FCGR2A CB024 -1.52  VEZT CB086 1.22 
SUSD1 CB013 -1.26  MYLK CB044 1.24 
CD27-AS1 CB011 -1.15  HSD17B7 CB016 1.27 
PCNT CB017 -1.15  FDFT1 CB025 1.29 
SLC25A36 CB021 -1.12  RSRC2 CB046 1.30 
LRRTM4 CB006 -1.09  TF CB004 1.31 
GABPA CB005 -1.08  TF CB003 1.34 
HAPLN4 CB001 -1.08  ATRNL1 CB048 1.34 
MORC3 CB018 -1.08  ATAD5 CB021 1.35 
MORC3 CB017 -1.07  HMGCS1 CB025 1.38 
CCDC91 CB027 -1.06  RSRC2 CB047 1.50 
GRAMD3 CB020 -1.05  CCDC141 CB004 1.51 
CDK17 CB018 -1.05  RICTOR CB002 1.51 
BARD1 CB018 -1.05  KALRN CB071 1.52 
CHCHD2 CB001 -1.05  USH2A CB001 1.52 
LYPLA1 CB008 -1.05  THAP9-AS1 CB009 1.54 
MKLN1 CB016 -1.05  NBEAL2 CB083 1.55 











Figure 29. DEXSeq differentially used exon plot. This figure shows the difference in exon 
usage for counting bin #13 of the IDI1 locus. This counting bin was selected as an illustrative 
example, as its usage level had the largest positive fold change in our sALS sample group 









                          Table 10: IPA results for sALS group-specific DUEs 
Top Canonical Pathways Overlapping Genes p-Value 
Superpathway of Cholesterol Biosynthesis 4/28 2.40E-07 
Cholesterol Biosynthesis I 2/13 2.82E-04 
Mevalonate Pathway I 2/13 2.82E-04 
Cholesterol Biosynthesis II 2/13 2.82E-04 
Cholesterol Biosynthesis III 2/13 2.82E-04 
     
Top Diseases and Disorders  p-Value 
Cardiovascular Disease  4.48E-02 - 1.16E-03 
Hematological Disease  3.44E-02 - 1.16E-03 
Cancer  4.81E-02 - 1.94E-03 
Connective Tissue Disorders  4.80E-02 - 1.94E-03 
Developmental Disorder  4.74E-02 - 1.94E-03 
    
Top Upstream Regulators Overlapping Genes 
 
p-Value 
FOXO4 4/26 1.23E-06 
SREBF2 4/37 8.33E-06 
Pitavastatin 3/13 9.10E-06 
NPPB 3/20 2.37E-05 









Aberrant RNA processing has been recurrently associated with ALS-group specific 
DEGs identified in tissues from both human patients (fALS and sALS) and fALS rodents 
(Heath, Kirby, Shaw 2013). This may reflect a disruption of TDP-43’s normal RNA 
processing activities as a result of reduced nuclear TDP-43 protein in ALS tissues. 
Reduced nuclear TDP-43 has been observed in cells with TDP-43 proteinopathy, a 
feature found in ~98% of ALS patients’ (both fALS and sALS) spinal motor neurons, spinal 
glial cells, and/or select brain cells (Lagier-Tourenne, Cleveland 2009, Donnelly, Grima, 
Sattler 2014, Yang et al. 2014).  
Reduced nuclear TDP-43 levels promoted neurodegeneration in various animal 
models (Schmid et al. 2003, Yang et al. 2014). Further, one of those studies demonstrated 
reduced nuclear TDP-43 caused TDP-43 splicing defects alongside neurodegeneration 
(Yang et al. 2014). It is unclear whether TDP-43 splicing defects functionally contribute to 
neurodegenerative processes. However, it seems plausible as TDP-43 regulates pre-
mRNA splicing for genes that 1) encode synaptic proteins (Polymenidou et al. 2011), 2) 
preserve neuronal integrity (Lagier-Tourenne et al. 2012), and 3) promote neuronal 
survival (Tollervey et al. 2011).  
To date, two ALS studies have used splicing-sensitive microarrays to identify 
statistically significant splicing differences in spinal motor neurons from sALS patients and 
neurologically healthy controls (Rabin et al. 2010, Highley et al. 2014). In both studies, 
researchers confirmed their sALS patients’ spinal motor neurons had TDP-43 
proteinopathy. The earlier study identified 411 aberrantly spliced genes, and over-





transmembrane receptor protein tyrosine kinase activity, and the extracellular matrix 
(Rabin et al. 2010).  The later study identified 6,449 sALS group-specific DUEs (in 4,311 
genes), and over-representation analyses revealed those genes were associated with 
ribonucleotide binding, cytoskeletal organization, protein localization, and macromolecule 
catabolic processes (Highley et al. 2014).  
In this chapter, we combined deep RNA-Sequencing and systems biology 
analyses to identify sALS group-specific DUEs in postmortem spinal tissues from sALS 
patients and neurologically healthy controls. We discovered 52 DUEs in 46 annotated 
genes. 15 of these DUEs’ fold change usage difference between groups was <10%. It is 
difficult to envision these differences playing a significant role in disease pathology. 
Nonetheless, over-representation analyses revealed the 46 genes containing DUEs were 
associated with cholesterol biosynthesis, the mevalonate pathway, and lipid metabolism. 
Cholesterol is an essential component of neuronal membranes, and is needed to 
form membrane lipid rafts necessary for protein anchorage and trafficking. Cholesterol is 
also used for continued axon growth and synapse remodeling in the mature adult brain, 
and serves as a precursor of neurosteroids (Anchisi, Dessi, Pani, Mandas 2013).  
Cholesterol biosynthesis involves a multi-step process beginning with conversion of 
acetyl-CoA to 3-hydroxy-3-methylglutaryl-CoA, followed by the generation of mevalonate 
(Martin, Pfrieger, Dotti 2014). After conversion into many other intermediary substrates, 
cholesterol is produced.  
Defects in cholesterol biosynthesis are known to cause several rare 





cerebrotendinous xanthomatosis, congenital hemidysplasia with ichthyosiform 
erythroderma and limb defects, and Smith-Lemli-Opitz Syndrome (SLOS) (Vance 2012). 
Dysregulated cholesterol homeostasis has separately been associated with more 
common neurodegenerative disorders (including Alzheimer’s disease, Huntington’s 
disease, and Parkinson’s disease). If and how defects in cholesterol biosynthesis or 
homeostasis functionally contribute to these disorders’ neurodegenerative processes 
remains largely unknown. However, we do know SLOS causal mutations in the 7-
Dehyrocholesterol reductase (DHCR7) gene lead to abnormally low levels of cholesterol 
(and high levels of 7-dehydrocholesterol) in cells, plasma, and the brain (Vance 2012). 
Our best understanding of how dysregulated cholesterol metabolism can 
functionally contribute to neurodegenerative processes comes from studies of Niemann-
Pick Type C (NPC), a neurodegenerative disorder affecting 1 in 150,000 people. In NPC, 
mutant NPC1 and NPC2 proteins fail to transport free cholesterol from lipoproteins into 
neuronal cells’ cytosols, leaving the cholesterol sequestered in late endosomes and/or 
lysosomes. This results in disproportionately low levels of cholesterol in affected neurons’ 
plasma membranes and axons (Vance 2012).  
Interestingly, subcutaneous injection of a cholesterol binding compound 
(cyclodextrin) into NPC -/- mice slowed neurodegeneration and extended their lifespan 
by 50% (Liu et al. 2009). A separate analysis showed administrating a low dose of 
cyclodextrin to NPC -/- neurons released sequestered cholesterol from their late 
endosomes and/or lysosomes into their cytoplasms (Vance 2012). Researchers have 
proposed cyclodextrin may stop neurodegeneration in NPC mouse models by re-





lysosomes into their plasma membranes (where it was low in concentration) (Martin, 
Pfreiger, Dotti 2014).  
Much less is known about how cholesterol biosynthesis, cholesterol homeostasis, 
or the distribution of cholesterol in neuronal cells may contribute to sALS pathology. A 
very early study (Cutler et al. 2002) reported elevated levels of sphingomyelin, ceramides, 
and cholesterol esters were found in the spinal cords of ALS patients and fALS rodents 
carrying a SOD1 mutation. Further, they speculated this could promote 
neurodegeneration via oxidative stress related apoptotic events. Several recent studies 
have shown ALS patients with higher circulating cholesterol levels (characterized by 
elevated LDL to HDL ratios) live longer than patients with lower cholesterol levels 
(D’Amico, Factor-Litvak, Santella, Mitsumoto 2013). It is tempting to think this protective 
effect is the result of higher cholesterol concentrations in those neurons’ plasma 
membranes, especially considering low cholesterol levels were linked to 
neurodegneration in SLOS and NPC. However, the CNS blocks entry of cholesterol-rich 
lipoproteins circulating in the blood via the blood brain barrier (BBB). Therefore, it is 
unclear how a higher circulating cholesterol level would protect disease-vulnerable cells 
in the spinal cord (Martin, Pfreiger, Dotti 2014). 
We cannot predict whether cholesterol biosynthesis was increased or decreased 
in our sALS samples based on our sALS group-specific DUEs alone. Further, it is unclear 
what significance these findings have for motor neurons, as the majority of RNA isolated 
from these spinal sections came from astrocytes and microglia. However, the link 
between cholesterol biosynthesis and neurodegeneration has been established 





plasma membranes and axons) have been linked to neurodegeneration in SLOS and 
NPC. For these reasons, I propose future experiments that first generate iPSC-derived 
astrocytes, iPSC-derived microglia, and iPSC-derived motor neurons using mononuclear 
blood cells drawn from sALS patients and neurologically healthy controls. I would co-
culture these cells using 3-dimensional scaffolding techniques in vitro, as described in 
this paper (Schwartz et al. 2015).  
I would then directly compare both membrane bound and free cholesterol levels in 
iPSC-derived motor neurons from sALS patients and neurologically healthy controls using 
immunohistochemistry and a colorimetric assay, respectively. My immunohistochemistry 
experiments would involving staining for Filipin, a highly fluorescent compound that 
specifically binds to cholesterol. Filipin staining is used to diagnosis NPC in clinical 
settings by assessing the level of cholesterol found sequestered in late endosomes and/or 
lysosomes and in the plasma membrane (Vanier, Latour 2015). I would also lyse equal 
amounts of each 3D culture prior to measuring total cholesterol levels (reflecting 
cholesterol biosynthesis) using a commercially available colorimetric assay.  I would be 
most interested in determining 1) whether iPSC-derived motor neurons from sALS 
patients (relative to neurologically healthy controls) had significantly different levels of 
cholesterol staining in their late endosomes or cell membranes, and 2) whether 3D 
neuronal models from sALS patients (relative to neurologically healthy controls) had 
significantly different levels of free cholesterol.  
If the sALS group did have significant differences in either measurement, I would 
assess whether those differences were seen alongside increased rates of motor neuron 





I would then begin testing whether different pharmacological agents 1) normalized these 
sALS-group specific differences in cholesterol distribution in the cell and/or cholesterol 





































ALS is a disease characterized by degeneration of upper and lower motor 
neurons in the brain stem and spinal cord. Average life expectancy after diagnosis is 
between 2-5 years, as the death of motor neurons innervating the lungs ultimately leads 
to many sALS patients’ deaths. Unfortunately, current treatments only extend life by 
several months. More effective therapies are sorely needed for this devastating illness.  
As of 2014, 68% of fALS in Caucasians was accounted for by causal mutations 
in 9 different genes. However, only 11% of sALS in Caucasians was accounted by 
mutations in these genes (Renton, Chio, Traynor 2014). Despite evidence for varying 
genetic etiologies, ALS gene expression studies dating back to 2001 suggest there is a 
convergent set of perturbed cellular processes germane to both fALS and sALS. ALS 
tissue-specific DEGs identified from human (fALS and sALS) patient and fALS model 
rodent samples were associated with oxidative stress, mitochondrial dysfunction, 
apoptosis, inflammation, RNA processing defects, and protein aggregation (Heath, 
Kirby, Shaw 2013). Researchers using separate molecular biology assays found these 
same cellular processes were perturbed in human (fALS and sALS) patient and fALS 





perturbations in these cellular processes contribute to ALS onset, progression, and 
symptoms. These findings also support the use of gene expression studies to identify 
cellular processes likely perturbed in ALS pathology moving forward.  
Follow-up molecular biology experiments can be used to test how sALS group-
specific differences (identified in gene expression studies) may have functional 
relevance to disease pathology. Further, these experiments could unveil novel 
therapeutic targets that may slow this devastating disorder. In the course of this 
dissertation project, we combined RNA-Sequencing, systems biology analyses, and 
molecular biology assays to elucidate sALS group-specific differences in postmortem 
spinal tissues that may be relevant to disease pathology.  
In chapter 2, we discovered inflammatory processes and TNF-α signaling were 
statistically significantly associated with sALS group-specific gene expression 
differences identified using independent exploratory DEG analyses and an 
unsupervised gene co-expression network analysis. Increased inflammatory processes 
and elevated TNF-α signaling have been recurrently reported in ALS tissues, and likely 
play a role in sALS pathology. We selected TNFAIP2, an upregulated sALS group-
specific DEG and network hub gene, for downstream molecular assays. Elevated TNF-α 
signaling is known to increase TNFAIP2 expression in a variety of cell types (Saito et al. 
2013, Zhou, Scoggin, Gaynor, Williams 2003, Tian et al 2005), and elevated TNFAIP2 
expression has previously been associated with increased apoptosis (Park et al. 2003, 
Rusiniak et al. 2000, Ma et al. 2003).  Studies linking elevated TNFAIP2 expression to 
increased apoptosis did not assess TNFAIP2’s cellular function or whether TNFAIP2 





Within in vitro models of sALS disease-vulnerable cell types, we wished to test 
whether 1) elevated TNF-α signaling increased TNFAIP2 expression, and 2) whether 
transient overexpression of TNFAIP2 increased cell death, potentially through the TNF 
superfamily mitochondrial apoptotic pathway. We discovered exposing neural stem cells 
to extracellular TNF-α increased TNFAIP2 gene expression by ~100 fold, along with 
elevating several other network hub genes’ expression levels. Transient overexpression 
of TNFAIP2 decreased neural stem cell viability, and simultaneous inhibition of 
activated caspase 9 (a protein necessary for TNF-α superfamily mitochondrial-mediated 
apoptosis) reversed this effect in these cells. Further, transient overexpression of 
TNFAIP2 with Green Fluorescent Protein (GFP) fused to its N terminus in iPSC-derived 
motor neurons led to increased cell death evidenced by decreased cell viability and 
increased caspase 3/7 levels.  
These proof of concept experiments within in vitro models of sALS disease-
vulnerable cell types demonstrated TNFAIP2 expression increased in response to 
elevated TNF-α signaling, and transient overexpression of TNFAIP2 promoted cell 
death.  TNFAIP2 may mediate cell death via the TNF-α superfamily mitochondrial-
mediated apoptotic pathway, as inhibition of activated Caspase 9 (a protein necessary 
for TNF-α superfamily mitochondrial-mediated apoptosis) prevented TNFAIP2-mediated 
cell death in our neural stem cells. Taken together, these findings support our 
hypotheses that elevated TNF-α signaling 1) increased TNFAIP2 expression in our 
sALS patients’ cervical spinal cells, and 2) TNFAIP2 functionally contributed to spinal 





Further research into the potential role of elevated TNF-α signaling (and TNFAIP2 
expression) in sALS pathology is needed.  
In chapter 3, we did not identify any statistically significant differences in 
mitochondrial gene expression in our sALS sample group vs. our neurologically healthy 
controls. However, there were trend level findings of reduced gene expression for the 
majority of mitochondrial protein coding genes (12 out of 13) in our sALS patients vs. 
our neurologically healthy controls. These genes encode components of ETC protein 
complexes, essential for mitochondrial OXPHOS. Defective mitochondrial OXPHOS has 
been linked to elevated oxidative stress, a phenomenon known to mediate 
neurodegeneration under certain circumstances. While we did not identify sALS group-
specific mitochondrial DEGs, it is possible our sALS patients carried mitochondrial 
SNVs or indels that perturbed mitochondrial OXPHOS in their disease-vulnerable cells. 
This may have contributed to their motor neurons dying. Further investigation into the 
potential role of pathogenic mitochondrial variants in our samples (and in sALS 
pathology) is needed.  
In chapter 4, we identified 52 sALS group-specific DUEs in 46 annotated genes, 
and over-representation analyses revealed those genes were associated with 
cholesterol biosynthesis. Defects in cholesterol biosynthesis and metabolism have been 
linked to numerous neurodegenerative disorders. In NPC, cholesterol sequestration in 
the late endosomes and/or lysosomes leads to lower levels of cholesterol in neurons’ 
membranes. While the exact mechanism is unknown, this ultimately promotes 





biosynthesis and/or metabolism play a role in ALS, cholesterol has been linked to 
neurodegeneration repeatedly in previous literature.  
It is not difficult to imagine how perturbations in the level or distribution of 
cholesterol in neurons could lead to pathological cellular processes. Cholesterol is an 
essential component of neuronal membranes, necessary for protein anchorage and 
trafficking. Further, cholesterol is used for continued axon growth and synapse 
remodeling in the mature adult brain, and serves as a precursor of neurosteroids 
(Anchisi, Dessi, Pani, Mandas 2013). Research into the potential role of aberrant 
cholesterol biosynthesis and/or metabolism in sALS pathology is needed. 
What I learned: 
In the course of this dissertation project, I have learned how many factors 
inherent to current RNA-Sequencing workflows influence gene expression estimates. 
Many of these factors are completely unrelated to gene expression levels in the original 
biological tissue. I will discuss the numerous factors in our workflow that likely 
influenced our annotated gene expression estimates.  
For review, the steps of our Illumina RNA-Sequencing workflow for each sample 
involved 1) isolating total RNA, 2) removing rRNAs from total RNA, 3) fragmenting 
isolated RNA transcripts into a distribution of smaller fragments, 4) converting RNA 
fragments into sequenceable dscDNA molecules, 5) increasing the proportion of 
properly ligated sequenceable dscDNA molecules via enrichment PCR, 6) binding 
denatured strands of sequenceable dscDNA molecules to an Illumina NextSeq500 





human reference transcriptome then genome, and 8) using bioinformatics analyses to 
generate each annotated gene’s expression level estimates. Nearly every one of these 
steps influences the final gene expression level estimates! 
The QIAGEN miRNeasy kit used in step 1 did not recover all RNA transcripts, as 
some were inevitably retained on its isolation column. Use of the RNeasy Micro kit for 
sample purification led to our losing various genes’ RNA transcripts <100 nucleotides in 
length, as that kit is designed to recover RNA transcripts >100 nucleotides in length. 
Finally, RNA transcripts are known to undergo varying levels of degradation during the 
RNA isolation process. For any given annotated gene, losing its RNA transcripts would 
lead to less 1) corresponding sequenceable dscDNA molecules and 2) paired end reads 
that could have aligned to that gene’s transcribed regions. This would lead to an 
underestimated gene expression level estimate for that annotated gene relative to its 
actual expression level in the biological sample.  
Paired end reads corresponding to RNA transcripts that incurred higher levels of 
degradation likely preserved shorter stretches (less nucleotides) of those RNA transcripts 
relative to RNA transcripts that incurred lower levels of degradation. Paired end reads 
preserving longer stretches of their corresponding RNA transcripts were generally more 
likely to accurately align to the hg19 human reference genome relative to paired end reads 
preserving shorter stretches of their corresponding RNA molecules. While the majority of 
our RNA transcripts were not likely to be significantly degraded (as we used RNA with an 
RQI score >7), this effect likely led to underestimated gene expression values for any 





The RNA fragmentation process used in step 3 broke all RNA transcripts into a 
tighter distribution of smaller fragments (between 120-210 nucleotides) prior to dscDNA 
generation in the next step. The length of a given isolated RNA transcript was positively 
correlated with both 1) the number of fragments generated from it, and 2) the number of 
corresponding sequenceable dscDNA molecules generated from its fragments in 
downstream steps. Relative to shorter RNA transcripts, longer RNA transcripts were 
generally more likely to have a greater number of corresponding paired end reads (and 
paired end read counts). This concept is illustrated in Figure 16, and was true even when 
a long and short RNA transcript had equal expression levels in the biological sample.  
As a result of this technical bias, it is highly probable that our annotated genes had 
disproportionately more or less aligned paired end reads relative to their actual 
expression levels in each sample’s postmortem tissues. This almost certainly influenced 
our annotated genes’ expression level estimates, as both HTSeq-Count and Cufflinks 
used the number of aligned paired end read counts to calculate their gene expression 
level estimates. While Cufflinks applied a normalize step to correct for this bias, it is 
unlikely to have completely resolved its effects as discussed later. 
The enrichment PCR process in step 5 was necessary to increase the number of 
sequenceable dscDNA molecules relative to dscDNA molecules improperly ligated with 
one or zero sequencing adaptors. This ensured a negligible amount of unsequenceable 
denatured strands (from improperly ligated dscDNA molecules) bound to the NextSeq 
500 flowcell. Unfortunately, this necessary step likely altered the amount of input 
sequenceable dscDNA molecules relative to each other. A previous study has shown 





preparation kits do not amplify equally (Kebschull and Zador, 2015). Depending on 
whether a given annotated gene’s sequenceable dscDNA molecules were 
disproportionately increased or decreased by enrichment PCR, that annotated gene 
would have more or less corresponding denatured strands able to hybridize the limited 
number of Illumina NextSeq 500 binding spots (covalently bound oligonucleotides) for 
sequencing. This technical property likely led to overestimated or underestimated gene 
expression values for affected annotated genes. 
Use of paired end reads that were >100 nucleotides in length likely increased our 
total number of aligned sequenced reads relative to if we used single end (or shorter 
paired end) reads (Salzman, Jiang, Wong 2011, Cho et al. 2014). This likely prevented 
underestimated gene expression values for at least a portion of our annotated genes, as 
a greater number of their corresponding paired end reads likely aligned to their 
transcribed regions.  
Perhaps the biggest influence on our downstream gene expression estimates was 
the number of paired end reads generated for each sample. The total number of 
sequenced reads obtained for a given sample is positively correlated with 1) the likelihood 
genes with lower expression levels are represented in their sequencing data, and 2) how 
accurate their gene expression estimates are likely to be. These concepts are illustrated 
in Figure 12.  
According to a recent study, 45-65 million RNA-sequencing reads generated from 
input total RNA (depleted of rRNAs) offers a detection level for lowly expressed protein 





one uses input polyA+ RNA instead, ~13 million reads allows a detection level for lowly 
expressed protein coding genes that is comparable to a standard Agilent microarray. 
There is not a consensus number of RNA-sequencing reads one should appropriate to 
each sample to achieve highly accurate gene expression estimates for very lowly 
expressed genes. An early study proposed 200 million reads per sample was necessary 
to detect the full range of expressed human RNA transcripts, including those from very 
lowly expressed genes (Tarazona et al. 2011). The ENCODE consortium reported ~36 
and ~80 million paired end reads per sample were necessary to accurately estimate 
genes with expression levels corresponding to FPKM values of >10 and <10, respectively.  
We obtained >55 million paired end reads for each of our samples. Taken together, 
we should have a comparable detection level for protein coding genes relative to using 
standard microarray technology. According to ENCODE’s estimates, our gene expression 
estimates for annotated genes with expression levels that correspond to an FPKM value 
of >10 should be highly accurate. Our gene expression estimates for annotated genes 
with expression levels that correspond to an FPKM value of <10 are likely less accurate 
(with decreasing accuracy tracking with lower gene expression levels).  
Use of Tophat2 likely had mixed effects on our downstream gene expression 
estimates. A group recently compared alignment results from 26 mapping protocols on 4 
common RNA-Sequencing read datasets (Engstrom et al. 2013). Tophat2 reported one 
the smaller numbers of total aligned reads due to its low tolerance for mismatching 
nucleotides, but one of the higher numbers of identified splice sites when used with a 
guide annotation. Overall, use of Tophat2 probably led to more underestimated gene 





successfully aligned to those genes’ transcribed regions. However, use of Tophat2 
probably prevented underestimated gene expression values for some annotated genes 
by using additional identified splice sites to correctly map paired end reads to those genes’ 
transcribed regions across introns. 
Finally, properties inherent to the bioinformatics tools used to calculate each 
sample’s annotated gene expression estimates were also likely to affect the accuracy of 
our gene expression estimates. For each sample, HTSeq-Count reported each 
annotated gene’s total number of paired end reads that aligned to its transcribed 
regions without accounting for the influences of transcript length or the sample’s total 
number of paired end reads on these counts. This likely led to overestimated and 
underestimated gene expression values for many of our annotated genes depending on 
how they were influenced by these technical factors. Cufflinks’ annotated gene 
expression estimates were likely more accurate for each sample, as their FPKM 
normalization accounted for transcript length, that sample’s total number of sequenced 
reads, and RNA composition biases. However, this is likely an imperfect solution. It is 
probable a portion of each sample’s endogenously smaller RNA transcripts didn’t have 
any corresponding paired end reads generated (despite equal expression levels to 
larger RNA transcripts) as a result of having less corresponding denatured strands to 
bind the flowcell for sequencing. Cufflinks can’t normalize aligned paired end read 
counts for a given annotated gene if that gene’s endogenously smaller RNA transcripts 
didn’t have any corresponding paired end reads.  
Provided a thoughtful experimental design that buffers the influences of these 





excellent research tool for estimating gene expression levels and performing 
downstream analyses. With technological advances, RNA-Sequencing’s ability to 1) 
accurately estimate gene expression levels, 2) detect and estimate lowly expressed 
genes’ expression levels, and 3) identify various RNA isoforms will only improve.  
Commonly used RNA-Sequencing workflows for DEG analyses rely on 
sequenceable dscDNA molecules made from fragmented RNA transcripts. Pacific 
Biosystem’s current RNA-sequencing workflow does not fragment RNA transcripts, and 
its sequencing technology routinely generates sequencing reads that are (on average) 
15,000 nucleotides. Generation of each sample’s RNA-Sequencing reads using this 
platform would greatly reduce (if not altogether eliminate) the influence of transcript 
length on downstream gene expression estimates, and mitigate Cufflinks’ uncertainty in 
assigning a given sequenced read to its corresponding RNA transcript. Further, gene 
expression estimates would likely be much more accurate as a result, and widespread 
use of this platform would produce more trustworthy differential transcript expression 
analyses.  
However, Pacific Biosystem’s RNA-Sequencing workflow is rarely used in 
preparation for DEG analyses today. The average cost per read is drastically higher 
compared to platforms that generate shorter reads. Typically, gene expression studies 
with DEG analyses involve generation of >10 million reads per sample (when using 
polyA+ enrichment input mRNAs) or >30 million reads per sample (when using rRNA-
depleted total RNA). It would be astronomically expensive to generate these numbers of 
reads per sample using the Pacific Biosystem RNA-Sequencing workflow. However, 





technology will become more affordable and replace the current workflows. 
A potentially superior approach to Pacific Biosystem’s RNA-Sequencing workflow 
in the future would involve generating long sequencing reads (covering the entirety of 
the RNA transcript) directly from every RNA transcript in each tested sample. That 
would eliminate influences on gene expression estimates introduced by 1) transcript 
length, 2) PCR amplification biases, 3) RNA transcripts lost across the library 
preparation workflow, and 4) the effects of a sampling procedure for sequencing. 
Numerous companies (including Oxford Nanopore Technologies) are in the process of 
creating a technology that can generate long sequencing reads (covering the entirety of 
the RNA transcript) from every RNA transcript in each tested sample. 
Future Directions: 
Clinical trials that aim to inhibit TNF-α synthesis may prove fruitful in sALS as 
they have in other chronic diseases with an inflammatory component (Probert 2015). 
However, the use of non-selective TNF-α inhibitors has exacerbated symptoms in 
human multiple sclerosis patients, and induced new cases of demyelinating disease and 
neuropathies in other clinical populations. Side effects have included an elevated risk 
for bacterial sepsis and invasive fungal infections as a result of suppressed immune 
function (Probert 2015). 
Additionally, elevated TNF-α signaling can lead to increased cell survival 
processes via NFKB signaling under certain biological conditions, so inhibiting it 
altogether may prevent those protective processes from occurring in sALS patients’ 





superfamily apoptotic pathways may prove to be a superior treatment strategy for sALS 
patients if therapeutic efforts to generally inhibit TNF-α synthesis have significant 
shortcomings. 
In our studies presented in Chapter 2, we found exposing neural stem cells to 
extracellular TNF-α increased TNFAIP2 gene expression by ~100 fold. We 
demonstrated transient overexpression of TNFAIP2 promoted cell death within in vitro 
models of sALS disease-vulnerable cell types. Further, we discovered inhibiting 
caspase 9 (a protein necessary for TNF-α superfamily mitochondrial-mediated 
apoptosis) decreased TNFAIP2-mediated cell death in our neural stem cells. Taken 
together, these findings suggest TNFAIP2 may functionally contribute to TNF 
superfamily mitochondrial-mediated apoptosis in disease-vulnerable cell types in sALS 
patients.  
For follow up experiments, I would like to assess whether TNFAIP2 functionally 
contributes to apoptosis within iPSC-derived motor neurons in vitro and within 
transgenic mice in vivo. The results of these experiments would have important 
implications for TNFAIP2’s potential therapeutic relevance in sALS, as it may represent 
a good candidate for therapeutic targeting if it does functionally contribute to apoptosis 
in one or both models.  
In preparation for the in vitro experiment, I would use CRISPR/Cas9 technology 
to establish an iPSC-derived motor neuron line without a functional copy of the 
TNFAIP2 gene (TNFAIP2 -/-). I would then empirically determine what amount of 





expose wildtype and TNFAIP2 -/- iPSC-derived motor neuron groups to that pre-
determined amount of TNF-α for 6 hours, followed by assessing cell viability in both 
groups using the MTT assay. If wildtype iPSC-derived motor neurons showed a 
statistically significant reduction in cell viability compared to TNFAIP2 -/- iPSC-derived 
motor neurons, this would suggest TNFAIP2 functionally contributes to apoptosis 
mediated by elevated TNF-α signaling.  
In preparation for the in vivo experiment, I would use CRISPR/Cas9 technology 
to insert a doxycycline-inducible human TNFAIP2 transgene (coupled to a motor neuron 
specific promoter) into various transgenic mouse lines (to assess against different 
genomic backgrounds). I would then raise these mice to adulthood, and administer 
varying doses of doxycycline to these mice and their littermates (who would serve as 
controls). I would then assess whether varying levels of TNFAIP2 overexpression led to 
a neurodegenerative phenotype characterized by muscle weakness, paralysis, muscle 
wasting, and early death. If it does, I would confirm TNFAIP2 overexpression occurred 
in spinal motor neurons, and that death of upper and lower motor neurons was 
observed.  
These findings (along with those presented in data chapter 2) could provide the 
bases for a future clinical trial assessing whether TNFAIP2 knockdown in the CNS 
ameliorates symptoms related to motor neuron death in sALS patients. Clinical metrics 
to assess disease progression, such as the revised ALS functional rating scale used in 
previous studies (Tateishi 2010), could be a preliminary measure of treatment efficacy.  





involving the enrollment of 20,000 sALS patients and 20,000 healthy controls (without 
ALS or any other neurological disorder) that are matched for age, ethnicity, and gender. 
To better understand the different molecular etiologies of sALS, I would perform 
multiple experiments that require collection of DNA samples from sALS patients and 
neurologically healthy controls. To avoid an invasive procedure, I would collect blood 
samples from sALS patients and neurologically healthy controls upon entry into our 
study. I would also collect blood samples from each sALS patient’s parents and an 
unaffected sibling whenever available. For healthy controls, I would contact them every 
6 months (for 20 years) to ensure they did not develop a neurological disorder. If they 
did, I’d remove them from our study. 
A recent publication (Kiezun et al. 2012) suggested 1) most of the rare coding 
variants in the human population are deleterious, 2) increased sequencing sample sizes 
are positively correlated with the number of rare coding variants identified, and 3) 
>10,000 cases and controls are likely necessary for sufficient statistical power to identify 
a single gene harboring an excess number of rare coding variants in a gene burden 
test. These researchers calculated sample sizes of 10,000 would be needed via 
simulations that modeled typical numbers of rare variants identified in disease vs. 
control groups.  
For my first experiment, I would aim to identify genes carrying a statistically 
significant excess of rare (minor allele frequency <1%) protein-coding variants in sALS 
patients vs. neurologically healthy controls. Variants in these genes could contribute to 





sALS patients and 20,000 healthy controls. I would then generate, align, and process 
whole exome sequencing data for all 40,000 samples using appropriate kits, computing 
resources, and bioinformatics software programs.  
I would next perform a gene burden test to identify any gene in the hg38 human 
genome that harbors a statistically significant excess of rare coding variants in our sALS 
patients vs. our neurologically healthy controls. For each annotated gene, the gene 
burden test compares the total number of rare coding variants in our sALS patients vs. 
our neurologically healthy controls’ exome sequencing data. A corresponding p-value is 
generated, and a Bonferroni correction is applied to account for multiple testing. A 
significant p-value for a single gene would be p < 1.04X10^-6. That is a p-value of < 
0.05 after applying a Bonferroni correction for 48,000 genes tested, as the hg38 human 
genome has ~48,000 annotated genes.  
I would be particularly interested in any rare variant (in any gene) that was 
observed multiple times in our sALS samples’ exome sequencing data, but not found in 
our healthy controls’ exome sequencing data. If any of these rare variants were not 
found in publically available exome sequencing datasets generated from individuals that 
do not have any neurological disorders, I would validate each of them using Sanger 
sequencing. I would then generate separate transgenic mouse lines (using 
CRISPR/Cas9 technology) that carry each of these validated rare variants to assess 
whether any of them cause an ALS-like neurodegenerative phenotype characterized by 
muscle weakness, muscle wasting, spinal motor neuron death, paralysis, and early 
death. This could lead to the discovery of novel loci that carry causal ALS mutations, 





For my second experiment, I would aim to identify de novo coding variants that 
cause sALS. I would first isolate blood mononuclear cells’ DNA from both parents and 
an unaffected sibling for every qualifying sALS patient. I would then generate, align, and 
process exome sequencing data using these family members’ DNA via the same 
methods proposed in my first experiment. For each trio (2 parents and their sALS-
affected offspring), I would identify all coding variants found only in the sALS-affected 
offspring’s exome sequencing data. I would apply this same approach to each trio 
comprised of each sALS patient’s 2 parents and unaffected sibling, identifying all coding 
variants found only in the unaffected sibling’s exome sequencing data compared to their 
parents’ exome sequencing data.  
I would be particularly interested in all de novo coding variants identified in sALS-
affected offspring that were not found in their unaffected siblings. If these de novo 
variants were also not found in publically available exome sequencing datasets 
generated from individuals that do not have any neurological disorders, I would validate 
each variant using Sanger sequencing. I would then generate separate transgenic 
mouse lines (using CRISPR/Cas9 technology) that carry each of these validated rare 
variants to assess whether it leads to an ALS-like neurodegenerative phenotype 
characterized by muscle weakness, muscle wasting, spinal motor neuron death, 
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